Methods of Treating Mitochondrial Myopathies Using Anti-GDF15 Antibodies
Anti-GDF15 antibodies provide a novel therapeutic approach by neutralizing GDF15 to improve muscle weakness, fatigue, and exercise tolerance in primary mitochondrial myopathies, addressing the lack of effective treatments for these conditions.
Patent Information
- Application Number
- JP2024524991
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-07-15
- Filing Date
- 2022-10-31
- Publication Date
- 2024-11-13
AI Technical Summary
There are no disease-modifying treatments for primary mitochondrial myopathies (PMM), and current treatments only aim to improve or eliminate specific symptoms, leaving a significant unmet need for effective treatment options.
The use of anti-GDF15 antibodies to bind and neutralize GDF15, administered to subjects with elevated levels of the cytokine, which has been shown to improve muscle weakness, fatigue, and exercise tolerance in preclinical models of PMM.
Anti-GDF15 antibodies significantly improve weight gain, increase lean and skeletal muscle mass, restore muscle strength, and enhance exercise performance in mitochondrial myopathy models, offering a novel therapeutic approach for PMM.
Smart Images

Figure 2024541933000001_ABST
Abstract
Description
[Technical field]
[0001] FIELD OF THE PRESENT APPLICATION The present invention relates to methods of preventing, ameliorating and / or treating mitochondrial myopathies using anti-GDF15 antibodies. [Background technology]
[0002] Growth differentiation factor 15 (GDF15), also known as macrophage inhibitory cytokine 1 (MIC-1), prostate-derived factor (PDF), placental bone morphogenetic protein (PLAB), NSAID-activated gene 1 (NAG-1) and placental transforming growth factor beta (PTGFB), is a 12 kDa secreted protein that forms a 25 kDa disulfide-linked homodimer that is a member of the transforming growth factor beta (TGFβ) superfamily. GDF15 is an established biomarker of cellular stress and heart failure (Anand et al., 2010). GDF15 acts through a receptor complex expressed exclusively in the hindbrain, through which it activates neuronal pathways perceived as aversive and suppresses food intake (Lockhart et al., 2020). Reduced food intake has been shown to mediate most of the effects of GDF15 on body weight (Emmerson et al., 2017) (Macia et al., 2012) (Mullican et al., 2017). Recently, GDF15 administration was shown to induce conditioned taste avoidance in mice, and GDF15 expression was regulated by the integrated stress response (ISR) in response to nutritional stress ( Borner et al., 2020 ; Patel et al., 2019a ).
[0003] WO2020 / 039321 discloses anti-GDF15 antibodies and uses thereof, the entirety of which is incorporated herein by reference. These anti-GDF15 antibodies have been shown to be useful in treating cachexia associated with several diseases, including cancer and heart failure.
[0004] Primary mitochondrial myopathies (PMM) are a group of genetic disorders caused by pathogenic mutations in genes found within nuclear DNA (nDNA) and / or mitochondrial DNA (mtDNA). These genes code for mitochondrial proteins, or proteins involved in mitochondrial function (Gorman et al., 2015). PMM predominantly, but not exclusively, affects skeletal muscle, and the most common symptoms are muscle weakness, exercise tolerance, and progressive external ophthalmoplegia, for which no approved treatment exists (Mancuso et al., 2016). GDF15 is a cytokine reported to cause anorexia, aversion / vomiting, and weight loss in preclinical models, and is associated with cancer cachexia and poor survival in patients (Breit et al., 2021; Lerner et al., 2015). Neutralization of GDF15 was reported to alleviate anorexia, weight loss, and improve muscle function and physical performance in preclinical cancer cachexia models (Lerner et al., 2015; Breen et al., 2020). Interestingly, elevated circulating GDF15 has been reported in patients with PMM (Montano et al., Neurol Genet. 2020), but whether GDF15 contributes to muscle weakness, fatigue, and exercise tolerance in these patients is unknown. Summary of the Invention [Problem to be solved by the invention]
[0005] Summary of the Invention There are no disease-modifying treatments for patients with PMM; current therapies are aimed at improving or eliminating specific symptoms. There remains a significant unmet need for therapeutic options for PMM. [Means for solving the problem]
[0006] The present invention provides methods for preventing, ameliorating, and / or treating mitochondrial myopathies using antibodies and antigen-binding fragments thereof that bind to GDF15.
[0007] In some aspects, a method of treating primary mitochondrial myopathy (PMM) is provided, comprising administering to a subject in need thereof a therapeutically effective amount of an isolated antibody that binds to GDF-15.
[0008] In some embodiments, the primary mitochondrial myopathy is Leigh syndrome, Kearns-Sayre syndrome, Alpers-Huttenlocher syndrome, mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes, or mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes. episodes (MELAS) and ataxia neuropathy syndrome (ataxia neuropathy In some embodiments, administration of the anti-GDF15 antibody results in an improvement in one or more signs or symptoms of PMM compared to before administration. In some embodiments, the one or more signs or symptoms of PMM include physical fatigue, muscle weakness, and / or exercise tolerance. In some embodiments, the improvement in one or more signs or symptoms of PMM includes increased weight gain, increased lean muscle mass, increased skeletal muscle mass, restored muscle strength, and / or improvement in exercise capacity. In some embodiments, the subject does not have cachexia, cancer, and / or heart failure. In some embodiments, the subject has elevated GDF15 levels and / or activity prior to administration of the isolated antibody or antigen-binding fragment thereof.
[0009] In some embodiments, the antibody or antigen-binding fragment thereof comprises an LCDR-1 comprising the amino acid sequence of SEQ ID NO:95, an LCDR-2 comprising the amino acid sequence of SEQ ID NO:28, an LCDR-3 comprising the amino acid sequence of SEQ ID NO:9, an HCDR-1 comprising the amino acid sequence of SEQ ID NO:32, an HCDR-2 comprising the amino acid sequence of SEQ ID NO:165, and an HCDR-3 comprising the amino acid sequence of SEQ ID NO:52. In some embodiments, the antibody or antigen-binding fragment thereof comprises a VH comprising the amino acid sequence of SEQ ID NO:166 and a VL amino acid sequence of SEQ ID NO:163. In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:164 and a light chain comprising the amino acid sequence of SEQ ID NO:162.
[0010] In some embodiments, the antibody or antigen-binding fragment thereof is administered subcutaneously. In some embodiments, the antibody or antigen-binding fragment thereof is administered intravenously. In some embodiments, the antibody or antigen-binding fragment thereof is administered about twice a week, once a week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, once every eight weeks, once every nine weeks, once every ten weeks, twice a month, once a month, once every two months, once every three months, or once every four months, once every five months, once every six months, once every seven months, once every eight months, once every nine months, once every ten months, once every eleven months, or once every twelve months. In some embodiments, the antibody or antigen-binding fragment thereof is administered once a week at a dose between about 0.1 mg and about 1000 mg. In some embodiments, the antibody or antigen-binding fragment thereof is administered at a dose between about 1 mg and about 500 mg once a week. In some embodiments, the antibody or antigen-binding fragment thereof is administered at a dose between about 0.1 mg and about 500 mg once every two weeks. In some embodiments, the antibody or antigen-binding fragment thereof is administered at a dose between about 0.1 mg and about 500 mg once every four weeks.
[0011] In some embodiments, the antibody or antigen-binding fragment thereof comprises the amino acid sequence encoded by an insert in a plasmid deposited with the ATCC and having ATCC Accession No. PTA-125038, and the amino acid sequence encoded by an insert in a plasmid deposited with the ATCC and having ATCC Accession No. PTA-125039.
[0012] In some aspects, a method of treating primary mitochondrial myopathy (PMM) is provided, comprising administering to a subject in need thereof a therapeutically effective amount of an isolated antibody that binds to GDF-15, the subject having elevated GDF15 levels and / or activity prior to administration, and administration of the anti-GDF15 antibody results in an improvement in physical fatigue, muscle weakness and / or exercise tolerance in the subject compared to prior to administration, and the antibody or antigen-binding fragment thereof comprises LCDR-1 comprising the amino acid sequence of SEQ ID NO:95, LCDR-2 comprising the amino acid sequence of SEQ ID NO:28, LCDR-3 comprising the amino acid sequence of SEQ ID NO:9, HCDR-1 comprising the amino acid sequence of SEQ ID NO:32, HCDR-2 comprising the amino acid sequence of SEQ ID NO:165 and HCDR-3 comprising the amino acid sequence of SEQ ID NO:52.
[0013] In some embodiments, the antibody or antigen-binding fragment thereof comprises a VH comprising the amino acid sequence of SEQ ID NO: 166 and a VL amino acid sequence of SEQ ID NO: 163. In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 164 and a light chain comprising the amino acid sequence of SEQ ID NO: 162. [Brief description of the drawings]
[0014] [Figure 1-1] 1A shows a graph depicting the transition temperature (Tm1) for an anti-GDF15 antibody of the invention as determined by differential scanning calorimetry (DSC). Tm1 represents the temperature at which the CH2 of the antibody is 50% unfolded. [Figure 1-2]1B shows a graph depicting the transition temperature (Tm2) for an anti-GDF15 antibody of the invention as determined by differential scanning calorimetry (DSC). Tm2 represents the temperature at which the Fab of the antibody is 50% unfolded. [Figure 1-3] 1C shows a graph depicting the transition temperature (Tm3) for an anti-GDF15 antibody of the invention as determined by differential scanning calorimetry (DSC). Tm3 represents the temperature at which the CH3 of the antibody is 50% unfolded. [Diagram 2] Figure 2 shows the viscosity of GDF15_001, analyzed by an Anton Parr instrument. The acceptable viscosity limit (20 cP) is reached at approximately 140 mg / ml. [Diagram 3] FIG. 3 provides a table showing the SEQ ID NOs corresponding to the GDF15 antibodies of the invention. [Figure 4] Figures 4A and 4B show plasma GDF15 (Figure 4A) and FGF21 (Figure 4B) levels in WT and PolG mice at 3, 6 and 10 months of age. [Diagram 5] FIG. 5 is a graph showing exercise performance during voluntary wheel running by PolG and WT mice, demonstrating that PoIG mice had lower exercise performance during voluntary wheel running compared to WT. [Figure 6] FIG. 6 is a graph showing muscle function during in vivo force measurements of PolG and WT mice, demonstrating that PolG mice had lower muscle function during in vivo force measurements compared to WT mice. [Figure 7] FIG. 7 shows the body weight (grams) of PolG vs. WT mice following treatment with GDF15 mAb2, demonstrating the weight gain due to GDF15 mAb2 treatment in PolG mice. [Figure 8] Figures 8A and 8B demonstrate that lean mass (Figure 8A) and fat mass (Figure 8B) were significantly increased by GDF15 mAb2 treatment in PolG mice, as were muscle weights at 22 and 57 days after treatment. [Figure 9]Figures 9A and 9B demonstrate that muscle mass, particularly the gastrocnemius (Figure 9A) and tibialis anterior (Figure 9B), was significantly increased by GDF15 mAb2 treatment in PolG mice by muscle weight at the end of the study (day 87 post-treatment). [Figure 10] FIG. 10 is a graph demonstrating that muscle function was significantly increased by GDF15 mAb2 treatment in PolG mice. [Figure 11] Figures 11A and 11B demonstrate that GDF15 mAb2 treatment improved exercise performance in PolG mice, including treadmill running endurance (Figure 11A) and voluntary running distance (Figure 11B). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0015] Detailed Description of the Invention Although elevated circulating levels of GDF15 have been reported in patients with primary mitochondrial myopathies (Montano et al., Neurol Genet. 2020), it is unclear whether GDF15 contributes to the signs and symptoms associated with these myopathies, such as muscle weakness, physical fatigue, and exercise tolerance. The present invention relates to the unexpected observation that blocking GDF15 activity using anti-GDF15 antibodies improves exercise capacity and physical fatigue in a preclinical mouse model that exhibits similar characteristics to patients with PMM. In particular, it was determined that GDF15 blockade significantly improved weight gain and increased lean muscle mass and skeletal muscle mass in PolG mice (mitochondrial DNA mutator mice). Furthermore, treatment with GDF15 antibodies fully restored muscle strength and improved exercise capacity in these mice as determined using treadmill running and voluntary wheel running tests. Thus, the data disclosed herein provide the first evidence that blocking GDF15 activity ameliorates the signs and symptoms associated with primary mitochondrial myopathy, and that GDF15 inhibition provides a new therapeutic approach for primary mitochondrial myopathy.Thus, in some aspects, the present disclosure provides a method for preventing, ameliorating and / or treating primary mitochondrial myopathy using anti-GDF15 antibodies, such as, but not limited to, GDF15_001 (also referred to herein as ponsegromab, PF-06946860) and GDF15_0301 (also referred to herein as mAB2).
[0016] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0017] All references cited herein, including patent applications, patent publications, and Genbank accession numbers, are herein incorporated by reference as if each individual reference was specifically and individually indicated to be incorporated by reference in its entirety.
[0018] The techniques and procedures described or referred to herein are generally well understood and may be found in, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual 3rd ed. (2001) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (FMA Usubel et al., eds. (2003)); series METHODS IN ENZYMOLOGY (Academic Press, Inc.): PCR 2: A PRACTICAL APPROACH (MJ MacPherson, BD Hames, and GR Taylor, eds. (1995)), Harlow and Lane, eds. (1988) ANTIBODIES, A LABORATORY MANUAL, and ANIMAL CELL CULTURE (RI Freshney, ed. (1987)); Oligonucleotide Synthesis (MJ Gait, ed., 1984); Methods in Molecular Biology, Humana Press; Cell Biology: A Laboratory Notebook (ed. J. E. Elis, 1998) Academic Press; Animal Cell Culture (ed. R. I. Freshney, 1987); Introduction to Cell and Tissue Culture (ed. J. P. Mather and P. E. Oberts, 1998) Plenum Press; Cell and Tissue Culture Laboratory Procedures (eds. A. Doyle, J. B. Griffiths and D. G. Newell, 1993-8) J. Wiley and Sons; Handbook of Experimental Immunology (eds. D. M. Weir and C. C. Blackwell); Gene Transfer Vectors for Mammalian Cells (ed. J. M. Miller and M. P.Calos, 1987); PCR: The Polymerase Chain Reaction (Mullis et al., 1994); Current Protocols in Immunology (JE Coligan et al., 1991); Short Protocols in Molecular Biology (Wiley and Sons, 1999); Immunobiology (C.A. Janeway and P. Travers, 1997); Antibodies (P. Finch, 1997); Antibodies: A Practical Approach (D. Catty, IRL Press, 1988-1989); Monoclonal Antibodies: A Practical Approach (P. Shepherd and C. Dean, Oxford University Press, 2000); Using Antibodies: A Laboratory Manual (E. Harlow and D. Lane (Cold Spring Harbor Laboratory Press, 1999)); The Antibodies (M. Zanetti and JD Capra, Harwood Academic Press, 1999) Publishers, 1995); and Cancer: Principles and Practice of Oncology (eds. VT DeVita et al., JBLippincott Company, 1993); and the latest editions thereof, are generally used using conventional methodologies by those skilled in the art.
[0019] antibody An "antibody" or "Ab" is an immunoglobulin molecule capable of recognizing and binding to a specific target or antigen (Ag), such as a carbohydrate, polynucleotide, lipid, polypeptide, etc., via at least one antigen recognition site located in the variable region of the immunoglobulin molecule. As used herein, the term "antibody" can encompass any type of antibody, including, but not limited to, monoclonal antibodies, polyclonal antibodies, antigen-binding fragments (or portions) of intact antibodies that retain the ability to specifically bind to a given antigen (e.g., GDF15).
[0020] The term "antigen" refers to a molecular entity that is used for immunization of an immunocompetent vertebrate to produce antibodies that recognize Ag or to screen an expression library (e.g., phage, yeast or ribosome display library, among others).As used herein, Ag is a broader term and is generally intended to include the target molecule that is specifically recognized by Ab, and thus includes the fragment or mimic of the molecule used in the immunization process to generate Ab or in library screening to select Ab.Thus, for the antibody of the present invention that binds to GDF15, the full-length GDF15 from mammalian species (e.g., human, monkey, mouse and rat GDF15), including its monomer and multimer, e.g., dimer, trimer, etc., as well as truncated and other variants of GDF15, are referred to as antigens.
[0021] "Antigen-binding fragment" of an antibody refers to a fragment of a full-length antibody that retains the ability to specifically bind to an antigen (preferably with substantially the same binding affinity). Examples of antigen-binding fragments include (i) Fab fragments, which are monovalent fragments consisting of VL, VH, CL and CH1 domains; (ii) F(ab')2 fragments, which are bivalent fragments containing two Fab fragments linked by disulfide bridges at the hinge region; (iii) Fd fragments consisting of VH and CH1 domains; (iv) Fv fragments consisting of the VL and VH domains of a single arm of an antibody; (v) dAb fragments consisting of one VH domain (Ward et al., 1989 Nature 341:544-546); and (vi) isolated complementarity determining regions (CDRs), disulfide-linked Fvs (dsFvs), as well as anti-idiotypic (anti-Id) antibodies and intracellular antibodies. Furthermore, although the two domains of the Fv fragment, VL and VH, are encoded by separate genes, they can be joined using recombinant methods by a synthetic linker that allows them to be produced as a single protein chain in which the VL and VH regions pair to form a monovalent molecule (also known as single-chain Fv (scFv)); see, e.g., Bird et al. Science 242:423-426 (1988) and Huston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883. Other forms of single chain antibodies, such as diabodies, are also encompassed. Diabodies are bivalent, bispecific antibodies in which the VH and VL domains are expressed on a single polypeptide chain, but use a linker that is too short to allow pairing between the two domains on the same chain, thereby allowing these domains to pair with the complementary domains on another chain and create two antigen-binding sites (see, e.g., Holliger et al., 1993, Proc. Natl. Acad. Sci. USA 90:6444-6448; Poljak et al., 1994, Structure 2:1121-1123).
[0022] An antibody "variable domain" refers to the variable region of an antibody light chain (VL) or the variable region of an antibody heavy chain (VH), either alone or in combination. As is known in the art, the variable regions of the heavy and light chains each consist of four framework regions (FR) connected by three complementarity determining regions (CDRs), which contribute to the formation of the antigen-binding site of the antibody.
[0023] "Complementarity determining regions" (CDRs) can be identified according to the Kabat, Chothia, Kabat and Chothia combination, AbM, contact, North and / or conformation definitions or any method of CDR determination known in the art. See, for example, Kabat et al., 1991, Sequences of Proteins of Immunological Interest, 5th ed. (hypervariable regions); Chothia et al., 1989, Nature 342:877-883 (structural loop structures). The identity of the amino acid residues that make up the CDRs in a particular antibody can be determined using methods well known in the art. The AbM definition of CDRs is a compromise between Kabat and Chothia and uses Oxford Molecular's AbM antibody modeling software (Accelrys®). The "contact" definition of CDRs is based on observed antigen contacts as set forth in MacCallum et al., 1996, J. Mol. Biol., 262:732-745. The "conformational" definition of CDRs is based on the residues that contribute enthalpic to antigen binding (see, e.g., Makabe et al., 2008, J. Biol. Chem., 283:1156-1166). North uses a different set of preferred CDR definitions to identify canonical CDR conformations (North et al., 2011, J. Mol. Biol. 406:228-256). In another approach, referred to herein as the "conformational definition" of CDRs, the positions of CDRs can be identified as residues that contribute enthalpic to antigen binding (Makabe et al., 2008, J. Biol. Chem. 283:1156-1166). Still other CDR boundary definitions may not strictly follow one of the above approaches, but nevertheless overlap with at least a portion of the Kabat CDRs, but they may be shortened or extended in light of predictions or experimental findings that certain residues or groups of residues, or even entire CDRs, do not significantly affect antigen binding. As used herein, CDRs may refer to CDRs defined by any approach known in the art, including a combination of approaches.The methods used herein may utilize CDRs defined according to any of these approaches. For any given embodiment that includes more than one CDR, the CDRs (or other residues of the antibody) may be defined according to any of the Kabat, Chothia, North, extended, AbM, contact and / or conformation definitions.
[0024] "Framework" (FR) residues are those antibody variable domain residues other than the CDR residues. A VH or VL domain framework comprises four framework subregions FR1, FR2, FR3 and FR4 interspersed with the CDRs in the following structure: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
[0025] As known in the art, a "constant region" of an antibody refers to the constant region of the antibody light chain or the constant region of the antibody heavy chain, either alone or in combination.
[0026] The terms "Fc region", "Fc domain" and "Fc", as used interchangeably herein, refer to the portion of an immunoglobulin (Ig) molecule that correlates with the crystallizable fragment obtained by papain digestion of the Ig molecule. As used herein, these terms refer to the constant region of an antibody excluding the first constant region immunoglobulin domain, and further to portions of that region. Thus, Fc refers to the last two constant region immunoglobulin domains of IgA, IgD and IgG, and the last three constant region immunoglobulin domains of IgE and IgM, and the flexible hinges N-terminal to these domains, or portions thereof. For IgA and IgM, Fc may include the J chain.
[0027] For IgG, Fc includes immunoglobulin domains Cγ2 and Cγ3 (Cgamma2 and Cgamma3) and the hinge between Cγ1 (Cgamma1) and Cγ2 (Cgamma2). Although the boundaries of the Fc region can vary, the human IgG heavy chain Fc region is usually defined to include residues C226 or P230 to its carboxyl terminus, with this numbering according to the EU index of Edelman et al., 1969, Proc. Natl. Acad. Sci. USA 63(1):78-85, as described in Kabat et al., 1991. Typically, the Fc domain includes amino acid residues from about 236 to about 447 of the human IgG1 constant domain. An exemplary human wild-type IgG1 Fc domain amino acid sequence is set forth in SEQ ID NO:31. Fc polypeptide can refer to this region in isolation, or in the context of an antibody or antigen-binding portion thereof, or an Fc fusion protein.
[0028] The heavy chain constant domain comprises the Fc region, and further comprises the CH1 domain and hinge and CH2 and CH3 domains of IgG heavy chains (and optionally CH4 domains of IgA and IgE).
[0029] In certain embodiments, the antibodies or antigen-binding fragments thereof described herein comprise an Fc domain. The Fc domain can be derived from IgA (e.g., IgA1 or IgA2), IgD, IgE, IgM, or IgG (e.g., IgG1, IgG2, IgG3, or IgG4).
[0030] An "Fc fusion" protein is a protein in which one or more polypeptides are operably linked to an Fc polypeptide. An Fc fusion combines the Fc region of an immunoglobulin with a fusion partner.
[0031] "Epitope" refers to an area or region of an antigen to which an antibody specifically binds, e.g., an area or region that contains residues that interact with an antibody. Epitopes can be linear or conformational.
[0032] At its most detailed level, an epitope for an interaction between an Ag and an Ab can be defined by spatial coordinates that define the atomic contacts present during the Ag-Ab interaction, as well as information about their relative contribution to binding thermodynamics. At a less detailed level, an epitope can be characterized by spatial coordinates that define the atomic contacts between the Ag and the Ab. At an even less detailed level, an epitope can be characterized by specific criteria, for example, the amino acid residues it contains, defined by the distance between atoms (e.g., heavy atoms, i.e., non-hydrogen atoms) in the Ab and the Ag. At an even less detailed level, an epitope can be characterized via function, for example, by competitive binding with other Abs. An epitope can also be defined more generally as including amino acid residues whose substitution with another amino acid (e.g., using alanine scanning) alters the characteristics of the interaction between the Ab and the Ag.
[0033] Due to the fact that epitope description and definition depending on the epitope mapping method used can be obtained at different levels of detail, it follows that comparison of epitopes for different Abs on the same Ag can be performed at different levels of detail as well.
[0034] Epitopes described at the amino acid level, for example as determined from X-ray structures, are said to be identical if they contain the same set of amino acid residues. Epitopes are said to overlap if at least one amino acid is shared by the epitopes. Epitopes are said to be separate (unique) if no amino acid residue is shared by the epitopes.
[0035] Epitopes characterized by competitive binding are said to overlap if the binding of the corresponding antibodies is mutually exclusive, i.e., binding of one antibody precludes the simultaneous or sequential binding of the other antibody. Epitopes are said to be separate (unique) if the antigen is capable of simultaneously accepting the binding of both corresponding antibodies.
[0036] An antibody that "preferentially binds" or "specifically binds" (used interchangeably herein) to an epitope is a term well understood in the art, and methods for determining such specific or preferential binding are also well known in the art. A molecule is said to exhibit "specific binding" or "preferential binding" if it reacts or associates with a particular cell or substance more frequently, more rapidly, with a longer duration, and / or with a higher affinity than it reacts or associates with alternative cells or substances. An antibody "specifically binds" or "preferentially binds" to a target if it binds with higher affinity, avidity, more readily, and / or for a longer duration than it binds to other substances. For example, an antibody that specifically or preferentially binds to a GDF15 epitope is an antibody that binds to this epitope with higher affinity, avidity, more readily, and / or for a longer duration than it binds to other GDF15 epitopes or non-GDF15 epitopes. Generally, but not necessarily, reference to binding refers to preferential binding. "Specific binding" or "preferential binding" includes compounds, e.g., proteins, nucleic acids, antibodies, etc., that recognize and bind to a particular molecule in a sample but do not substantially recognize or bind to other molecules in the sample. For example, an antibody or peptide receptor that recognizes and binds to its cognate ligand or binding partner in a sample but does not substantially recognize or bind to other molecules in the sample will specifically bind to its cognate ligand or binding partner. Thus, under specified assay conditions, a specified binding moiety (e.g., an antibody or antigen-binding portion thereof, or a receptor or ligand-binding portion thereof) will preferentially bind to a particular target molecule and will not bind in significant amounts to other components present in the test sample.
[0037] A variety of assay formats can be used to select antibodies or peptides that specifically bind to a molecule of interest. Among the many assays that can be used to identify antibodies that specifically react with an antigen, or receptors or their ligand-binding portions that specifically bind to their cognate ligands or binding partners, are, for example, solid-phase ELISA immunoassays, immunoprecipitation, BIAcore™ (GE Healthcare, Piscataway, NJ), fluorescence-activated cell sorting (FACS), Octet™ (ForteBio, Inc., Menlo Park, CA) and Western blot analysis. Typically, a specific or selective response is at least two times the background signal or noise, more typically more than 10 times the background, and even more specifically, an antibody that has an equilibrium dissociation constant (K D ) is said to "specifically bind" to an antigen when it is ≦1 μM, preferably ≦100 nM, more preferably ≦10 nM, even more preferably ≦100 pM, still more preferably ≦10 pM, and even more preferably ≦1 pM.
[0038] The term "compete" as used herein with respect to antibodies means that the binding of a first antibody or an antigen-binding portion thereof to an antigen reduces the subsequent binding of the same antigen by a second antibody or an antigen-binding portion thereof. Generally, the binding of a first antibody creates a steric hindrance, a conformational change, or binding to a common epitope (or a portion thereof) such that the binding of the second antibody to the same antigen is reduced. A standard competition assay can be used to determine whether two antibodies compete with each other. One suitable assay for antibody competition involves the use of Biacore technology, which can use surface plasmon resonance (SPR) technology to measure the degree of interaction, typically using a biosensor system (e.g., a BIACORE system). For example, SPR can be used in an in vitro competitive binding inhibition assay to determine the ability of one antibody to inhibit the binding of a second antibody. Another assay for measuring antibody competition uses an ELISA-based approach.
[0039] Furthermore, a high-throughput process for "binning" antibodies based on their competition is described in International Patent Application Publication WO2003 / 48731. Competition exists when one antibody (or fragment) reduces the binding of another antibody (or fragment) to GDF15. For example, sequential binding competition assays can be used, where different antibodies are added sequentially. The first antibody can be added until near-saturation binding is reached. Then the second antibody is added. These two antibodies are considered to compete with each other if the binding of the second antibody to GDF15 is not detected or is significantly reduced (e.g., at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80% or at least about 90%) compared to a parallel assay in the absence of the first antibody (which value can be set to 100%).
[0040] Variant antibodies may include 1, 2, 3, 4, 5, up to 10, up to 20, up to 30, or more amino acid substitutions and / or deletions and / or insertions from the specific sequences and fragments discussed above. "Deletion" variants may include deletion of individual amino acids, deletion of small groups of amino acids, e.g., 2, 3, 4, or 5 amino acids, or deletion of larger amino acid regions, e.g., deletion of specific amino acid domains or other features. "Insertion" variants may include insertion of individual amino acids, insertion of small groups of amino acids, e.g., 2, 3, 4, or 5 amino acids, or insertion of larger amino acid regions, e.g., insertion of specific amino acid domains or other features. "Substitution" variants preferably involve replacement of one or more amino acids with the same number of amino acids, and making conservative amino acid substitutions. For example, an amino acid can be substituted with an alternative amino acid having similar properties, such as another basic amino acid, another acidic amino acid, another neutral amino acid, another charged amino acid, another hydrophilic amino acid, another hydrophobic amino acid, another polar amino acid, another aromatic amino acid, or another aliphatic amino acid. Some properties of the 20 main amino acids that can be used to select appropriate replacements are as follows:
[0041] Substitution variants have at least one amino acid residue in an antibody molecule removed and a different residue inserted in its place. The most targeted sites for substitution mutagenesis include hypervariable regions, but framework changes are also contemplated. Conservative substitutions are shown in Table 1 under the heading of "conservative substitutions". If such substitutions result in changes in biological activity, more substantial changes can be introduced, referred to as "exemplary substitutions" shown below, or further described below with reference to amino acid classes, and the products can be screened.
[0042] [Table 1]
[0043] Substantial alterations in the biological properties of the antibody are achieved by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example as a beta-sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into the following groups based on common side chain properties: i. Non-polar: Norleucine, Met, Ala, Val, Leu, Ile; ii. Uncharged polar: Cys, Ser, Thr, Asn, Gln; iii. Acidic (negatively charged): Asp, Glu; iv. Basic (positively charged): Lys, Arg; v. Residues that influence chain orientation: Gly, Pro; and vi. Aromatics: Trp, Tyr, Phe, His.
[0044] Non-conservative substitutions are made by exchanging a member of one of these classes for another class.
[0045] For example, one type of substitution that can be made is to change one or more cysteines in an antibody that may be chemically reactive to another residue, such as, without limitation, alanine or serine.For example, there may be a non-canonical cysteine substitution.The substitution may be made in the CDR or framework region of the variable domain of the antibody, or in the constant region.In some embodiments, the cysteine is canonical.Any cysteine residue that is not involved in maintaining the proper conformation of the antibody may also be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent abnormal cross-linking.Conversely, cysteine bonds may be added to an antibody to improve its stability, especially when the antibody is an antibody fragment such as an Fv fragment.
[0046] In a process known as "germlining", certain amino acids in the VH and VL sequences can be mutated to match amino acids naturally found in germline VH and VL sequences. In particular, the amino acid sequences of the framework regions in the VH and VL sequences can be mutated to match the germline sequences to reduce the risk of immunogenicity when the antibody is administered. As used herein, the term "germline" refers to the nucleotide and amino acid sequences of antibody genes and gene segments as they are passed from parents to offspring through germ cells. This germline sequence is distinguished from the nucleotide sequences that encode antibodies in mature B cells, which have been altered by recombination and hypermutation events during the process of B cell maturation. An antibody that "utilizes" a particular germline has a nucleotide or amino acid sequence that most closely aligns with that germline nucleotide sequence or the amino acid sequence that it specifies. Such antibodies are frequently mutated compared to the germline sequence. Germline DNA sequences for human VH and VL genes are known in the art (see, e.g., the "Vbase" human germline sequence database; see also Kabat, EA et al., 1991, Sequences of Proteins of Immunological Interest, 5th ed., USDepartment of Health and Human Services, NIH Publication No. 91-3242; Tomlinson et al., J. Mol. Biol. 227:776-798, 1992; and Cox et al., Eur. J. Immunol. 24:827-836, 1994).
[0047] binding affinity The binding affinity of an antibody refers to the dissociation rate of a particular antigen-antibody interaction, K D It can be expressed as a value K D is the "off-rate (k off ) and the association rate, or "on-rate (k on )" Therefore, K D is k off / k on and is expressed as molar concentration (M), K D The smaller the K for an antibody, the stronger the affinity of the binding. D Values can be determined using methods well established in the art. One exemplary method for measuring Kd is surface plasmon resonance (SPR), typically using a biosensor system such as the BIACORE® system. BIAcore kinetic analysis involves analyzing the binding and dissociation of antigens from chips with molecules (e.g., molecules that contain epitope binding domains) immobilized on their surface. Another method for determining the Kd of an antibody is by using Bio-Layer Interferometry, typically using OCTET technology (Octet QKe system, ForteBio). Alternatively, or in addition, KinExA (Kinetic Exclusion Assay) assays available from Sapidyne Instruments (Boise, Id.) can also be used.
[0048] Antibodies against GDF15 The present invention provides anti-GDF15 antibody.Anti-GDF15 antibody, preferably high affinity antibody, can be effective in plasma and multiple tissue compartments where GDF15 is thought to act on its target cells.The antibody of the present invention has the potential to modify the pathways that drive the development and progression of cachexia associated with cancer, heart failure or COPD, among others.
[0049] Neutralizing or "blocking" antibody refers to an antibody whose binding to GDF15 prevents, limits or inhibits the interaction between GDF15 or GDF15 fragment and GDF15 receptor, such as GFRAL or GDF15 receptor component; and / or (ii) causes the inhibition of at least one biological function of GDF15. The assay for determining neutralization by the antibody of the present invention is described elsewhere herein and is well known in the art.
[0050] As used herein, the term "GDF15" includes variants, isoforms, homologs, orthologs and paralogs of human GDF15. In some embodiments of the present invention, the antibody cross-reacts with GDF15 from species other than human, such as mouse, rat or non-human primate GDF15, as well as different forms of GDF15. In other embodiments, the antibody may be completely specific for human GDF15 and may not exhibit species or other type cross-reactivity. As used herein, the term GDF15 refers to naturally occurring human GDF15, unless the context dictates otherwise. Thus, "GDF15 antibody," "anti-GDF15 antibody" or other similar designation refers to any antibody (as defined herein) that specifically associates, binds or reacts with a ligand or isoform of GDF15 type, or a fragment or derivative thereof. The full-length mature form of human GDF15, as represented by UniProtKB / Swiss-Prot accession number Q99988.1, is provided herein as SEQ ID NO: 1.
[0051] Without wishing to be bound by any particular theory, upon interaction with GDF15, GFRAL interacts with the proto-oncogene tyrosine protein kinase receptor Ret (RET) and induces cell signaling through activation of MAPK signaling pathway and AKT signaling pathway. RET signaling then induces or mediates, for example, the phosphorylation of ERK, S6, among others. As used herein, the term "GFRAL" includes variants, isoforms, homologs, orthologs and paralogs of human GFRAL. The full-length mature form of human GFRAL is represented by UniProtKB / Swiss-Prot accession number Q6UXV0. As used herein, the term "RET" includes variants, isoforms, homologs, orthologs and paralogs of human RET. The full-length mature form of human RET is represented by UniProtKB / Swiss-Prot accession number P07949.
[0052] The "biological function" or "biological activity" of GDF15 includes regulating inflammation and apoptosis pathways in tissues, and cellular stress response programs after cell injury.The "biological function" or "biological activity" of GDF15 includes, among others, increasing cachexia, reducing food intake, reducing appetite, reducing body weight, weight loss, reducing fat mass, reducing lean mass, binding GFRAL, activating RET, phosphorylating ERK, and mediating phosphorylation of S6, which are currently known or later identified in the art.The biological function or activity of GDF15 can be, but need not be, mediated by the interaction between GDF15 and its cognate receptor GFRAL.
[0053] The present invention includes an antibody or antigen-binding portion thereof that can modulate the biological activity of GDF15. That is, the present invention includes an isolated antibody or antigen-binding portion thereof that specifically binds to GDF15 and modulates at least one detectable GDF15 activity, such as: (a) increasing food intake; (b) increasing appetite; (c) increasing body weight; (d) decreasing weight loss; (e) increasing fat mass; (f) increasing lean mass; (g) decreasing fat mass loss; (h) decreasing lean muscle mass loss; (i) decreasing GDF15 binding to GFRAL; (j) decreasing downstream signaling mediated by RET; (k) decreasing or inhibiting ERK phosphorylation; (l) decreasing or inhibiting S6 phosphorylation; (m) decreasing RET activation of MAPK signaling pathway; (n) decreasing RET activation of AKT signaling pathway; and / or (o) decreasing activation of PLC-γ1 signaling pathway.
[0054] The biological activity of GDF15 and GDF15-dependent signaling activity can be evaluated in vitro using HEK293 or CHO cells that co-express GFRAL and RET, among many other art-recognized assays. The activation of MAPK pathway after stimulation with GDF15 can be measured using luciferase-based gene reporter systems (e.g., PathDetect, Agilent Technologies), among others. Phosphoprotein assays based on homogeneous time-resolved fluorescence technology (Cisbio Inc.) can also be used as an orthogonal approach to measure the activation of MAPK and AKT pathways (e.g., phosphorylated ERK1 / 2) in response to GDF15 binding to its receptor. The ability of neutralizing antibodies to prevent GDF15-dependent signaling can also be evaluated by incubating cells with a fixed concentration of GDF15 in the absence or presence of increasing concentrations of anti-GDF15 antibodies.
[0055] In one embodiment of the present invention, the GDF15 antibodies of the present invention include antibodies that compete for binding to human GDF15 with and / or bind to the same epitope as an antibody or antigen-binding fragment thereof having the amino acid sequence of the heavy chain variable region shown as SEQ ID NO: 166 and the amino acid sequence of the light chain variable region shown as SEQ ID NO: 163.
[0056] In one embodiment of the invention, GDF15 antibodies of the invention include antibodies that inhibit or reduce binding of GDF15 to GFRAL.
[0057] In one aspect, the present invention encompasses an antibody that competes with an antibody having the amino acid sequence of a heavy chain variable region shown as SEQ ID NO: 166 and the amino acid sequence of a light chain variable region shown as SEQ ID NO: 163, or an antigen-binding fragment thereof, in inhibiting binding of GDF15 to GFRAL.
[0058] In some embodiments of the invention, the antibody or antigen-binding fragment thereof comprises an IgG1 heavy chain constant region, e.g., the GDF15 heavy chain set forth as SEQ ID NO: 164. In other embodiments, the antibody or antigen-binding fragment thereof comprises a kappa light chain constant region, e.g., the GDF15 light chain set forth as SEQ ID NO: 162.
[0059] Table 2 provides the amino acid (protein) and related nucleic acid (DNA) sequences of the anti-GDF15 antibodies of the invention. The CDRs of the anti-GDF15 VH and anti-GDF15 VL as defined by Kabat and by Chothia are shown as separate sequences.
[0060] In some embodiments, the CDRs include SEQ ID NOs: 171, 172, 173, 174, 175, and 176. These CDR sequences incorporate consensus based on the preferred sequence analysis and biophysical profile data shown in Examples 1-10 below. These CDR sequences possess advantages based on their sequence, binding, thermal stability, stability at low pH, and viscosity profiles.
[0061] [Table 2-1]
[0062] [Table 2-2]
[0063] [Table 2-3]
[0064] [Table 2-4]
[0065] [Table 2-5]
[0066]
Table 2-6
[0067]
Table 2-7
[0068]
Table 2-8
[0069]
Table 2-9
[0070]
Table 2-10
[0071]
Table 2-11
[0072]
Table 2-12
[0073]
Table 2-13
[0074]
Table 2-14
[0075]
Table 2-15
[0076] [Table 2-16]
[0077] [Table 2-17]
[0078] [Table 2-18]
[0079] [Table 2-19]
[0080] [Table 2-20]
[0081] [Table 2-21]
[0082] In certain embodiments, the substitutions are human germline substitutions in which (donor) CDR residues are replaced with corresponding human germline (acceptor) residues to increase the human amino acid content and potentially reduce the immunogenicity of the antibody, e.g., as described in U.S. Patent Application Publication No. 2017 / 0073395 and Townsend et al., 2015, Proc. Nat. Acad. Sci. USA 112(50):15354-15359. For example, human germline IGHV1-69 CDR residues are replaced with corresponding human germline (acceptor) residues to increase the human amino acid content and potentially reduce the immunogenicity of the antibody, e.g., as described in U.S. Patent Application Publication No. 2017 / 0073395 and Townsend et al., 2015, Proc. Nat. Acad. Sci. USA 112(50):15354-15359. * When the 01 framework is used and an exemplary antibody, GDF15_001VH (SEQ ID NO: 166), is compared, the GDF15_001 antibody (SEQ ID NO: 32) and the human germline IGHV1-69 * The alignment of HCDR-1 of 01 is as follows:
[0083] [Table 3]
[0084] For amino acid positions 26, 28, 29, 30, 31, 32, and 34 (italicized), the human germline residue (acceptor) and the corresponding GDF15_001 residue (donor) are identical, and no germline substitutions are possible. For positions 27, 33, and 35 (bold and underlined), the human germline (acceptor) residue and the corresponding GDF15_001 (donor) residue are different. The GDF15_001 residues at these positions were replaced with the corresponding human germline IGHV1-69 residues to further increase the human residue content. * 01 residue may be replaced with the mouse residue 02. The same process may be followed for each heavy and light chain CDR to increase the content of human amino acid residues while minimizing the content of murine residues, thereby preserving the binding characteristics, e.g., epitope binding, affinity, etc., while reducing any potential immunogenicity, e.g., human anti-mouse antibody (HAMA) immune response, to the antibody in humans.
[0085] Methods and libraries for introducing human germline residues into antibody CDRs are described in detail in U.S. Patent Application Publication No. 2017 / 0073395 and Townsend et al., 2015, Proc. Natl. Acad. Sci. USA. 112(50):15354-15359, both of which are incorporated by reference in their entireties.
[0086] The anti-GDF15 antibody or antigen-binding fragment thereof may comprise a VH framework comprising a human germline VH framework sequence. In some embodiments, VH frameworks from the following germlines may be used: IGHV1-2 * 02, IGHV1-3 * 01, IGHV1-46 * 01, IGHV1-69 * 01, IGHV1-69 * 02, IGHV1-8 * 01, IGHV3-13 * 01, IGHV3-23* 01, IGHV3-23 * 04, IGHV3-30 * 01, IGHV3-30 * 18. IGHV5-10-1 * 01, IGHV5-10-1 * 04 or IGHV5-51 * 01 (germline designations are based on IMGT germline definitions). In some embodiments, VL frameworks from the following germlines may be used: IGKV1-12 * 01, IGKV1-13 * 02, IGKV1-33 * 01, IGKV1-39 * 01, IGKV1-5 * 01, IGKV3-11 * 01, IGKV3-15 * 01, IGKV3-20 * 01, IGKV3D-20 * 02 and IGKV4-1 * 01 (Germline designations are based on the IMGT germline definitions). Human germline framework sequences are available from various public databases, such as V-base, IMGT, NCBI, or Abysis.
[0087] The anti-GDF15 antibody or antigen-binding fragment thereof may comprise a VL framework comprising a human germline VL framework sequence. The VL framework may comprise one or more amino acid substitutions, additions or deletions while still retaining functional and structural similarity with the germline from which it is derived. In some embodiments, the VL framework is at least 53%, 58%, 60%, 63%, 71%, 72%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the human germline sequence from which it is derived. In some embodiments, the antibody or antigen-binding fragment thereof comprises a VL framework comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 amino acid substitutions, additions or deletions compared to the human germline VL framework sequence. In some embodiments, the 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions, additions or deletions are only in the framework region. In some aspects, the percent (%) identity is based on similarity to the VL excluding the portions defined herein as the CDRs.
[0088] The anti-GDF15 antibody or antigen-binding fragment thereof may comprise a VH framework comprising a human germline VH framework sequence. The VH framework may comprise one or more amino acid substitutions, additions or deletions while still retaining functional and structural similarity with the germline from which it is derived. In some embodiments, the VH framework is at least 72%, 74%, 75%, 77%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the human germline sequence from which it is derived. In some embodiments, the antibody or antigen-binding fragment thereof comprises a VH framework comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 amino acid substitutions, additions or deletions compared to the human germline VH framework sequence. In some embodiments, the 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions, additions or deletions are only in the framework region. In some aspects, the % identity is based on similarity to the VH excluding the portions defined herein as the CDRs.
[0089] The anti-GDF15 antibody or antigen-binding fragment thereof may comprise a VH comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 6. The VH may comprise an amino acid sequence at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 21, 34, 44, 53, 60, 68, 73, 80, 86, 93, 99, 106, 112, 120, 127, 136, 142, 148, 155, 161 and 166. The VH may comprise the amino acid sequence of SEQ ID NO: 21, 34, 44, 53, 60, 68, 73, 80, 86, 93, 99, 106, 112, 120, 127, 136, 142, 148, 155, 161 and 166.
[0090] The antibody or antigen-binding fragment may comprise a VL comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 1. The VL may comprise an amino acid sequence at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 11, 30, 39, 49, 56, 64, 71, 77, 83, 90, 96, 103, 109, 115, 123, 131, 139, 144, 151, 158 and 163. The VL may comprise the amino acid sequence of SEQ ID NO: 11, 30, 39, 49, 56, 64, 71, 77, 83, 90, 96, 103, 109, 115, 123, 131, 139, 144, 151, 158 and 163.
[0091] In some embodiments, the antibody or antigen-binding portion thereof comprises LCDR-1, LCDR-2 and LCDR-3 as set forth in at least one of the amino acid sequences of SEQ ID NOs: 11, 30, 39, 49, 56, 64, 71, 77, 83, 90, 96, 103, 109, 115, 123, 131, 139, 144, 151, 158 and 163.
[0092] In some embodiments, the antibody or antigen-binding portion thereof further comprises HCDR-1, HCDR-2 and HCDR-3 as set forth in at least one of the amino acid sequences of SEQ ID NOs: 21, 34, 44, 53, 60, 68, 73, 80, 86, 93, 99, 106, 112, 120, 127, 136, 142, 148, 155, 161 and 166.
[0093] In some embodiments, the antibody or antigen-binding portion thereof comprises LCDR-1, LCDR-2, LCDR-3 set forth in the amino acid sequence of SEQ ID NO: 163, and HCDR-1, HCDR-2 and HCDR-3 set forth in the amino acid sequence of SEQ ID NO: 166.
[0094] The antibody or antigen-binding portion thereof may comprise a VL comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 163. The VL may comprise an amino acid sequence at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 163. The VL may comprise the amino acid sequence of SEQ ID NO:163.
[0095] The antibody or antigen-binding portion thereof may comprise a VH comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 166. The VH may comprise an amino acid sequence at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 166. The VH may comprise the amino acid sequence of SEQ ID NO:166.
[0096] The antibody or antigen-binding fragment may comprise a HC comprising an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 164. The HC may comprise the amino acid sequence of SEQ ID NO:164.
[0097] The antibody or antigen-binding fragment may comprise a LC comprising an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 162. The LC may comprise the amino acid sequence of SEQ ID NO:162.
[0098] PD-1 axis-binding antagonists The term "PD-1 axis binding antagonist," as used herein, refers to a molecule that inhibits the interaction of a PD-1 axis binding partner with any one or more of its binding partners, such that T cell dysfunction resulting from signaling on the PD-1 signaling axis (also referred to as the "PD-1 / PD-L pathway" or "PD-1 / PD-L signaling pathway") is ablated, resulting in restoration or enhancement of T cell function. As used herein, PD-1 axis binding antagonists include PD-1 binding antagonists, PD-L1 binding antagonists, and PD-L2 binding antagonists. In some embodiments, the PD-1 axis binding antagonist is an anti-PD-1 antibody. In some embodiments, the PD-1 axis binding antagonist is an anti-PD-L1 antibody. In some embodiments, the PD-1 axis binding antagonist is an anti-PD-L2 antibody.
[0099] In some embodiments, the PD-1 axis antagonist, the PD-1 axis binding antagonist, the PD-1 binding antagonist, and the anti-PD-L1 antibody do not include avelumab, i.e., optionally, avelumab is excluded from agents that inhibit the PD-1 axis signaling axis.
[0100] Exemplary PD-1 axis binding antagonists for use in the treatment methods, medicaments and uses of the present invention include, without limitation, nivolumab, pembrolizumab, AMP-224 with or without signal sequence, as described in International Patent Application Publication Nos. WO2010 / 027827 and WO2011 / 066342, mAb7 and mAb15, as disclosed in International Patent Application Publication Nos. WO2016 / 092419, and avelumab, as described in WO2013 / 079174. The disclosures of WO2010 / 027827, WO2011 / 066342, WO2016 / 092419 and WO2013 / 079174 are incorporated herein by reference in their entirety. Table 3 lists various sequences of some of the exemplary PD-1 axis binding antagonists.
[0101] [Table 4-1]
[0102] [Table 4-2]
[0103] The term "PD-1 binding antagonist" as used herein refers to a molecule that specifically binds to PD-1 and reduces, blocks, inhibits, neutralizes or prevents signaling resulting from the interaction of PD-1 with one or more of its binding partners, e.g., PD-L1, PD-L2. In some embodiments, a PD-1 binding antagonist is a molecule that inhibits the binding of PD-1 to its binding partners. In a specific aspect, a PD-1 binding antagonist specifically binds to PD-1, thereby inhibiting the binding of PD-1 to PD-L1 and / or PD-L2. For example, PD-1 binding antagonists include anti-PD-1 antibodies, antigen-binding fragments thereof, immunoadhesins, fusion proteins, oligopeptides and other molecules that reduce, block, inhibit, neutralize or prevent signaling resulting from the interaction of PD-1 with PD-L1 and / or PD-L2. In one embodiment, the PD-1 binding antagonist specifically binds to PD-1, thereby reducing the negative costimulatory signal mediated by or through cell surface proteins expressed on T lymphocytes, mediated through signaling through PD-1, such that dysfunctional T cells become less dysfunctional. In some embodiments, the PD-1 binding antagonist is an anti-PD-1 antibody, including, but not limited to, nivolumab, pembrolizumab, spartalizumab, tisletizumab, pidilizumab, AMP-224, AMP-554, cemiplimab, and PF-06801591.
[0104] PF-06801951 is also known as Sasanlimab (CAS Registry Number 2206792-50-7), RN888, and is disclosed in International Patent Application Publication No. WO2016 / 092419, the entire contents of which are incorporated by reference as if set forth herein. Sasanlimab is a humanized hinge-region stabilized IgG4-kappa (κ) monoclonal antibody. The amino acid sequence of Sasanlimab (PF-06801951; RN888) is shown in Table 4 below.
[0105] In a specific embodiment, the PD-1 binding antagonist is nivolumab. In another specific embodiment, the PD-1 binding antagonist is pembrolizumab. In another specific embodiment, the PD-1 binding antagonist is pidilizumab.
[0106] The term "PD-L1 binding antagonist" as used herein refers to a molecule that specifically binds to PD-L1 and reduces, blocks, inhibits, neutralizes or prevents signaling resulting from the interaction of PD-L1 with one or more of its binding partners, e.g., PD-1, B7-1. In some embodiments, a PD-L1 binding antagonist is a molecule that inhibits the binding of PD-L1 to its binding partners. In some aspects, a PD-L1 binding antagonist does not include avelumab. In a specific aspect, a PD-L1 binding antagonist inhibits the binding of PD-L1 to PD-1 and / or B7-1. In some embodiments, the PD-L1 binding antagonists include anti-PD-L1 antibodies, antigen-binding fragments thereof, immunoadhesins, fusion proteins, oligopeptides, and other molecules that reduce, block, inhibit, neutralize, or interfere with signaling resulting from the interaction of PD-L1 with one or more of its binding partners, e.g., PD-1, B7-1. In one embodiment, the PD-L1 binding antagonists reduce the negative co-stimulatory signal mediated by or through cell surface proteins expressed on T lymphocytes, which are mediated by signaling through PD-L1, such that dysfunctional T cells become less non-dysfunctional. In some embodiments, the PD-L1 binding antagonist is an anti-PD-L1 antibody. In a specific aspect, the anti-PD-L1 antibody is avelumab (disclosed as A09-246-2 in International Patent Application Publication No. WO2013 / 079174). In some embodiments, avelumab is not included as a PD-1 axis antagonist.
[0107] In another specific embodiment, the anti-PD-L1 antibody is atezolizumab.In another specific embodiment, the anti-PD-L1 antibody is durvalumab.In another specific embodiment, the anti-PD-L1 antibody is BMS-936559 (MDX-1105).
[0108] As used herein, an anti-human PD-L1 antibody refers to an antibody or portion thereof that specifically binds to mature human PD-L1, the mature human PD-L1 molecule consisting of amino acids 19 to 290 of the following sequence: MRIFAVFIFMTYWHLLNAFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNERTHLVILGAILLCLGVALTFIFRLRKGRMMDVKKCGIQDTNSKKQSDTHLEET (SEQ ID NO: 221)
[0109] [Table 5-1]
[0110] [Table 5-2]
[0111] The term "PD-L2 binding antagonist" as used herein refers to a molecule that specifically binds to PD-L2 and reduces, blocks, inhibits, neutralizes or prevents signaling resulting from the interaction of PD-L2 with any one or more of its binding partners, e.g., PD-1. In some embodiments, a PD-L2 binding antagonist is a molecule that inhibits the binding of PD-L2 to its binding partner. In a specific aspect, a PD-L2 binding antagonist inhibits the binding of PD-L2 to PD-1. In some embodiments, PD-L2 antagonists include anti-PD-L2 antibodies, antigen-binding fragments thereof, immunoadhesins, fusion proteins, oligopeptides and other molecules that specifically bind to PD-L2 and reduce, block, inhibit, neutralize or prevent signaling resulting from the interaction of PD-L2 with any one or more of its binding partners, e.g., PD-1. In one embodiment, the PD-L2 binding antagonist reduces the negative costimulatory signal mediated by or through a cell surface protein expressed on T lymphocytes, mediated through signaling through PD-L2, such that dysfunctional T cells become less non-dysfunctional. hi some embodiments, the PD-L2 binding antagonist is a PD-L2 immunoadhesin.
[0112] nucleic acid The invention also provides polynucleotides encoding any of the antibodies of the invention, including antibody portions and modified antibodies described herein. The invention also provides methods of making any of the polynucleotides described herein. Polynucleotides can be made and expressed by procedures known in the art.
[0113] The sequence of the desired antibody or antigen-binding fragment thereof and the nucleic acid encoding such an antibody or antigen-binding fragment thereof can be determined using standard sequencing techniques. The nucleic acid sequence encoding the desired antibody or antigen-binding fragment thereof can be inserted into various vectors (e.g., cloning and expression vectors) for recombinant production and characterization. The nucleic acid encoding the heavy chain or antigen-binding fragment of the heavy chain and the nucleic acid encoding the light chain or antigen-binding fragment of the light chain can be cloned into the same vector or different vectors.
[0114] In one aspect, the invention provides polynucleotides encoding the amino acid sequence of any of the following GDF15 antibodies and antigen-binding portions thereof: GDF15_001, GDF15_002, GDF15_003, GDF15_004, GDF15_005, GDF15_006, GDF15_007, GDF15_008, GDF15_009, GDF15_010, GDF15_011, GDF15_012, GDF1 5_013, GDF15_014, GDF15_015, GDF15_017, GDF15_018, GDF15_020, GDF15_021, GDF15_022, GDF15_100, GDF15_200, GDF15_297, GDF15_301, GDF15-470
[0115] The invention provides polynucleotides encoding one or more proteins comprising an amino acid sequence selected from the group consisting of: (i) SEQ ID NOs: 21, 34, 44, 53, 60, 68, 73, 80, 86, 93, 99, 106, 112, 120, 127, 136, 142, 148, 155, 161, 166, 11, 30, 39, 49, 56, 64, 71, 77, 83, 90, 96, 103, 109, 115, 123, 131, 139, 144, 151, 158, 163, 166, 183, 187, 189, 191, 193 and 195.
[0116] The present invention provides a polynucleotide comprising a nucleic acid sequence set forth as one or more of SEQ ID NO: 167, 168, 169 and 170. The present invention provides a polynucleotide comprising a nucleic acid sequence set forth as SEQ ID NO: 167. The present invention provides a polynucleotide comprising a nucleic acid sequence set forth as SEQ ID NO: 168. The present invention provides a polynucleotide comprising a nucleic acid sequence set forth as SEQ ID NO: 169. The present invention provides a polynucleotide comprising a nucleic acid sequence set forth as SEQ ID NO: 170. Due to the degeneracy of the genetic code, the present invention further provides a nucleic acid sequence in which the nucleotide at position number 1344 of SEQ ID NO: 170 can be A, C, G, T, and / or the nucleotide at position number 1347 can be A, C, G, T. The last two codons provided in SEQ ID NO: 170 still code for proline and glycine, respectively.
[0117] The present invention provides a polynucleotide comprising the nucleic acid sequence of the insert of a plasmid deposited with ATCC and having accession number PTA-125038, encoding the VH domain of GDF15_001. The present invention also provides a polynucleotide comprising the nucleic acid sequence of the insert of a plasmid deposited with ATCC and having accession number PTA-125039, encoding the VL domain of GDF15_001. In addition, the present invention provides a polypeptide comprising the amino acid sequence encoded by the DNA insert of a plasmid deposited with ATCC and having accession number PTA-125038, encoding the VH domain of GDF15_001. The present invention further provides a polypeptide comprising the amino acid sequence encoded by the insert of a plasmid deposited with ATCC and having accession number PTA-125039, encoding the VL domain of GDF15_001.
[0118] The present invention also provides a polynucleotide comprising the nucleic acid sequence of an insert of a plasmid deposited with the ATCC and having accession number PTA-125038, which encodes the VH domain of GDF15_001, and the nucleic acid sequence of an insert of a plasmid deposited with the ATCC and having accession number PTA-125039, which encodes the VL domain of GDF15_001.
[0119] In another aspect, the present invention provides polynucleotides encoding anti-GDF15 antibodies and variants thereof, such variant polynucleotides sharing at least 70%, at least 75%, at least 80%, at least 85%, at least 87%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% nucleic acid sequence identity to any of the nucleic acid sequences disclosed or referenced herein. These amounts are not meant to be limiting and increments between the recited percentages are specifically contemplated as part of this disclosure.
[0120] The present invention provides polypeptides encoded by the nucleic acid molecules described herein.
[0121] In one embodiment, the VH and VL domains or antigen-binding portions thereof, or the full-length HC or LC, are encoded by separate polynucleotides. Alternatively, the VH and VL or antigen-binding portions thereof, or the HC and LC, are both encoded by a single polynucleotide.
[0122] Polynucleotides complementary to any such sequences are also encompassed by the present disclosure.Polynucleotides can be single-stranded (coding or antisense) or double-stranded, and can be DNA (genomic, cDNA or synthetic) or RNA molecules.RNA molecules include HnRNA molecules, which contain introns and correspond to DNA molecules in a one-to-one manner, and mRNA molecules, which do not contain introns.Additional coding or non-coding sequences may, but need not, be present within the polynucleotides of the present disclosure, and polynucleotides may, but need not, be linked to other molecules and / or support materials.
[0123] The polynucleotide may comprise a nucleic acid sequence encoding an antibody or a portion thereof, or may comprise a variant of such a sequence. A polynucleotide variant comprises one or more substitutions, additions, deletions and / or insertions such that the binding characteristics of the encoded polypeptide are attenuated compared to a native antibody molecule. The effect on the binding characteristics of the polypeptide encoded by the variant nucleic acid sequence can generally be evaluated as described herein. In some embodiments, a polynucleotide variant exhibits at least about 70% identity, in some embodiments at least about 80% identity, in some embodiments at least about 90% identity, and in some embodiments at least about 95% identity to the polynucleotide sequence encoding the original (parent) antibody or a portion thereof that does not contain any substitutions, additions, deletions and / or insertions. These percent identities are not meant to be limiting, and increments between the recited percentages are specifically contemplated as part of this disclosure.
[0124] Two polynucleotide or polypeptide sequences are said to be "identical" if the sequences of nucleotides or amino acids in the two sequences are the same when aligned for maximum correspondence, as described below. Comparison between two sequences is typically performed by comparing the sequences over a comparison window to identify and compare local regions of sequence similarity. A "comparison window," as used herein, refers to a segment of at least about 20, usually 30 to about 75 or 40 to about 50 contiguous positions, where a sequence can be compared to a reference sequence for the same number of contiguous positions after optimally aligning the two sequences.
[0125] Optimal alignment of sequences for comparison can be performed using the MegAlign® program in the Lasergene® suite of bioinformatics software (DNASTAR®, Inc., Madison, WI) using default parameters. This program embodies several alignment schemes described in the following references: Dayhoff, MO, 1978, A model of evolutionary change in proteins-Matrices for detecting distant relationships., in Dayhoff, MO (ed.) Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, Washington DC, Vol. 5, Suppl. 3, pp. 345-358; Hein J., 1990, Unified Approach to Alignment and Phylogenes, pp. 626-645, Methods in Enzymology, Vol. 183, Academic Press, Inc., San Diego, CA; Higgins, DG and Sharp, PM, 1989, CABIOS 5:151-153; Myers, EW and Muller W., 1988, CABIOS 4:11~17; Robinson, ED, 1971, Comb. Theor. 11:105; Santou, N., Nes, M., 1987, Mol. Biol. Evol. 4:406~425; Sneath, PHA and Sokal, RR, 1973, Numerical Taxonomy the Principles and Practice of Numerical Taxonomy, Freeman Press, San Francisco, CA; Wilbur, WJ and Lipman, DJ, 1983, Proc. Natl. Acad. Sci. USA 80:726–730.
[0126] In some embodiments, the "percentage of sequence identity" is determined by comparing two optimally aligned sequences over a comparison window of at least 20 positions, where the portion of the polynucleotide or polypeptide sequence in the comparison window may contain no more than 20 percent, typically 5-15 percent or 10-12 percent, additions or deletions (i.e., gaps) compared to the reference sequence (which contains no additions or deletions) due to optimal alignment of the two sequences. The percentage is calculated by determining the number of positions where identical nucleic acid bases or amino acid residues are present in both sequences to obtain the number of matched positions, dividing the number of matched positions by the total number of positions in the reference sequence (i.e., the window size), and multiplying the result by 100 to obtain the percentage of sequence identity.
[0127] Polynucleotide variants may also, or alternatively, be substantially homologous to the gene, or a portion or complement thereof, such that they are capable of hybridizing under moderately stringent conditions to a naturally occurring DNA sequence encoding an antibody (or a complementary sequence).
[0128] Suitable "moderately stringent conditions" include a pre-wash in a solution of 5x SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); hybridization overnight in 5x SSC (0.75 M NaCl, 0.075 M sodium citrate) at about 50°C to 65°C; followed by two washes for 20 minutes each in 2x, 0.5x and 0.2x SSC containing 0.1% SDS at 65°C.
[0129] As used herein, "highly stringent conditions" or "high stringency conditions" are conditions that: (1) use low ionic strength and high temperature, e.g., 50°C, 0.015 M sodium chloride / 0.0015 M sodium citrate / 0.1% sodium dodecyl sulfate for washing; (2) use of a denaturing agent, e.g., formamide, e.g., 50% (v / v) formamide in 0.1% bovine serum albumin / 0.1% Ficoll / 0.1% polyvinyl chloride with 750 mM sodium chloride, 75 mM sodium citrate, during hybridization. or (3) 50% formamide, 5×SSC, 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5×Denhardt's solution, sonicated salmon sperm DNA (50 μg / mL), 0.1% SDS and 10% dextran sulfate at 42° C., with washes in 0.2×SSC (sodium chloride / sodium citrate) at 42° C. and 50% formamide at 55° C., followed by a high stringency wash consisting of 0.1×SSC with EDTA at 55° C. One of skill in the art will know how to adjust temperature, ionic strength, etc., as necessary to accommodate factors such as, for example, probe length.
[0130] It will be understood by those skilled in the art that, as a result of the degeneracy of the genetic code, there are many nucleotide sequences that code for the polypeptides described herein. Some of these polynucleotides bear minimal homology to the nucleotide sequence of any native gene. Nevertheless, polynucleotides that vary due to differences in codon usage are specifically contemplated by the present disclosure. Furthermore, alleles of genes that comprise the polynucleotide sequences provided herein are within the scope of the present disclosure. An allele is an endogenous gene that has been altered as a result of one or more mutations, such as deletions, additions, and / or substitutions, of nucleotides. The resulting mRNA and protein may, but need not, have an altered structure or function. Alleles can be identified using standard techniques (e.g., hybridization, amplification, and / or database sequence comparison).
[0131] The polynucleotide of the present disclosure can be obtained by chemical synthesis, recombinant method or PCR.The method of chemical polynucleotide synthesis is well known in the art and does not need to be described in detail herein.Those skilled in the art can use the sequence provided herein and commercially available DNA synthesizers to produce desired DNA sequence.
[0132] To prepare a polynucleotide using recombinant methods, a polynucleotide containing a desired sequence can be inserted into a suitable vector, which can then be introduced into a suitable host cell for replication and amplification, as further discussed herein. A polynucleotide can be inserted into a host cell by any means known in the art. A cell is transformed by introducing an exogenous polynucleotide by direct uptake, endocytosis, transfection, F-mating, or electroporation. Once introduced, the exogenous polynucleotide can be maintained in the cell as a non-integrated vector (e.g., a plasmid) or can be integrated into the host cell genome. The polynucleotide thus amplified can be isolated from the host cell by methods well known in the art. See, for example, Sambrook et al., 1989.
[0133] Alternatively, PCR allows the reproduction of DNA sequences. PCR technology is well known in the art and is described in U.S. Patent Nos. 4,683,195, 4,800,159, 4,754,065 and 4,683,202, and PCR: The Polymerase Chain Reaction, edited by Mullis et al., Birkauswer Press, Boston, 1994.
[0134] RNA can be obtained by using the isolated DNA in a suitable vector and inserting it into a suitable host cell. When the cell replicates and the DNA is transcribed into RNA, the RNA can be isolated using methods well known to those skilled in the art, for example, as shown in Sambrook et al., 1989.
[0135] As used herein, "vector" refers to a construct that can deliver one or more genes or sequences of interest into host cell, and preferably express them in host cell.Examples of vectors include, but are not limited to, virus vectors, naked DNA or RNA expression vectors, plasmids, cosmids or phage vectors, DNA or RNA expression vectors associated with cationic condensing agents, DNA or RNA expression vectors encapsulated in liposomes, and certain eukaryotic cells, such as production cells.
[0136] Suitable cloning and expression vectors may contain various components, such as promoters, enhancers and other transcriptional regulatory sequences. Vectors may also be constructed to allow for the subsequent cloning of antibody variable domains into different vectors. Suitable cloning vectors may be constructed according to standard techniques or may be selected from a large number of cloning vectors available in the art. The cloning vector selected may vary according to the host cell intended for use, but useful cloning vectors will generally have the ability to replicate autonomously, may carry a single target for a particular restriction endonuclease, and / or may carry a marker gene that can be used in selecting clones containing the vector. Suitable examples include plasmids and bacterial viruses, such as pUC18, pUC19, Bluescript (e.g., pBS SK+) and its derivatives, mp18, mp19, pBR322, pMB9, ColE1, pCR1, RP4, phage DNA, and shuttle vectors, such as pSA3 and pAT28. These and many other cloning vectors are available from suppliers such as BioRad, Strategene and Invitrogen. Expression vectors are further provided. Expression vectors are generally replicable polynucleotide constructs that contain a polynucleotide according to the present disclosure. It is implied that expression vectors must be replicable in host cells, either as episomes or as an integral part of chromosomal DNA. Suitable expression vectors include, but are not limited to, plasmids, viral vectors including adenoviruses, adeno-associated viruses, retroviruses, cosmids, and the expression vectors disclosed in PCT Publication No. WO87 / 04462. Vector components may generally include, but are not limited to, one or more of the following: signal sequence; origin of replication; one or more marker genes; appropriate transcription control elements (e.g., promoters, enhancers and terminators). For expression (i.e., translation), one or more translation control elements are also usually required, such as ribosome binding sites, translation initiation sites and stop codons.
[0137] The vector containing the polynucleotide of interest and / or the polynucleotide itself can be introduced into the host cell by any of several suitable means, including transfection using electroporation, calcium chloride, rubidium chloride, calcium phosphate, DEAE-dextran, or other substances; particle bombardment; lipofection; and infection (e.g., when the vector is an infectious agent such as vaccinia virus). The choice of introducing the vector or polynucleotide often depends on the characteristics of the host cell.
[0138] Thus, a "host cell" includes an individual cell or cell culture that can be or has been a recipient of a polynucleotide and / or a vector containing a polynucleotide, for incorporation of the polynucleotide and / or vector. A host cell includes the progeny of a single host cell, which may not necessarily be completely identical (in morphology or genomic DNA complement) to the original parent cell due to natural, accidental or deliberate mutation. A host cell includes cells that have been transfected and / or transformed in vivo with a polynucleotide of the invention.
[0139] The antibody or antigen-binding fragment thereof can be produced recombinantly using a suitable host cell. The nucleic acid encoding the antibody or antigen-binding fragment thereof can be cloned into an expression vector, which can then be introduced into a host cell that does not otherwise produce immunoglobulin proteins, such as Escherichia coli (E. coli) cells, yeast cells, insect cells, monkey COS cells, Chinese hamster ovary (CHO) cells or myeloma cells, to obtain the synthesis of the antibody in the recombinant host cell. Preferred host cells include CHO cells, human embryonic kidney (HEK) 293 cells, NS0 cells or Sp2.0 cells, among many other cells well known in the art. Antibody fragments can be produced by proteolytic or other degradation of full-length antibodies, by recombinant methods, or by chemical synthesis. Polypeptide fragments of antibodies, especially shorter polypeptides of up to about 50 amino acids, can be conveniently produced by chemical synthesis. Methods of chemical synthesis for proteins and peptides are known in the art and are commercially available.
[0140] The antibody or antigen-binding fragment of the present invention can be affinity matured.For example, affinity matured antibody can be produced by procedures known in the art (Marks et al., 1992, Bio / Technology, 10:779-783; Barbas et al., 1994, Proc Nat.Acad.Sci, USA 91:3809-3813; Schier et al., 1995, Gene, 169:147-155; Yelton et al., 1995, J.Immunol., 155:1994-2004; Jackson et al., 1995, J.Immunol., 154(7):3310-9; Hawkins et al., 1992, J.Mol.Biol., 226:889-896; and WO2004 / 058184).
[0141] immunogenicity Immunogenicity is a major barrier to the development and utilization of protein therapeutics, including antibodies and Fc fusion proteins. Several factors can contribute to protein immunogenicity, including but not limited to protein sequence, route and frequency of administration, and patient population. Although immune responses are typically most vigorous against non-human proteins, such as mouse antibodies, even therapeutics with predominantly or entirely human sequence content can be immunogenic. Immunogenicity is a complex set of responses to substances perceived as foreign, which can include the production of neutralizing and non-neutralizing antibodies, immune complex formation, complement activation, mast cell activation, inflammation, and anaphylaxis. Unwanted immune responses can reduce the efficacy of antibody and Fc fusion protein therapeutics by directly interfering with antigen recognition, altering interactions with effector molecules, or perturbing the serum half-life or tissue distribution of the therapeutic.
[0142] Protein therapeutics can be analyzed to predict the presence of potential immunogenic epitopes using commercially available services such as those provided by Epivax, Inc. of Providence, RI. In some embodiments, in silico algorithms can predict epitopes that bind to class II MHC molecules. Analysis of a data set of polypeptides with such algorithms provides predicted epitopes. The predicted epitopes are used to generate peptides that are prepared by standard methods of automated peptide synthesis or recombinant DNA technology. Scoring information provided by Epivax can provide an indication of how widespread the recognized predicted epitopes are in a population.
[0143] As described in Example 10 below, the antibodies of the present invention were screened for the presence of epitopes recognized by T cells, also referred to herein as T cell epitopes, "T-regitopes" or "tRegs," using the EpiMatrix algorithm developed by EpiVax. The antibody sequence was parsed into overlapping 9-mer frames, each frame overlapping at the end by 8 amino acids. Each of the resulting frames was then cloned to match eight common MHC class II HLA alleles (DRB1 * 0101, DRB1 * 0301, DRB1 * 0401, DRB1 * 0701, DRB1 * 0801, DRB1 * 1101, DRB1 * 1301 and DRB1 * Each peptide is scored for predicted binding affinity against a panel of 1501 peptides. Raw scores are normalized against the scores of a larger sample of randomly generated peptides, and the resulting "Z" score is reported.
[0144] The tReg adjusted score, which is the overall sequence score, can be calculated using EpiMatrix Z score to predict the immunogenicity of an antibody. As described in Example 10, the tReg adjusted score is calculated by summing the EpiMatrix Z scores of the 9-mer frame (intermediate sum) and noting the number of HLA type observations. Every individual combination of 9-mer and HLA type ("observation") is tested, regardless of whether the 9-mer is an epitope. If a particular observation indicates that the peptide is in the top 5% of binding partners for a given HLA type, the EpiMatrix Z score for this observation is added to the intermediate sum associated with the entire protein sequence. The total number of observations tested is also recorded. The only exception is that all observations for 9-mers identified as "T-resitopes" by the ISPRI software package developed by EpiVax are assumed to have an EpiMatrix score of zero. As used herein, a "T-resitope" is an amino acid sequence within a monoclonal antibody framework region that can potentially activate natural regulatory T cells and reduce unwanted immune responses. The tReg-adjusted score is calculated as follows: tReg-adjusted score = (intermediate sum) * 1000 / (number of observations). For the intermediate total, 0.05 * A baseline score of 2.2248 is subtracted from each observation (including the T-resitope). Lower tReg adjusted scores predict lower potential immunogenicity risk.
[0145] use Methods for treating primary mitochondrial myopathy In some aspects, the disclosure relates to a method for preventing, ameliorating, and / or treating a primary mitochondrial myopathy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a GDF15 antibody (e.g., a GDF15 antibody described herein).
[0146] Primary mitochondrial myopathies (PMM) are a group of genetic disorders associated with alterations (e.g., but not limited to, depletions, deletions, or mutations) found in mitochondrial DNA (mtDNA) or in genes outside of mitochondria (nuclear DNA) that predominantly affect skeletal muscles. Mitochondria are found in all cells of the body. Mitochondria are responsible for regulating the production of cellular energy and carry the genetic blueprint for this process in their own unique DNA (mtDNA). PMM often impedes the ability of affected cells to break down food and oxygen and produce energy. Mitochondria provide more than 90% of the energy used by the body's tissues; mitochondrial disorders are characterized by a lack of sufficient energy for the body's cells to function properly. Thus, tissues with high energy demands, such as muscle, brain, or heart tissue, are most likely to be affected by mitochondrial disorders. Mitochondrial diseases can affect more than one organ system of the body. However, many mitochondrial diseases primarily affect muscle (myosopathy), where muscle disease is the sole or predominant manifestation of the mitochondrial disorder and is therefore defined as PMM. There are no disease-modifying treatments for PMM; treatments are aimed at improving or eliminating specific symptoms (Primary Mitochondrial Myopathies - NORD (National Organization for Rare Disorders) (rarediseases.org)).
[0147] As used herein, the term primary mitochondrial myopathies includes, but is not limited to, Leigh syndrome, Kearns-Sayre syndrome, Alpers-Huttenlocher syndrome, mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) and ataxic neuropathy syndrome.
[0148] In some aspects, the present disclosure provides a method for treating primary mitochondrial myopathy (PMM) in a subject in need thereof. These methods include administering an anti-GDF15 antibody or an antigen-binding fragment thereof, and the administration of the anti-GDF15 antibody or an antigen-binding fragment thereof results in the improvement of one or more signs or symptoms of PMM. The main signs or symptoms of PMM include, but are not limited to, physical fatigue, muscle weakness, and exercise tolerance. Muscle weakness can occur in the muscles that control eye and eyelid movement, resulting in a gradual paralysis of eye movement, called progressive external ophthalmoplegia (PEO), and drooping of the upper eyelid, called ptosis. Muscle weakness and wasting can also occur in other muscles of the face, neck, and arms. Exercise tolerance, also called exertional fatigue, refers to the unusual feeling of exhaustion brought about by physical exertion, such as exercise, such as jogging, or even everyday activities, such as walking or lifting milk cartons.
[0149] In some embodiments, administration of an anti-GDF15 antibody or antigen-binding fragment thereof results in (but is not limited to) increased weight gain, increased lean muscle mass, increased skeletal muscle mass, restored muscle strength, and / or improvement in athletic performance compared to before administration. The improvement can be at least 0.5%, at least 1%, at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 100%.
[0150] In some embodiments, the subject has elevated levels of GDF15. In some embodiments, the level of GDF15 is > 2000 ng / L. In some embodiments, the subject has abnormal levels of one or more energy biomarkers compared to control subjects. Energy biomarkers include lactate (lactate) levels; pyruvate (pyruvate) levels; lactate / pyruvate ratio; creatine phosphate levels; NADH (NADH+H + ) or NADPH (NADPH + H +) levels; NAD or NADP levels; ATP levels; reduced coenzyme Q (CoQ red ) levels; oxidized coenzyme Q (CoQ ox ) levels; total coenzyme Q (CoQ tot ) levels; oxidized cytochrome C levels; reduced cytochrome C levels; oxidized cytochrome C / reduced cytochrome C ratio; acetoacetate levels; beta-hydroxybutyrate levels; acetoacetate / beta-hydroxybutyrate ratio; 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels; levels of reactive oxygen species; oxygen consumption (VO2), carbon dioxide output (VCO2) and respiratory quotient (VCO2 / VO2).
[0151] In some embodiments, the subject does not have cachexia. In some embodiments, the subject does not have cancer. In some embodiments, the subject does not have heart failure. In some embodiments, the subject has cachexia but has not received anti-GDF15 therapy. In some embodiments, the subject has cancer but has not received anti-GDF15 therapy. In some embodiments, the subject has heart failure but has not received anti-GDF15 therapy.
[0152] The term "treatment" or "treated" includes prophylactic (i.e., preventative) and / or therapeutic treatment. A treatment is considered prophylactic if administered prior to clinical observation of a condition. Therapeutic treatment includes, for example, ameliorating or reducing the severity of a disease or shortening the length of a disease.
[0153] The methods disclosed herein include administering any anti-GDF15 antibody or antigen-binding fragment thereof. Examples of anti-GDF15 antibodies are known in the art (see, for example, WO14100689, WO2015 / 196142 and WO2020 / 039321). In some embodiments, the methods disclosed herein include administering GDF15_001 (including HCDR-1: SEQ ID NO: 32, HCDR-2: SEQ ID NO: 165, HCDR-3: SEQ ID NO: 52, LCDR-1: SEQ ID NO: 95, LCDR-2: SEQ ID NO: 28, LCDR-3: SEQ ID NO: 9) or GDF15_0301 (including HCDR-1: SEQ ID NO: 179, HCDR-2: SEQ ID NO: 180, HCDR-3: SEQ ID NO: 181, LCDR-1: SEQ ID NO: 184, LCDR-2: SEQ ID NO: 185, LCDR-3: SEQ ID NO: 186).
[0154] Methods for Treating Heart Failure In some aspects, the present disclosure provides a method for treating cardiac disorder or dysfunction in a subject in need thereof. In some aspects, the present disclosure provides a method for treating heart failure (e.g., heart failure with reduced ejection fraction (HFrEF)) in a subject in need thereof. These methods include administering a therapeutically effective amount of an anti-GDF15 antibody (e.g., but not limited to, the antibody disclosed herein) or an antigen-binding fragment thereof to ameliorate one or more signs or symptoms of HFrEF.
[0155] HFrEF is a clinical syndrome in which diseased myocardium with impaired contractile function results in dyspnea or exertional limitations, thereby limiting the patient's ability to perform activities of daily living. Based on data collected from the National Health and Nutrition Examination Survey from 2013 to 2016, an estimated 6.2 million American adults have heart failure, and its prevalence is expected to increase to more than 8 million adults by 2030; 50% of adults with heart failure have HFrEF. It is generally a chronic, progressive condition that can be stabilized with medications and / or therapeutic devices, or, in suitable candidates, treated by heart transplantation. The primary goals of heart failure care are prevention of disease progression, remission of symptoms, and prevention of cardiovascular mortality.
[0156] Circulating GDF-15 concentrations have been identified as a prognostic biomarker for cardiovascular morbidity and mortality, particularly in populations with HFrEF. In patients with HFrEF, circulating GDF-15 levels are also inversely correlated with body mass index and highly associated with HF symptom severity, functional status and exercise capacity. Furthermore, elevated GDF-15 levels predict increased risk of death and adverse heart failure events in patients with HFrEF.
[0157] The subject has heart failure classified as II-IV based on the New York Heart Association (NYHA) functional classification. In some embodiments, the subject has elevated GDF15 levels in bodily fluids (e.g., serum). In some embodiments, the subject's serum GDF15 level is ≧2000 pg / mL. In some embodiments, the subject exhibits a left ventricular ejection fraction (LVEF) less than / equal to 40%. In some embodiments, the subject exhibits an LVEF of less than 50% at the most recent measurement (e.g., within the last 12 months). In some embodiments, the subject exhibits a peak VO2 of less than 14 mL / kg / min. In some embodiments, the subject exhibits an N-terminal pro b-type natriuretic peptide (NT-proBNP) level equal to or greater than 400 pg / mL. In some embodiments, the subject exhibits a BNP level greater than 100 g / ml. In some embodiments, the subject exhibits a serum cardiac troponin I (cTnl) level greater than 1.5 ng / mL.
[0158] In some embodiments, the subject exhibits evidence of cachexia or fatigue or functional impairment as demonstrated by at least one of the following: Non-edematous involuntary weight loss ≥ 5% in the last 6 months associated with subjective fatigue or anorexia, or current BMI < 20 kg / m 2 ;or b. Fatigue at least three times per week and at least moderately bothersome fatigue in the past 2 weeks; or c. A score of <60 on the Physical Limitations Domain of the KCCQ 23 administered at screening.
[0159] In some embodiments, the subject has a Kansas City Cardiomyopathy Questionnaire (KCCQ)-Clinical Summary Score (CSS) of less than 75. The KCCQ is a self-administered questionnaire that quantifies physical limitations, symptoms, self-efficacy, social interference and quality of life for participants with congestive heart failure (Microsoft Word - Q160011 Qualification Summary_FINAL.docx (fda.gov)). The KCCQ is sensitive to clinical change, is a straightforward instrument for participants to complete, and reduces burden compared to other patient-reported outcomes (PROs). The benefits and importance of functional status and PRO data are recognized as important clinical endpoints in CHF research.
[0160] In some embodiments, the subject exhibits evidence of cachexia, fatigue, or functional impairment, as demonstrated by at least one of the following: (i) non-edematous involuntary weight loss ≧5% in 12 months associated with subjective fatigue or anorexia, or a BMI<20 kg / m 2 (ii) fatigue at least 3 times per week and at least moderately bothersome fatigue in the past 2 weeks, and (iii) a score of <60 on the Physical Limitations Domain of the KCCQ-23 administered at the screening visit.
[0161] Administration of an anti-GDF15 antibody or antigen-binding fragment thereof ameliorates one or more signs or symptoms of HFrEF. These include, but are not limited to, physical fatigue / tiredness, shortness of breath, paroxysmal nocturnal dyspnea, edema / swelling, weight loss, and physical activity limitations (e.g., difficulty walking, measured by, for example, the 6-minute walk test, reduced physical strength). In some embodiments, the amelioration of one or more signs or symptoms of HFrEF is measured as a change from baseline (i.e., before administration) in one or more PROs. Examples of PROs include, but are not limited to, KCCQ-23, Patient Global Impression of Severity (PGI-S), Fatigue Severity Daily Diary, PROMIS-Fatigue 7a (revised "past 7 days"), Patient Global Impression of Change (PGI-C), and / or Appetite Assessment.
[0162] The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a self-reported 23-item questionnaire that assesses HRQL in participants with heart failure. Items assess physical limitations, symptoms (frequency, severity, and recent change over time), QoL, social interference, and self-efficacy. Response options vary by question. Within the KCCQ there are 10 summary scores: physical limitations, symptom stability, symptom frequency, symptom burden, total symptom score, self-efficacy, quality of life, social limitations, global summary score, and clinical summary score. Raw summary scores are converted to a scale of 0 to 100, with higher scores indicating better health status.
[0163] Fatigue Severity Daily Diary: The Fatigue Severity Daily Diary is a daily self-report questionnaire that measures fatigue severity. It was developed based on qualitative studies with patients and a review of the literature and other existing relevant scales. The scale consists of a single question that asks study participants to rate the severity of their fatigue over the past 24 hours on an 11-point NRS ranging from 0 - "no fatigue" to 10 - "worst fatigue."
[0164] Appetite Assessment: The Appetite Assessment is a self-report questionnaire that measures the severity of anorexia. It was developed based on qualitative studies with patients and a review of the literature and other existing relevant scales. The scale consists of one question that asks study participants to rate their appetite over the past 7 days on an 11-point NRS ranging from 0 - "no appetite" to 10 - "very good appetite."
[0165] PROMIS Fatigue (Version 7a): PROMIS Fatigue 7a is a self-report measure that assesses symptoms ranging from a mild subjective feeling of tiredness over the past 7 days to an overwhelming, debilitating, and persistent sense of exhaustion that is likely to reduce a person's ability to carry out daily activities and function normally in family or social roles.
[0166] The short-form 7A consists of seven items that study participants rate from 1: “never” to 5: “always.” An overall raw score ranging from 7 to 35 was calculated and can be converted to a T-score (mean = 50, SD = 10) using the applicable score conversion table provided in the PROMIS User's Manual.
[0167] Patient's Global Impression of Severity (PGI-S): The PGI-S is a three-question scale that asks study participants to rate the severity of their fatigue, symptoms attributable to heart failure, and daily activity limitations over the past 14 days on a five-point verbal response scale ranging from "none" to "very severe." The PGI-S has been recommended by the FDA for use as an anchor measure to generate appropriate thresholds that indicate meaningful intraindividual change in the target patient population.
[0168] Patient's Global Impression of Change (PGI-C): The PGI-C is a three-question measure that asks study participants to rate the overall change in their fatigue, symptoms attributable to heart failure, and ability to perform daily activities on a five-point verbal rating scale ranging from "much better" to "much worse." The PGI-C has been recommended by the FDA for use as an anchor measure to generate appropriate thresholds that indicate meaningful intraindividual change in target patient populations.
[0169] 6-Minute Walk Test (6MWT) The 6MWT is a submaximal exercise test that involves measuring the distance walked over a 6-minute period. The 6MWD (distance traveled in meters) provides a measure of the integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise. The Borg Fatigue Scale, which assesses shortness of breath and fatigue severity, can be administered before and after the walking distance assessment as part of the 6MWT.
[0170] In some embodiments, administration of an anti-GDF15 antibody results in a change from baseline in KCCQ-CSS (e.g., 1 day, 2 days, 4 days, 1 week, 5 weeks, 7 weeks, 10 weeks, 15 weeks, 20 weeks, 21 weeks, 22 weeks, or 25 weeks after administration). In some embodiments, administration of an anti-GDF15 antibody results in a change from baseline in KCCQ-CSS, overall summary score (OSS), total symptom score (TSS), and / or physical limitations. In some embodiments, administration of an anti-GDF15 antibody results in an increase in one or more PROs of at least 5 points from baseline (i.e., before administration). In some embodiments, administration of an anti-GDF15 antibody results in an increase in KCCQ-CSS of at least 5 points from baseline (i.e., before administration). In some embodiments, administration of an anti-GDF15 antibody results in an increase in KCCQ-CSS of at least 5 points from baseline (i.e., before administration). In some embodiments, administration of an anti-GDF15 antibody results in a change from baseline in 6MWD.
[0171] The methods disclosed herein include administering any anti-GDF15 antibody or antigen-binding fragment thereof. Examples of anti-GDF15 antibodies are known in the art (see, for example, WO14100689, WO2015 / 196142 and WO2020 / 039321). In some embodiments, the methods disclosed herein include administering GDF15_001 (including HCDR-1: SEQ ID NO: 32, HCDR-2: SEQ ID NO: 165, HCDR-3: SEQ ID NO: 52, LCDR-1: SEQ ID NO: 95, LCDR-2: SEQ ID NO: 28, LCDR-3: SEQ ID NO: 9) or GDF15_0301 (including HCDR-1: SEQ ID NO: 179, HCDR-2: SEQ ID NO: 180, HCDR-3: SEQ ID NO: 181, LCDR-1: SEQ ID NO: 184, LCDR-2: SEQ ID NO: 185, LCDR-3: SEQ ID NO: 186).
[0172] The present disclosure provides a method for treating heart failure with reduced ejection fraction in a subject in need thereof, comprising administering a therapeutically effective amount of an anti-GDF15 antibody or antigen-binding fragment thereof, wherein the subject has an LVEF less than / equal to 40%, a serum GDF15 level greater than / equal to 2000 ng / L, a KCCQ-CSS less than 75, and shows evidence of cachexia, fatigue, or functional impairment; administration of the anti-GDF15 antibody results in a change (e.g., an increase of at least 5 points) from baseline (i.e., pre-administration) in KCCQ-CSS compared to post-administration, and the anti-GDF15 antibody is (a) LCDR-1 comprising the amino acid sequence of SEQ ID NO: 95; (b) LCDR-2 comprising the amino acid sequence of SEQ ID NO: 28; (c) LCDR-3 comprising the amino acid sequence of SEQ ID NO:9; (d) HCDR-1 comprising the amino acid sequence of SEQ ID NO: 32; (e) HCDR-2 comprising the amino acid sequence of SEQ ID NO: 165; and (f) HCDR-3 comprising the aa sequence of SEQ ID NO: 52 Includes.
[0173] In some embodiments, the anti-GDF15 antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 166 and a VL comprising the amino acid sequence of SEQ ID NO: 163. In some embodiments, the antibody comprises a HC comprising the amino acid sequence of SEQ ID NO: 164 and a LC comprising the amino acid sequence of SEQ ID NO: 162. In some embodiments, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, or 500 mg of an anti-GDF15 antibody (e.g., GDF15_001) is administered subcutaneously every 4 weeks. In some embodiments, 100 mg, 200 mg, or 300 mg of an anti-GDF15 antibody (e.g., GDF15_001) is administered subcutaneously every 4 weeks. In some embodiments, 300 mg of an anti-GDF15 antibody is administered every 4 weeks.
[0174] Diagnostic methods The anti-GDF15 antibodies, antibody compositions and methods of the present disclosure have in vitro and in vivo utility, including immunoassays and uses for the diagnosis of primary mitochondrial myopathy and the evaluation of its treatment. These methods include a method for detecting the presence of GDF15 in a sample, which comprises contacting a sample suspected of containing GDF15 with an antibody specific to GDF15 and detecting the presence of GDF15 bound to the antibody, thereby detecting GDF15 in the sample. Methods for detecting GDF15 bound to an antibody are well known in the art, including, but not limited to, an assay in which GDF15 is bound to a solid support and a sample is added thereto, allowing the antibody to bind to GDF15 in the sample. A second GDF15 antibody, which is the same as or different from the antibody bound to the solid support, is added and can be detected by direct labeling (i.e., the second antibody is conjugated to a detectable label) or by adding a third antibody from another species, which reacts with the constant domain of the second antibody and contains a detectable label, for example. Thus, the assay can be used to detect the presence or absence of GDF15 in a sample from a subject with PMM.
[0175] In another embodiment, the invention includes a kit for detecting the presence of GDF15 in a sample from a subject with PMM, comprising an antibody specific for GDF15, an applicator, and instructional materials for their use.
[0176] The present invention also provides a method for determining the concentration of GDF15 in a sample from a subject with PMM, comprising the steps of: providing a labeled competitor comprising GDF15 coupled to a detectable label; providing an antibody or antigen-binding fragment thereof that specifically binds to GDF15; combining the sample, the antibody and the labeled competitor, wherein the GDF15 in the sample competes with the labeled competitor for binding to the antibody; and determining the concentration of GDF15 in the sample by measuring the amount of labeled competitor that is not bound to the antibody by detecting the label. The amount of labeled competitor that is bound to the antibody in the absence of sample is compared with the amount of labeled competitor that is bound to the antibody when the sample is added. The amount of reduction of the bound labeled competitor in the presence of sample is an indication of the amount of unlabeled GDF15 present in the sample, and thus this assay can be used to evaluate the presence and level of GDF15 in a sample from a subject with PMM.
[0177] In one embodiment, the invention provides a method for assessing the effectiveness of a treatment for a disease or disorder associated with increased levels of GDF15 in a subject with PMM, comprising administering the treatment to the subject and comparing the level of GDF15 in a sample obtained from the subject before the treatment with the level of GDF15 in an otherwise identical sample obtained from the subject after the treatment, wherein the level of GDF15 in the sample is assessed using a GDF15-specific antibody, and further wherein a lower level of GDF15 in the sample collected from the subject after the treatment compared to the level of GDF15 in the sample collected from the subject before the treatment is an indication of the effectiveness of the course of treatment.
[0178] With respect to GDF15-specific antibody or labeled competitor, the term "labeled" includes direct labeling by coupling (i.e., physically linking) a detectable substance to the antibody or labeled competitor, as well as indirect labeling of the antibody or labeled competitor by coupling it to another reagent that is directly labeled. One example of indirect labeling includes the detection of a primary antibody using a fluorescently labeled secondary antibody. In vitro techniques for detecting the polypeptide of the present invention include enzyme-linked immunosorbent assay (ELISA), Western blot, immunoprecipitation and immunofluorescence.
[0179] The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject with PMM.
[0180] The antibodies, labeled competitors, and potential therapeutic compounds described herein are also suitable for use with any of a number of other homogeneous and heterogeneous immunoassays using a variety of detection systems.
[0181] composition The GDF15 antibody of the present invention may be formulated as a pharmaceutical composition. The pharmaceutical composition may further comprise a pharma- ceutically acceptable carrier, excipient and / or stabilizer (Remington: The Science and practice of Pharmacy, 21st ed., 2005, Lippincott Williams and Wilkins, ed. KE Hoover) in the form of a lyophilized formulation or an aqueous solution. Acceptable carriers, excipients or stabilizers are non-toxic to recipients at dosages and concentrations, and include buffers, such as phosphate, citric acid and other organic acids; antioxidants, including ascorbic acid and methionine; preservatives (e.g., octadecyldimethylbenzyl ammonium chloride); chloride); hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens, such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers, such as polyvinylpyrrolidone; amino acids, such as glycine, glutamine, asparagine, histidine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates, including glucose, mannose or dextran; chelating agents, such as EDTA; sugars, such as sucrose, mannitol, trehalose or sorbitol; salt-forming counterions, such as sodium; metal complexes (e.g., Zn-protein complexes); and / or non-ionic surfactants, such as TWEEN™, PLURONICS™ or polyethylene glycol (PEG). Pharmaceutically acceptable excipients are further described herein.
[0182] The pharmaceutical composition of the present disclosure may further comprise a PD-1 axis antagonist as described herein and a GDF15 inhibitor as described herein. In one embodiment, the GDF15 inhibitor is an anti-GDF15 antibody GDF15_001 or GDF15_297, and the PD-1 axis antagonist is optionally selected from the group consisting of avelumab, PF-06801591 (also known as "sasanlimab" and "RN-888" and mAb7, all of which are disclosed in WO2016 / 092419), nivolumab, pembrolizumab, atezolizumab and durvalumab. In one embodiment, the PD-1 axis antagonist does not include avelumab.
[0183] The pharmaceutical compounds of the present disclosure may include one or more pharma- ceutically acceptable salts. Examples of such salts include acid addition salts and base addition salts. Acid addition salts include those derived from non-toxic inorganic acids, such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, phosphorous acid, and the like, and those derived from non-toxic organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic acids, aromatic acids, aliphatic and aromatic sulfonic acids, and the like. Base addition salts include those derived from alkaline earth metals, such as sodium, potassium, magnesium, calcium, and the like, and those derived from non-toxic organic amines, such as N,N'-dibenzylethylenediamine, N-methylglucamine, chloroprocaine, choline, diethanolamine, ethylenediamine, procaine, and the like.
[0184] The pharmaceutical composition of the present disclosure may also contain a pharma- ceutically acceptable antioxidant. Examples of pharma-ceutically acceptable antioxidants include: (1) water-soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, etc.; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, etc.; and (3) metal chelating agents, such as citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, etc.
[0185] Examples of suitable aqueous and non-aqueous carriers that can be used in the pharmaceutical compositions of the present disclosure include water, ethanol, polyol (e.g., glycerol, propylene glycol, polyethylene glycol, etc.) and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.Proper fluidity can be maintained, for example, by using coating materials such as lecithin, by maintaining the required particle size in the case of dispersion, and by using surfactants.
[0186] These compositions may also contain adjuvants, such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the presence of microorganisms can be ensured by both sterilization procedures and the inclusion of various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol sorbic acid, etc. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, etc., in the composition. In addition, prolonged absorption of injectable pharmaceutical forms can be brought about by including agents that delay absorption, such as aluminum monostearate and gelatin.
[0187] Pharmaceutical compositions must typically be sterile and stable under the conditions of manufacture and storage. The compositions can be formulated as solutions, microemulsions, liposomes or other ordered structures suitable for high drug concentrations. The carrier can be a solvent or dispersion medium, including, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like) and suitable mixtures thereof. Proper fluidity can be maintained, for example, by the use of coatings, such as lecithin, by maintaining the required particle size in the case of dispersions, and by the use of surfactants. In many cases, it is appropriate to include isotonic agents, such as sugars, polyalcohols, such as mannitol, sorbitol, or sodium chloride, in the composition. Prolonged absorption of injectable compositions can be brought about by including in the composition agents that delay absorption, such as monostearate salts and gelatin.
[0188] Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in the appropriate solvent with one or a combination of ingredients enumerated above, followed by sterilization microfiltration, as required.
[0189] Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred method of preparation is vacuum drying and freeze-drying (lyophilization) which yields a powder of the active ingredient plus any additional desired ingredients from its previously sterile-filtered solution.
[0190] A pharmaceutical composition of the disclosure may be prepared, packaged, or sold in a formulation suitable for ophthalmic administration. Such a formulation may be in the form of, for example, eye drops comprising, for example, a 0.1% to 1.0% (w / w) solution or suspension of the active ingredient in an aqueous or oily liquid carrier. Such eye drops may further comprise a buffer, salt, or one or more other of the additional ingredients described herein. Other ophthalmically administrable formulations that are useful include those comprising the active ingredient in microcrystalline form or in a liposomal preparation.
[0191] As used herein, "additional components" include, but are not limited to, one or more of the following: excipients; surface active agents; dispersing agents; inert diluents; granulating and disintegrating agents; binders; lubricants; sweeteners; flavoring agents; coloring agents; preservatives; physiologically degradable compositions, such as gelatin; aqueous vehicles and solvents; oily vehicles and solvents; suspending agents; dispersing or wetting agents; emulsifying agents, demulsifying agents; buffers; salts; thickening agents; fillers; emulsifiers; antioxidants; antibiotics; antifungal agents; stabilizers; and pharmaceutically acceptable polymeric or hydrophobic materials. Other "additional components" that can be included in the pharmaceutical compositions of the present disclosure are known in the art and are described, for example, in Remington's Pharmaceutical Sciences, edited by Genaro, Mack Publishing Co., Easton, PA (1985), which is incorporated herein by reference.
[0192] In one embodiment, the GDF15 antibody or antigen-binding portion thereof is administered in an intravenous formulation as a sterile aqueous solution containing 5 mg / mL, or in some embodiments, about 10 mg / mL, or in some embodiments, about 15 mg / mL, or in some embodiments, about 20 mg / mL of antibody, or in some embodiments, about 25 mg / mL, or in some embodiments, about 50 mg / mL, with sodium acetate, polysorbate 80, and sodium chloride at a pH ranging from about 5 to 6. In some embodiments, the intravenous formulation is a sterile aqueous solution containing 5 or 10 mg / mL of antibody, with 20 mM sodium acetate, 0.2 mg / mL polysorbate 80, and 140 mM sodium chloride at a pH of 5.5. Additionally, the solution containing the antibody or antigen-binding portion thereof may contain histidine, mannitol, sucrose, trehalose, glycine, poly(ethylene) glycol, EDTA, methionine, and any combination thereof, among many other compounds, as well as many other compounds known in the art.
[0193] In one embodiment, the pharmaceutical composition of the present disclosure comprises the following components: 50 mg / mL of the GDF15 antibody or antigen-binding portion of the present disclosure, 20 mM histidine, 8.5% sucrose, and 0.02% polysorbate 80, 0.005% EDTA at pH 5.8; in another embodiment, the pharmaceutical composition of the present disclosure comprises the following components: 100 mg / mL of the GDF15 antibody or antigen-binding portion of the present disclosure, 10 mM histidine, 5% sucrose, and 0.01% polysorbate 80 at pH 5.8. The composition can be provided as a liquid formulation or as a lyophilized powder. When the powder is reconstituted at its maximum volume, the composition retains the same formulation. Alternatively, the powder can be reconstituted in half volume, in which case the composition comprises 100 mg of a GDF15 antibody or antigen-binding portion thereof of the present disclosure, 20 mM histidine, 10% sucrose, and 0.02% polysorbate 80 at pH 5.8.
[0194] In one embodiment, a portion of the dose is administered by intravenous bolus and the remainder is administered by infusion of the antibody formulation. For example, a 0.01 mg / kg intravenous injection of the GDF15 antibody or antigen-binding portion thereof can be given as a bolus, and the remainder of the antibody dose can be administered by intravenous injection. A given dose of the GDF15 antibody or antigen-binding portion thereof can be administered over a period of, for example, 1.5 to 2 to 5 hours.
[0195] With respect to therapeutic agents, if the agent is, for example, a small molecule, it may be present in the pharmaceutical composition in the form of a physiologically acceptable ester or salt, e.g., in combination with a physiologically acceptable cation or anion, as is well known in the art.
[0196] The preparation of pharmaceutical composition described herein can be prepared by any method known or developed in the field of pharmacology.In general, such preparation method includes the step of combining active ingredient with carrier or one or more other auxiliary ingredients, and then, if necessary or desired, shaping or packaging the product into desired single dose unit or multiple dose unit.
[0197] In one embodiment, the composition of the present disclosure is a pyrogen-free formulation that is substantially free of endotoxins and / or related pyrogens. Endotoxins include toxins that are restricted inside microorganisms and are released when the microorganism is destroyed or dies. Pyrogens also include fever-inducing, thermostable substances (glycoproteins) from the outer membrane of bacteria and other microorganisms. Both of these substances can cause fever, hypotension and shock when administered to humans. Due to potential adverse effects, it is advantageous to remove even low amounts of endotoxins from pharmaceutical drug solutions administered intravenously. The Food and Drug Administration ("FDA") has set an upper limit of 5 endotoxin units (EU) per dose per kilogram of body weight in a single hourly period for intravenous drug applications (The United States Pharmacopeial Convention, Pharmacopeial Forum 26(1):223(2000)). When therapeutic proteins are administered in amounts of hundreds or thousands of milligrams per kilogram of body weight, it is advantageous to remove even trace amounts of endotoxins. In one embodiment, the level of endotoxins and pyrogens in the composition is less than 10 EU / mg, or less than 5 EU / mg, or less than 1 EU / mg, or less than 0.1 EU / mg, or less than 0.01 EU / mg, or less than 0.001 EU / mg. In another embodiment, the level of endotoxins and pyrogens in the composition is less than about 10 EU / mg, or less than about 5 EU / mg, or less than about 1 EU / mg, or less than about 0.1 EU / mg, or less than about 0.01 EU / mg, or less than about 0.001 EU / mg.
[0198] In one embodiment, the disclosure comprises administering a composition, which administration is oral, parenteral, intramuscular, intranasal, vaginal, rectal, lingual, sublingual, buccal, intrabuccal, intravenous, cutaneous, subcutaneous, or transdermal.
[0199] In another embodiment, the present disclosure further comprises administering the composition in combination with other treatments, such as surgery, chemotherapy, hormonal therapy, biological therapy, immunotherapy, or radiation therapy.
[0200] Dosage To prepare a pharmaceutical or sterile composition comprising a GDF15 antibody or antigen-binding portion thereof of the disclosure, the antibody is admixed with a pharma- ceutically acceptable carrier or excipient. Formulations of therapeutic and diagnostic agents can be prepared, for example, by mixing with physiologically acceptable carriers, excipients, or stabilizers in the form of lyophilized powders, slurries, aqueous solutions, lotions, or suspensions (see, e.g., Hardman et al. (2001) Goodman and Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, NY; Gennaro (2000) Remington: The Science and Practice of Pharmacy, Lippincott, Williams, and Wilkins, New York, NY; Avis et al. (eds.) (1993) Pharmaceutical Dosage Forms: Parenteral Medications, Marcel Dekker, NY; Lieberman et al. (eds.) (1990) Pharmaceutical Dosage Forms: Tablets, Marcel Dekker, NY; Lieberman et al. (eds.) (1990) Pharmaceutical Dosage Forms: Disperse Systems, Marcel Dekker, NY, and others). Dekker, NY; Weiner and Kotkoskie (2000) Excipient Toxicity and Safety, Marcel Dekker, Inc., New York, NY).
[0201] Selecting a dosing regimen for a therapeutic agent depends on several factors, including the serum or tissue turnover rate of the entity, the level of symptoms, the immunogenicity of the entity, and the accessibility of target cells in the biological matrix.In certain embodiments, the dosing regimen maximizes the amount of therapeutic agent delivered to the patient, consistent with an acceptable level of side effects.Thus, the amount of biologic delivered depends in part on the specific entity and the severity of the condition being treated. Guidance on selecting appropriate doses of antibodies, cytokines and small molecules is available (e.g., Wawrzynczak, 1996, Antibody Therapy, Bios Scientific Pub. Ltd, Oxfordshire, UK; Kresina (ed.), 1991, Monoclonal Antibodies, Cytokines and Arthritis, Marcel Dekker, New York, NY; Bach (ed.), 1993, Monoclonal Antibodies and Peptide Therapy in Autoimmune Diseases, Marcel Dekker, New York, NY; Baert et al., 2003, New Engl. J. Med. 348:601-608; Milgrom et al., 1999, New Engl. J. Med. 341:1966-1973; Slamon et al., 2001, New Engl. J. Med. 344:783-792; Beniaminovitz et al., 2000, New Engl. J. Med. 342:613-619; Ghosh et al., 2003, New Engl. J. Med. 348:24-32; Lipsky et al., 2000, New Engl. J. Med. 343:1594-1602).
[0202] The determination of the appropriate dose is made by the clinician, for example, using parameters or factors known in the art or suspected or predicted to affect treatment. Generally, the dose is initiated at an amount somewhat less than the optimal dose and then increased by small increments until the desired or optimal effect is achieved relative to any negative side effects.
[0203] "Reducing the level of GDF15" or "reducing the level of GDF15", as these terms are used herein, means reducing the level of free GDF15 compared to the level of free GDF15 before any therapeutic intervention. As used herein, "free GDF15" means GDF15 that is not bound or otherwise not in a complex with another molecule (e.g., an antibody or binding molecule present in plasma, etc.).
[0204] The level of GDF15 includes the level of free GDF15 in the subject, which is assessed using the methods disclosed herein or any other method for assessing the level of free GDF15 known in the art.
[0205] In one embodiment, the level of free GDF15 is reduced compared to the level of GDF15 in the subject before administration of the antibody of the invention. In one embodiment, the level of free GDF15 is reduced compared to a standard level of free GDF15 that is associated with or indicates that the subject is not affected by a disease, disorder or condition associated with or mediated by an increased level of free GDF15. In one embodiment, the standard or reference level of free GDF15 is about 0.05 ng / mL to about 3 ng / mL in plasma. In another embodiment, the standard or reference level of free GDF15 has a lower limit of 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9 ng / mL and wherein the upper limit is within the range selected from the group consisting of 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9 and 3.0 ng / mL. In a further embodiment, the standard or reference level of free GDF15 is less than 1 ng / mL, preferably less than 0.9 ng / mL, even more preferably less than 0.8 ng / mL, even more preferably less than 0.7 ng / mL, even more preferably less than 0.6 ng / mL, even more preferably less than 0.5 ng / mL, even more preferably less than 0.4 ng / ml. In one embodiment, the level of free GDF15 is the level in plasma.
[0206] The present invention is not limited to free GDF15 levels below 0.5ng / mL; instead, it is understood by those skilled in the art that therapeutic levels may be lower or higher than 0.5ng / mL for a particular subject.Thus, the present invention encompasses reducing the level of free GDF15 to a level where there is a reduction or complete absence of detectable adverse effects mediated by or associated with increased levels of free GDF15.Such effects include, but are not limited to, cachexia, reduced food intake, reduced appetite, reduced body weight, weight loss, reduced body fat mass, reduced lean mass, etc.
[0207] As used herein, an "effective dosage," "effective dose," "effective amount," or "therapeutically effective amount" of a drug, compound, or pharmaceutical composition is an amount sufficient to produce any one or more beneficial or desired results. For prophylactic use, beneficial or desired results include eliminating or reducing the risk, reducing the severity, or delaying the onset of disease, including the biochemical, histological, and / or behavioral symptoms of the disease, its complications, and intermediate pathological phenotypes present during disease development. For therapeutic use, beneficial or desired results include reducing or decreasing the rate of detectable clinical results, such as reducing the rate of weight loss, or reducing one or more symptoms resulting from high expression of active GDF15 (e.g., reduced food intake, reduced appetite, reduced body weight, weight loss, reduced fat mass, and reduced lean mass), reducing the dose of other medications required to treat the disease, enhancing the effect of another medication, and / or delaying the progression of the disease in a patient. An effective dosage may be administered in one or more administrations. For the purposes of the present invention, an effective dosage of a drug, compound or pharmaceutical composition is an amount sufficient to directly or indirectly achieve a prophylactic or therapeutic treatment.As understood in a clinical context, an effective dosage of a drug, compound or pharmaceutical composition may or may not be achieved in conjunction with another drug, compound or pharmaceutical composition.Accordingly, an "effective dosage" may be considered in terms of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount when, in conjunction with one or more other agents, a desired result can be achieved or is achieved.
[0208] In some embodiments, the effective dosage of the antibody or antigen-binding fragment thereof of the present invention is based on the plasma concentration of free GDF-15 in healthy human volunteers and diseased patients. The overall effective dose is based on the initial plasma concentration of free GDF-15 in diseased patients. In one embodiment, the effective dosage can be a dosage that has the ability to lower or reduce the free GDF15 level in a subject to the same or lower average level measured in healthy human volunteers at steady state throughout the dosing interval. In another embodiment, the effective dosage can be a dosage that has the ability to lower or reduce the free GDF15 level in a patient to less than 0.5 ng / mL at steady state throughout the dosing interval. In yet another embodiment, the effective dosage can be a dosage given to a 70 kg subject that can lower or reduce the free GDF15 level in the subject to less than 0.5 ng / mL at steady state throughout the dosing interval.
[0209] An "individual", "patient" or "subject" is a mammal, more preferably a human. Mammals also include, but are not limited to, livestock, sport animals, pets, primates, horses, dogs, cats, mice and rats. In some embodiments, the individual is considered to be at risk for a disease, disorder or condition mediated by or associated with GDF15 binding to its receptor and signal transduction mediated thereby. In certain embodiments, the subject has cancer, chemotherapy, chemotherapy combined with cancer immunotherapy, chronic heart failure, congestive heart failure, sarcopenia, cachexia associated with chronic obstructive pulmonary disease (COPD), sarcopenia and chronic kidney disease (CKD).
[0210] In some embodiments, the method or use comprises administering an initial dose of about 0.025 mg / kg to about 20 mg / kg of the antibody or antigen-binding fragment thereof or pharmaceutical composition of the present invention. The initial dose may be followed by one or more subsequent doses. In some embodiments, the one or more subsequent doses may be administered every week, every other week, every 3 weeks, every 4 weeks, every 5 weeks, every 6 weeks, every 7 weeks, every 8 weeks, every 9 weeks, every 10 weeks, every 11 weeks, or every 12 weeks.
[0211] In some embodiments, the method or use comprises administering a fixed dose of about 0.25 mg to about 2000 mg of an antibody or antigen-binding fragment thereof of the invention, in some embodiments, the antibody or antigen-binding fragment thereof is administered every week, every other week, every 3 weeks, every 4 weeks, every 5 weeks, every 6 weeks, every 7 weeks, every 8 weeks, every 9 weeks, every 10 weeks, every 11 weeks or every 12 weeks.
[0212] In other embodiments, the method or use comprises administering a fixed dose of about 0.1 to about 60 mg of the antibody or antigen-binding fragment thereof of the invention every week. In some embodiments, the fixed dose of the antibody or antigen-binding fragment thereof of the invention is about 2 mg, about 5 mg, about 7 mg, about 10 mg, about 12 mg, about 15 mg, about 25 mg, about 40 mg, and about 50 mg administered every week.
[0213] In some embodiments, the method or use comprises administering a fixed dose of about 0.1 to about 130 mg of an antibody or antigen-binding fragment thereof of the invention every other week. In some embodiments, the fixed dose of an antibody or antigen-binding fragment thereof of the invention is about 5 mg, about 12 mg, about 20 mg, about 25 mg, about 30 mg, about 40 mg, about 60 mg, about 90 mg, and about 125 mg administered every other week.
[0214] In some embodiments, the method or use comprises administering a fixed dose of about 0.1 to about 400 mg of an antibody or antigen-binding fragment thereof of the invention every four weeks. In some embodiments, the fixed dose of an antibody or antigen-binding fragment thereof of the invention is about 15 mg, about 40 mg, about 60 mg, about 75 mg, about 100 mg, about 115 mg, about 200 mg, about 300 mg, and about 385 mg administered every four weeks.
[0215] In some embodiments, the anti-GDF15 antibody is administered intravenously (IV) or subcutaneously (SC). In some embodiments, the antibody or antigen-binding fragment thereof is administered about twice a week, once a week, once every 2 weeks, once every 3 weeks, once every 4 weeks, once every 5 weeks, once every 6 weeks, once every 7 weeks, once every 8 weeks, once every 9 weeks, once every 10 weeks, twice a month, once a month, once every 2 months, once every 3 months, or once every 4 months, once every 5 months, once every 6 months, once every 7 months, once every 8 months, once every 9 months, once every 10 months, once every 11 months, or once every 12 months.
[0216] In some embodiments, the antibody or antigen-binding fragment thereof is administered once a week at a dose between about 0.1 mg and about 1000 mg. In some embodiments, the antibody or antigen-binding fragment thereof is administered once a week at a dose between about 1 mg and about 500 mg. In some embodiments, the antibody or antigen-binding fragment thereof is administered once a week at a dose selected from the group consisting of about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, and about 500 mg. In some embodiments, the antibody or antigen-binding fragment thereof is administered once every two weeks at a dose between about 0.1 mg and about 500 mg. In some embodiments, the antibody or antigen-binding fragment thereof is administered once every two weeks at a dose between about 10 mg and about 250 mg. In some embodiments, the antibody or antigen-binding fragment thereof is administered once every two weeks at a dose selected from the group consisting of about 5 mg, about 12 mg, about 20 mg, about 25 mg, about 30 mg, about 40 mg, about 60 mg, about 90 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, and about 500 mg. In some embodiments, the antibody or antigen-binding fragment thereof is administered once every four weeks at a dose between about 0.1 mg and about 500 mg. In some embodiments, the antibody or antigen-binding fragment thereof is administered once every four weeks at a dose between about 10 mg and about 500 mg. In some embodiments, the antibody or antigen-binding fragment thereof is administered once every four weeks at a dose selected from the group consisting of about 15 mg, about 40 mg, about 60 mg, about 75 mg, about 100 mg, about 115 mg, about 200 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, and about 500 mg.
[0217] kit The present invention also provides kits or articles of manufacture comprising the antibodies or antigen-binding fragments thereof of the present invention, and instructions for use. Thus, in some embodiments, a kit or article of manufacture is provided that includes a container, a composition comprising an anti-GDF15 antibody in the container, and a package insert that includes instructions for administering a therapeutically effective amount of the anti-GDF15 antibody for treating a subject with PMM.
[0218] In certain embodiments, the kits may include both a first container having a dried protein and a second container having an aqueous formulation. In certain embodiments, kits are included that include single and multi-chamber pre-filled syringes (e.g., liquid syringes and lyosyringes).
[0219] In one embodiment, the invention provides a kit for determining the concentration of GDF15 in a sample, comprising: a labeled competitor comprising GDF15 coupled to a detectable label; an antibody or antigen-binding fragment thereof that specifically binds to GDF15; an applicator; and instructional materials for their use.
[0220] The present invention further provides a competitive immunoassay kit for determining the amount of GDF15 in a test sample, comprising an antibody or antigen-binding fragment thereof that specifically binds to GDF15; a labeled competitor that comprises GDF15 conjugated to a detectable label; the labeled competitor competes with GDF15 in the test sample for binding to the antibody, and the label provides a signal that indicates the amount of GDF15 in the test sample.In an exemplary embodiment, the decrease in the label bound by the antibody in the test sample compared to the label bound by the antibody in an otherwise identical sample that does not contain GDF15 is an indication of the amount of GDF15 in the test sample.
[0221] In one embodiment, the invention provides a kit for determining the concentration of GDF15 in a sample, comprising: a labeled competitor comprising GDF15 coupled to a detectable label; an antibody or antigen-binding fragment thereof that specifically binds to GDF15; an applicator; and instructional materials for their use.
[0222] In an alternative embodiment, the present invention provides a kit for identifying a human patient at risk for cachexia, comprising a GDF15-specific antibody or antigen-binding fragment thereof, an applicator, and instructional materials for their use.
[0223] In some embodiments, a kit or article of manufacture is provided that includes a first container, a composition comprising an anti-GDF15 antibody within the container, a second container, a composition comprising a PD-1 axis binding antagonist within the second container, and a package insert that includes instructions for administering a therapeutically effective amount of the anti-GDF15 antibody and the PD-1 axis binding antagonist for treatment of a patient in need thereof.
[0224] The invention encompasses a kit or article of manufacture comprising a first container, a composition comprising a synergistic therapeutically effective amount of an anti-GDF15 antibody within the container, a second container, a composition comprising a therapeutically effective amount of a PD-1 axis binding antagonist within the second container, and a package insert comprising instructions for administering the synergistic therapeutically effective amounts of the anti-GDF15 antibody and the PD-1 axis binding antagonist for combination treatment of a patient in need thereof.
[0225] In some embodiments, the PD-1 axis binding antagonist is selected from the group consisting of a PD-1 antibody or an antigen-binding fragment thereof, a PD-L1 antibody or an antigen-binding fragment thereof, and a PD-L2 antibody or an antigen-binding fragment thereof. In some embodiments, the PD-1 antibody is selected from the group consisting of nivolumab, pembrolizumab, spartalizumab, tislelizumab, pidilizumab, AMP-224, AMP-514, cemiplimab, and PF-06801591 (sasanlimab, RN888). In other embodiments, the PD-L1 antibody is optionally selected from the group consisting of avelumab, atezolizumab, and durvalumab. In other embodiments, the PD-L1 antibody is not avelumab.
[0226] In other embodiments, a kit or article of manufacture is provided that includes a first container, a composition comprising an anti-GDF15 antibody within the container, a second container, a composition comprising an anti-cancer therapeutic within the second container, and a package insert that includes instructions for administering a therapeutically effective amount of the anti-GDF15 antibody and the anti-cancer therapeutic for treatment of a patient in need thereof. In some aspects, the anti-cancer therapeutic is an anti-CD40 antibody.
[0227] The invention encompasses a kit or article of manufacture that includes a first container, a composition comprising a synergistically therapeutically effective amount of an anti-GDF15 antibody in the container, a second container, a composition comprising a therapeutically effective amount of an anti-cancer therapeutic in the second container, and a package insert that includes instructions for administering the synergistically therapeutically effective amounts of the anti-GDF15 antibody and the anti-cancer therapeutic for combination treatment of a patient in need thereof. In some embodiments, the anti-cancer therapeutic is an anti-CD40 antibody.
[0228] The instructions for use of the antibody or antigen-binding fragment thereof of the present invention generally include information regarding dosage, dosing schedule, and route of administration for the intended treatment. The containers may be unit dose, bulk packaging (e.g., multi-dose packaging) or sub-unit dose. The instructions provided in the kit of the present invention are typically written instructions on a label or insert (e.g., a paper sheet included in the kit), although machine-readable instructions (e.g., instructions carried on a magnetic or optical storage disk) are also acceptable.
[0229] The kit of the present invention is in suitable packaging. Suitable packaging includes, but is not limited to, vials, bottles, jars, flexible packaging (e.g., sealed Mylar or plastic bags), etc. Packaging for use in combination with a specific device, such as an inhaler, a nasal administration device (e.g., an atomizer) or an injection device, such as a minipump, is also contemplated. The kit can have a sterile access port (e.g., the container can be an intravenous solution bag or a vial with a stopper that can be pierced by a hypodermic needle). The container can also have a sterile access port (e.g., the container can be an intravenous solution bag or a vial with a stopper that can be pierced by a hypodermic needle). The container can further comprise a second pharma- ceutically active agent.
[0230] The kit may optionally provide additional components, such as buffers and instructional information. Typically, the kit comprises a container and a label or package insert on or associated with the container.
[0231] definition "About" or "approximately," unless otherwise defined herein, when used in conjunction with a measurable numerical variable, refers to the stated value of the variable and all values of the variable within the greater of the experimental error of the stated value (e.g., a 95% confidence interval for the mean) or 10 percent of the stated value. Numerical ranges are inclusive of the numbers defining the range.
[0232] The term "identity", as known in the art, refers to the relatedness between the sequences of two or more polypeptide molecules or two or more nucleic acid molecules, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between polypeptide or nucleic acid molecule sequences, as the case may be, as determined by the match between strings of nucleotide or amino acid sequences. "Identity" measures the percentage of identical matches between two or more sequences, using gap alignment handled by a particular mathematical model computer program (i.e., "algorithm").
[0233] The term "similarity", a related concept, refers to a measure of similarity that includes both identical matches and conservative substitution matches, in contrast to "identity". Conservative substitution applies to polypeptides, but not to nucleic acid molecules, so similarity only deals with polypeptide sequence comparison. If two polypeptide sequences have, for example, 10 identical amino acids out of 20, and the rest are all non-conservative substitutions, the percent identity and similarity are both 50%. In the same example, if there are 5 additional positions where conservative substitutions exist, the percent identity remains 50%, but the percent similarity is 75% (15 out of 20). Thus, when conservative substitutions exist, the degree of similarity between two polypeptide sequences is higher than the percent identity between the two sequences.
[0234] The use of the term "or" in the claims is used to mean "and / or" unless expressly indicated to refer only to alternatives or that the alternatives are mutually exclusive, however, the present disclosure supports the definition to refer only to alternatives and "and / or". As used herein, "a" or "an" may mean one or more unless expressly indicated otherwise. As used herein in the claims, when used in conjunction with the word "comprising", the word "a" or "an" may mean one or more than one. As used herein, "another" may mean at least a second or more. Unless otherwise defined herein, scientific and technical terms used in conjunction with the present invention shall have the meanings commonly understood by those of ordinary skill in the art. Further, unless the context requires otherwise, singular terms shall include the plural and plural terms shall include the singular. The words "comprises / comprising" and "having / including", when used herein in relation to the present invention, are used to specify the presence of stated features, integers, steps or components, but do not exclude the presence or addition of one or more other features, integers, steps, components or groups thereof.
[0235] The terms "cancer", "cancerous" or "malignant" refer to or describe a physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include, but are not limited to, carcinoma, lymphoma, leukemia, blastoma and sarcoma. More specific examples of such cancer include squamous cell carcinoma, myeloma, small cell lung cancer, non-small cell lung cancer, glioma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, acute myeloid leukemia (AML), multiple myeloma, gastrointestinal (ductal) cancer, renal cancer, ovarian cancer, liver cancer, lymphoblastic leukemia, lymphocytic leukemia, colorectal cancer, endometrial cancer, kidney cancer, prostate cancer, thyroid cancer, melanoma, chondrosarcoma, neuroblastoma, pancreatic cancer, glioblastoma multiforme, cervical cancer, brain tumor, stomach cancer, bladder cancer, hepatoma, breast cancer, colon cancer and head and neck cancer. Another specific example of cancer includes renal cell carcinoma.
[0236] The term "treat," as used herein, unless otherwise indicated, means to reverse, alleviate, inhibit the progression of, or prevent the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.
[0237] The "patient" to be treated according to the present invention includes any warm-blooded animal, such as, but not limited to, a human, a monkey or other lower primate, a horse, a dog, a rabbit, a guinea pig or a mouse. For example, the patient is a human. Those skilled in the medical field can easily identify individual patients suffering from non-small cell lung cancer and in need of treatment.
[0238] The terms "treatment regimen," "dosing protocol," and dosing regimen are used interchangeably to refer to the dosage and timing of administration of each therapeutic agent in the combination of the invention.
[0239] "Ameliorating" refers to a decrease or improvement in one or more symptoms compared to when no treatment is administered. "Ameliorating" also includes a shortening or reduction in the duration of symptoms.
[0240] An "effective response" of a patient to a pharmaceutical treatment or a patient's "responsiveness" and similar phrases refer to a clinical or therapeutic benefit conferred on a patient at risk for or suffering from a disease or disorder, such as PMM. In one embodiment, such benefit includes any one or more of the following: producing an objective response (including complete).
[0241] As used herein, "in combination with" or "in conjunction with" refers to the administration of one treatment modality in addition to another treatment modality. Thus, "in combination with" or "in conjunction with" refers to the administration of one treatment modality before, during, or after the administration of another treatment modality to an individual.
[0242] "Low dose," as used herein, refers to an amount or dose of a substance, agent, compound or composition that is lower than the amount or dose typically used in a clinical setting.
[0243] The term "additive" is used to mean that the result of the combination of two compounds, components or targeted agents is less than or equal to the sum of each individual compound, component or targeted agent. The term "additive" means that there is no improvement in the disease state or disorder being treated beyond the use of each individual compound, component or targeted agent.
[0244] The term "synergy" or "synergistic" is used to mean that the effect of the combination of two compounds, components or targeted agents is greater than the sum of the effects each agent provides alone. The term "synergy" or "synergistic" means that there is an improvement in the disease state or disorder being treated that exceeds the use of each individual compound, component or targeted agent separately. This improvement in the disease state or disorder being treated is a "synergistic effect" or "synergistic therapeutic effect." A "synergistic amount," "synergistically effective amount," or "synergistically therapeutically effective amount" is an amount of a compound, component or targeted agent that produces a synergistic effect when administered in combination, and "synergistic" is defined herein. Once the synergistic interaction between two or more components is determined, the optimal range for effect and the absolute dose range of each component for effect can be determined categorically by administration of the components over different w / w (weight / weight) ratio ranges and doses to a patient in need of treatment. However, observations of synergy in in vitro or in vivo models may be predictive of effects in humans and other species, and in vitro or in vivo models exist for measuring synergistic effects, as described herein, and the results of such studies may also be used to predict effective dose and plasma concentration ratio ranges, as well as absolute doses and plasma concentrations, required in humans and other species by application of pharmacokinetic / pharmacodynamic methods.
[0245] Non-limiting embodiments The present invention provides a method for preventing, ameliorating and / or treating mitochondrial myopathy using an antibody that specifically binds to GDF15 and its antigen-binding fragment.Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein.Such equivalents are intended to be encompassed by the following embodiment (E).
[0246] E1. A method for preventing, ameliorating and / or treating primary mitochondrial myopathy (PMM), comprising administering to a subject in need thereof a therapeutically effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds GDF-15.
[0247] E2. A method for treating primary mitochondrial myopathy (PMM), comprising administering to a subject in need thereof a therapeutically effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds GDF-15.
[0248] E3. The method of E1, wherein the primary mitochondrial myopathy is selected from the group consisting of Leigh syndrome, Kearns-Sayre syndrome, Alpers-Huttenlocher syndrome, mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) and ataxic neuropathy syndrome.
[0249] E4. The method of any one of E1 to E3, wherein the administration results in an improvement in one or more signs or symptoms of PMM compared to pre-administration.
[0250] E5. The method of E4, wherein one or more signs or symptoms of PMM include physical fatigue, muscle weakness and / or exercise tolerance.
[0251] E6. The method of E4, wherein the improvement in one or more signs or symptoms of PMM comprises increased weight gain, increased lean muscle mass, increased skeletal muscle mass, restored muscle strength, and / or improvement in exercise capacity.
[0252] E7. The method of any one of E1 to E9, wherein the subject does not have cachexia, heart failure and / or cancer.
[0253] E8. The method of any one of E1-E9, wherein the subject has cachexia, heart failure and / or cancer.
[0254] E9. The method of E8, wherein the subject exhibits abnormal levels of one or more energy biomarkers compared to control subjects.
[0255] E10. Energy biomarkers include lactate (lactate) levels; pyruvate (pyruvate) levels; lactate / pyruvate ratio; creatine phosphate levels; NADH (NADH+H + ) or NADPH (NADPH + H + ) levels; NAD or NADP levels; ATP levels; reduced coenzyme Q (CoQ red ) levels; oxidized coenzyme Q (CoQ ox ) levels; total coenzyme Q (CoQ tot ) levels; oxidized cytochrome C levels; reduced cytochrome C levels; oxidized cytochrome C / reduced cytochrome C ratio; acetoacetate levels; beta-hydroxybutyrate levels; acetoacetate / beta-hydroxybutyrate ratio; 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels; reactive oxygen species levels; oxygen consumption (VO2), carbon dioxide output (VCO2) and respiratory quotient (VCO2 / VO2).
[0256] E11. The method of any one of E1 to E10, wherein the subject has elevated GDF15 levels and / or activity prior to administration of the isolated antibody or antigen-binding fragment thereof.
[0257] E12. The method of any one of E1 to E11, wherein the subject has reduced GDF15 levels and / or activity after administration of the isolated antibody or antigen-binding fragment thereof compared to before administration.
[0258] E13. GDF15 activity is (a) increasing GFRAL binding; (b) reducing food intake; (c) reducing body mass; (d) reducing muscle mass; (e) reducing body fat mass; (f) activating RET; (g) increasing the phosphorylation of ERK (pERK); and (h) increasing phosphorylation of ribosomal protein S6 (S6) (i) increasing phosphorylation of AKT; (j) increasing phosphorylation of MAPK; (k) increasing phosphorylation of PLC-γ1; (l) increasing fatigue; and (m) Reducing physical capacity / activity The method according to E11 or E12, wherein the method is selected from the group consisting of:
[0259] E14. The method of any one of E1 to E13, wherein the antibody or antigen-binding fragment thereof comprises HCDR-1, HCDR-2 and HCDR-3 sequences of one of the group consisting of SEQ ID NOs: 21, 34, 44, 53, 60, 68, 73, 80, 86, 93, 99, 106, 112, 120, 127, 136, 142, 148, 155, 161 and 166.
[0260] E15. The method of any one of E1 to E14, wherein the antibody or antigen-binding fragment thereof comprises LCDR-1, LCDR-2 and LCDR-3 sequences selected from the group consisting of SEQ ID NOs: 11, 30, 39, 49, 56, 64, 71, 77, 83, 90, 96, 103, 109, 115, 123, 131, 139, 144, 151, 158 and 163.
[0261] E16. The antibody or antigen-binding fragment thereof is selected from the group consisting of (a) to (f): (a) LCDR-1 selected from the group consisting of SEQ ID NOs: 7, 27, 36, 46, 55, 62, 82, 88, 95, 101, 129, 138, 150, and 157; (b) LCDR-2 selected from the group consisting of SEQ ID NOs: 8, 28, 37, 47, 70, 108, 114, 122 and 130; (c) LCDR-3 selected from the group consisting of SEQ ID NOs: 9, 29, 38, 48, 63, 76, 89 and 102; (d) HCDR-1 selected from the group consisting of SEQ ID NOs: 17, 32, 41, 58, 66, 117, 125, 133 and 153; (e) HCDR-2 selected from the group consisting of SEQ ID NOs: 18, 33, 42, 51, 59, 67, 85, 92, 98, 105, 118, 126, 134, 141, 146 and 165; (f) HCDR-3 selected from the group consisting of SEQ ID NOs: 1, 19, 43, 52, 79, 111, 119, 135, 147, 154 and 160 The method of any one of E1 to E15, comprising one or more of:
[0262] E17. An antibody or antigen-binding fragment thereof, comprising: i) an HCDR-1 comprising the amino acid sequence GYTFX1X2YNID, where X1 is S or T and X2 is S or D; ii) an HCDR-2 comprising the amino acid sequence X3INPX4X5GX6AX7X8X9QKFQG, where X3 is G or Q; X4 is I or N; X5 is F or N; X6 is T or L; X7 is F or N; X8 is Y or F and X9 is N or A; and iii) an HCDR-2 comprising the amino acid sequence EX 10 ITTX 11 GAMDX 12 wherein X 10 is A or Q;X 11 is V or I;X 12 is H or Y.
[0263] E18. An antibody or antigen-binding fragment thereof, comprising: i) an LCDR-1 comprising the amino acid sequence RX1SQX2X3X4X5YLA, where X1 is T or A, X2 is S or N, X3 is V or L, X4 is H or S, and X5 is N or S; ii) an LCDR-2 comprising the amino acid sequence DAX6X7RAX8, where X6 is S or K; X7 is T or N; and X8 is D or T; and iii) an amino acid sequence QQFX9X 10 X 11 PX 12 LCDR-3 containing T, wherein X9 is W or S; X 10 is S or N;X 11 is W or D;X 12 is W or Y.
[0264] E19. An antibody or antigen-binding fragment thereof, (a) LCDR-1 comprising the amino acid sequence of SEQ ID NO: 174; (b) LCDR-2 comprising the amino acid sequence of SEQ ID NO: 175; (c) LCDR-3 comprising the amino acid sequence of SEQ ID NO: 176; (d) HCDR-1 comprising the amino acid sequence of SEQ ID NO: 171; (e) HCDR-2 comprising the amino acid sequence of SEQ ID NO: 172; (f) HCDR-3 comprising the amino acid sequence of SEQ ID NO: 173 The method of any one of E1 to E18, comprising one or more of:
[0265] E20. The method of any one of E1 to E19, wherein the antibody or antigen-binding fragment thereof comprises HCDR-1, HCDR-2 and HCDR-3 sequences of at least one sequence selected from the group consisting of SEQ ID NOs: 34, 106, 148, 155 and 166.
[0266] E21. The method of any one of E1 to E20, wherein the antibody or antigen-binding fragment thereof comprises LCDR-1, LCDR-2 and LCDR-3 sequences of at least one sequence selected from the group consisting of SEQ ID NOs: 30, 103, 144, 151 and 163.
[0267] E22. The antibody or antigen-binding fragment thereof is selected from the group consisting of (a) to (f). (a) LCDR-1 selected from the group consisting of SEQ ID NOs: 27, 88, 95, 101 and 150 (b) LCDR-2 selected from the group consisting of SEQ ID NOs: 8, 28 and 108 (c) LCDR-3 selected from the group consisting of SEQ ID NOs: 9, 29, 38, 48 and 102 (d) HCDR-1 selected from the group consisting of SEQ ID NOs: 32, 41 and 153 (e) HCDR-2 selected from the group consisting of SEQ ID NOs: 33, 105, 146 and 165 (f) HCDR-3 selected from the group consisting of SEQ ID NOs: 19, 52, 147 and 154 The method of any one of E1 to E21, comprising one or more of:
[0268] E23. The method of any one of E1 to E22, wherein the antibody or antigen-binding fragment thereof comprises the HCDR-1, HCDR-2 and HCDR-3 sequences of SEQ ID NO: 166.
[0269] E24. The method of any one of E1 to E23, wherein the antibody or antigen-binding fragment thereof comprises the LCDR-1, LCDR-2 and LCDR-3 sequences of SEQ ID NO: 163.
[0270] E25. An antibody or antigen-binding fragment thereof, (a) LCDR-1 comprising the sequence of SEQ ID NO: 95; (b) LCDR-2 comprising the sequence of SEQ ID NO: 28; (c) LCDR-3 comprising the sequence of SEQ ID NO: 9; (d) HCDR-1 comprising the sequence of SEQ ID NO: 32; (e) HCDR-2 comprising the sequence of SEQ ID NO: 165, and (f) HCDR-3 comprising the sequence of SEQ ID NO: 52 The method of any one of E1 to E24, comprising one or more of:
[0271] E26. The method of any one of E1 to E25, wherein the antibody or antigen-binding fragment thereof comprises LCDR-1 comprising the amino acid sequence of SEQ ID NO: 95, LCDR-2 comprising the amino acid sequence of SEQ ID NO: 28, LCDR-3 comprising the amino acid sequence of SEQ ID NO: 9, HCDR-1 comprising the amino acid sequence of SEQ ID NO: 32, HCDR-2 comprising the amino acid sequence of SEQ ID NO: 165, and HCDR-3 comprising the amino acid sequence of SEQ ID NO: 52.
[0272] E27. An antibody or antigen-binding fragment thereof, comprising the following substitutions: (a) 1, 2, 3, 4, 5 or 6 substitutions in LCDR-1 with the corresponding residues in the human germline VL sequence; (b) 1, 2, 3, 4 or 5 substitutions in LCDR-2 with the corresponding residues in the human VL germline sequence; (c) 1, 2, 3, 4, 5, or 6 substitutions in LCDR-3 with the corresponding residues in the human germline VL sequence; (d) one substitution in HCDR-1 with the corresponding residue in the human germline VH sequence; (e) 1, 2, 3, 4, 5, 6, 7, or 8 substitutions in HCDR-2 with the corresponding residues of a human germline VH sequence. The method of any one of E1 to E26, comprising one or more of the following: * 01, IGKV1-13 * 02, IGKV1-33 * 01, IGKV1-39 * 01, IGKV1-5 * 01, IGKV3-11 * 01, IGKV3-15 * 01, IGKV3-20 * 01, IGKV3D-20 * 02 and IGKV4-1 *01, wherein the human germline VH is selected from the group consisting of IGHV1-2 * 02, IGHV1-3 * 01, IGHV1-46 * 01, IGHV1-69 * 01, IGHV1-69 * 02, IGHV1-8 * 01, IGHV3-13 * 01, IGHV3-23 * 01, IGHV3-23 * 04, IGHV3-30 * 01, IGHV3-30 * 18. IGHV5-10-1 * 01, IGHV5-10-1 * 04 and IGHV5-51 * 01. A method according to claim 1, wherein the method is selected from the group consisting of
[0273] E28. The antibody or antigen-binding fragment thereof is capable of detecting IGHV1-2 * 02, IGHV1-3 * 01, IGHV1-46 * 01, IGHV1-69 * 01, IGHV1-69 * 02, IGHV1-8 * 01, IGHV3-13 * 01, IGHV3-23 * 01, IGHV3-23 * 04, IGHV3-30 * 01, IGHV3-30 * 18. IGHV5-10-1 * 01, IGHV5-10-1 * 04 and IGHV5-51 * The method of any one of E1 to E27, comprising a VH framework sequence derived from a human germline VH sequence selected from the group consisting of: E1-E27.
[0274] E29. The antibody or antigen-binding fragment thereof is capable of detecting IGHV1-69 * 01 The method described in any one of E1 to E28, comprising a VH framework sequence.
[0275] E30. An antibody or antigen-binding fragment thereof, * 01, IGKV1-13 * 02, IGKV1-33 * 01, IGKV1-39 * 01, IGKV1-5 * 01, IGKV3-11 * 01, IGKV3-15 * 01, IGKV3-20 * 01, IGKV3D-20 * 02 and IGKV4-1 * The method of any one of E1 to E29, comprising a VL framework sequence derived from a human germline VL sequence selected from the group consisting of: E1-E29.
[0276] E31. An antibody or antigen-binding fragment thereof, * 01 The method described in any one of E1 to E30, comprising a VL framework sequence.
[0277] E32. The method of any one of E1 to E31, wherein the antibody or antigen-binding fragment thereof comprises a VL framework sequence and a VH framework sequence, wherein the VL framework sequence is at least 72% identical to the human germline sequence from which it is derived.
[0278] E33. The method of any one of E1 to E32, wherein the antibody or antigen-binding fragment thereof comprises a VL framework sequence and a VH framework sequence, and the VL framework sequence is at least 72%, 74%, 75%, 77%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the human germline sequence from which it is derived.
[0279] E34. The method of any one of E1 to E33, wherein the antibody or antigen-binding fragment thereof comprises a VL framework sequence and a VH framework sequence, wherein the VH framework sequence is at least 53% identical to the human germline sequence from which it is derived.
[0280] E35. The method of any one of E1 to E34, wherein the antibody or antigen-binding fragment thereof comprises a VL framework sequence and a VH framework sequence, and the VH framework sequence is at least 53%, 58%, 60%, 63%, 71%, 72%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the human germline sequence from which it is derived.
[0281] E36. The method of any one of E1 to E35, wherein the antibody or antigen-binding fragment thereof comprises a VH comprising an amino acid sequence at least 90% identical to SEQ ID NO: 166.
[0282] E37. The method of any one of E1 to E36, wherein the antibody or antigen-binding fragment thereof comprises a VH comprising an amino acid sequence at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 166.
[0283] E38. The method of any one of E1 to E37, wherein the antibody or antigen-binding fragment thereof comprises a VH comprising the amino acid sequence of SEQ ID NO: 166.
[0284] E39. The method of any one of E1 to E38, wherein the antibody or antigen-binding fragment thereof comprises a VL comprising an amino acid sequence at least 90% identical to SEQ ID NO: 163.
[0285] E40. The method of any one of E1 to E39, wherein the antibody or antigen-binding fragment thereof comprises a VL comprising an amino acid sequence at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 163.
[0286] E41. The method of any one of E1 to E40, wherein the antibody or antigen-binding fragment thereof comprises a VL comprising the amino acid sequence of SEQ ID NO: 163.
[0287] E42. The method of any one of E1 to E41, wherein the antibody or antigen-binding fragment thereof comprises a VH comprising the amino acid sequence of SEQ ID NO: 166 and a VL amino acid sequence of SEQ ID NO: 163.
[0288] E43. The method of any one of E1 to E42, wherein the antibody or antigen-binding fragment thereof comprises an Fc domain.
[0289] E44. The method of any one of E1 to E43, wherein the Fc domain is an Fc domain of IgA (e.g., IgA1 or IgA2), IgD, IgE, IgM or IgG (e.g., IgG1, IgG2, IgG3 or IgG4).
[0290] E45. The method of E43 or E44, wherein the Fc domain is an IgG Fc domain.
[0291] The method of E45, wherein IgG is selected from the group consisting of IgG1, IgG2, IgG3 or IgG4.
[0292] E47. The method according to E46, wherein the IgG is IgG1.
[0293] E48. The method of any one of E1 to E47, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain (HC) comprising an amino acid sequence at least 90% identical to SEQ ID NO: 164.
[0294] E49. The method of any one of E1 to E48, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain (HC) comprising an amino acid sequence at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 164.
[0295] E50. The method of any one of E1 to E49, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain (HC) comprising the amino acid sequence of SEQ ID NO: 164.
[0296] E51. The method of any one of E1 to E50, wherein the antibody or antigen-binding fragment thereof comprises a light chain (LC) comprising an amino acid sequence at least 90% identical to SEQ ID NO: 162.
[0297] E52. The method of any one of E1 to E51, wherein the antibody or antigen-binding fragment thereof comprises a LC comprising an amino acid sequence at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 162.
[0298] E53. The method of any one of E1 to E52, wherein the antibody or antigen-binding fragment thereof comprises a LC comprising the amino acid sequence of SEQ ID NO: 162.
[0299] E54. The method of any one of E1 to E53, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 164 and a light chain comprising the amino acid sequence of SEQ ID NO: 162.
[0300] E55. The method of any one of E1 to E50, wherein the antibody or antigen-binding fragment thereof comprises CDR1, CDR2 and CDR3 encoded by an insert of the plasmid deposited with the ATCC and having ATCC Accession No. PTA-125038.
[0301] E56. The method of any one of E1 to E55, wherein the antibody or antigen-binding fragment thereof comprises CDR1, CDR2 and CDR3 encoded by an insert in the plasmid deposited with the ATCC and having ATCC Accession No. PTA-125039.
[0302] E57. The method of any one of E1 to E56, wherein the antibody or antigen-binding fragment thereof is encoded by an insert in a plasmid deposited with the ATCC and having ATCC Accession No. PTA-125038.
[0303] E58. The method of any one of E1 to E57, wherein the antibody or antigen-binding fragment thereof is encoded by an insert in a plasmid deposited with the ATCC and having ATCC Accession No. PTA-125039.
[0304] E59. The method of any one of E1 to E58, wherein the antibody or antigen-binding fragment thereof comprises an amino acid sequence encoded by an insert in a plasmid deposited with the ATCC and having ATCC Accession No. PTA-125038, and an amino acid sequence encoded by an insert in a plasmid deposited with the ATCC and having ATCC Accession No. PTA-125039.
[0305] E60. The method of any one of E1 to E59, wherein the antibody or antigen-binding fragment is an Fc fusion protein, a monobody, a maxibody, a bifunctional antibody, an scFab, an scFv, a peptibody.
[0306] E61. The antibody or antigen-binding fragment thereof has a K of approximately selected from the group consisting of about 10 nM, 5 nM, 2 nM, 1 nM, 900 pM, 800 pM, 700 pM, 600 pM, 500 pM, 400 pM, 300 pM, 250 pM, 200 pM, 150 pM, 100 pM, 50 pM, 40 pM, 30 pM, 25 pM, 20 pM, 15 pM and 10 pM. D or less than that value D and binds to human GDF15.
[0307] E62. The antibody or antigen-binding fragment thereof has a K of approximately selected from the group consisting of about 10 nM, 5 nM, 2 nM, 1 nM, 900 pM, 800 pM, 700 pM, 600 pM, 500 pM, 400 pM, 300 pM, 250 pM, 200 pM, 150 pM, 100 pM, 50 pM, 40 pM, 30 pM, 25 pM, 20 pM, 15 pM, 13 pM, 10 pM and 9 pM. D or less than that value Dand binds to cynomolgus GDF15.
[0308] E63. The antibody or antigen-binding fragment thereof has a K of about 8 pM or 9 pM. D The method according to any one of E1 to E62, wherein the antibody binds to cynomolgus GDF15 at
[0309] E64. The antibody or antigen-binding fragment thereof has a K D The method according to any one of E1 to E63, wherein the antibody binds to cynomolgus GDF15 at
[0310] E65. The method of any one of E1 to E64, wherein the antibody or antigen-binding fragment thereof has a terminal half-life in humans that is at least about 16 days.
[0311] E66. The method of any one of E1 to E65, wherein the antibody or antigen-binding fragment thereof has a terminal half-life in humans that is at least 17 days.
[0312] E67. The method of any one of E1 to E66, wherein the antibody or antigen-binding fragment thereof has a predicted immunogenic potential as indicated by a t-regitope (tReg) adjusted score of less than about -24.
[0313] E68. The method of any one of E1 to E67, wherein the predicted immunogenic potential of the antibody as indicated by the tReg-adjusted score is less than a tReg-adjusted score selected from the group consisting of about -24, -26, -27, -30, -32, -33, -34, -35, -36, -37, -38, -39, -40, -41, -42, -43, -50 and -51.
[0314] E69. The method of any one of E1 to E68, wherein the predicted immunogenic potential of the antibody, as indicated by the tReg adjusted score, is selected from the group consisting of about -26, -34, -36, -41 and -42.
[0315] The method of any one of E1 to E69, wherein the predicted immunogenic potential of the antibody, as indicated by the E70.tReg adjusted score, is about -41 or -42.
[0316] E71. The method of any one of E1 to E70, wherein the antibody or antigen-binding fragment thereof has a viscosity selected from the group consisting of at least about 10 centipoise (cP), at least about 15 cP, at least about 20 cP, at least about 40 cP and at least about 70 cP, when measured at 25° C.
[0317] E72. The method of any one of E1-E71, wherein the antibody or antigen-binding fragment has a viscosity of about 20 cP when measured at 25° C.
[0318] E73. The method of any one of E1-E72, wherein the antibody or antigen-binding fragment thereof has a viscosity of 20 cP when measured at 25° C.
[0319] E74. The K of an antibody or antigen-binding fragment thereof to human GDF15 compared to binding to mouse GDF15. D The method of any one of E1 to E73, wherein the ratio of is between about 0.05 and about 0.10.
[0320] E75. K of an antibody or antigen-binding fragment thereof to human GDF15 compared to binding to mouse GDF15 D The method of any one of E1 to E74, wherein the ratio is about 0.07.
[0321] E76. K of an antibody or antigen-binding fragment thereof to human GDF15 compared to binding to mouse GDF15 D The method of any one of E1 to E75, wherein the ratio is 0.07.
[0322] E77. K of an antibody or antigen-binding fragment thereof to human GDF15 compared to binding to cynomolgus monkey GDF15 DThe method of any one of E1 to E76, wherein the ratio is between about 1.0 and about 1.5.
[0323] E78. The K of an antibody or antigen-binding fragment thereof to human GDF15 compared to binding to cynomolgus monkey GDF15. D The method of any one of E1 to E77, wherein the ratio is about 1.2.
[0324] E79. K of an antibody or antigen-binding fragment thereof to human GDF15 compared to binding to cynomolgus monkey GDF15 D The method of any one of E1 to E78, wherein the ratio is 1.21.
[0325] E80. K of an antibody or antigen-binding fragment thereof to cynomolgus monkey GDF15 compared to binding to mouse GDF15 D The method of any one of E1 to E79, wherein the ratio is between about 0.03 and about 0.09.
[0326] E81. K of an antibody or antigen-binding fragment thereof to cynomolgus monkey GDF15 compared to binding to mouse GDF15 D The method of any one of E1 to E80, wherein the ratio is between about 0.04 and 0.08.
[0327] E82. K of an antibody or antigen-binding fragment thereof to cynomolgus monkey GDF15 compared to binding to mouse GDF15 D The method of any one of E1 to E81, wherein the ratio is between 0.05 and 0.06.
[0328] E83. K of an antibody or antigen-binding fragment thereof to cynomolgus monkey GDF15 compared to binding to mouse GDF15 D The method of any one of E1 to E82, wherein the ratio is 0.05.
[0329] E84. The antibody or antigen-binding fragment thereof has a melting temperature (T) of about 71° C. or higher, as measured by differential scanning calorimetry. m 1) or antibody CH The method of any one of E1 to E83, wherein 2 is thermostable at a temperature of 50% unfolded.
[0330] E85. The antibody has a melting temperature (T) between 71°C and 72°C as measured by differential scanning calorimetry. m 1) or antibody C H The method of any one of E1 to E84, wherein 2 is thermostable at a temperature of 50% unfolded.
[0331] E86. The antibody or antigen-binding fragment thereof has a melting temperature (T) between 71°C and 72°C as measured by differential scanning calorimetry. m 1) or antibody C H The method of any one of E1 to E85, wherein 2 is thermostable at a temperature of 50% unfolded.
[0332] E87. The antibody has a melting temperature (T) of about 80°C or higher, as measured by differential scanning calorimetry. m 2) or the method of any one of E1 to E86, wherein the antibody Fab is thermostable at a temperature at which it is 50% unfolded.
[0333] E88. The antibody has a melting temperature (T) between 80°C and 86°C as measured by differential scanning calorimetry. m 2) or the method of any one of E1 to E87, wherein the antibody Fab is thermostable at a temperature at which it is 50% unfolded.
[0334] E89. The antibody has a melting temperature (T) between 84°C and 85°C as measured by differential scanning calorimetry. m 2) or the method of any one of E1 to E88, wherein the antibody Fab is thermostable at a temperature at which it is 50% unfolded.
[0335] E90. The antibody has a melting temperature (T) of about 82°C or greater, as measured by differential scanning calorimetry. m 3) or antibody C HThe method of any one of E1 to E89, wherein 3 is thermostable at a temperature of 50% unfolded.
[0336] E91. The antibody has a melting temperature (T) between 83° C. and 91° C. as measured by differential scanning calorimetry. m 3) or antibody C H The method of any one of E1 to E90, wherein 3 is thermostable at a temperature of 50% unfolded.
[0337] E92. The antibody has a melting temperature (T) between 87°C and 89°C as measured by differential scanning calorimetry. m 3) or antibody C H The method of any one of E1 to E91, wherein 3 is thermostable at a temperature of 50% unfolded.
[0338] E93. The method of any one of E1 to E92, wherein the antibody or antigen-binding fragment thereof is encoded by a nucleic acid molecule comprising the nucleic acid sequence of SEQ ID NO: 167, the nucleic acid sequence of SEQ ID NO: 168, or both.
[0339] E94. The method of any one of E1 to E93, wherein the antibody or antigen-binding fragment thereof is encoded by a nucleic acid molecule comprising the nucleic acid sequence of SEQ ID NO: 169, the nucleic acid sequence of SEQ ID NO: 170, or both.
[0340] E95. The method of any one of E1 to E94, wherein the antibody or antigen-binding fragment thereof is encoded by a nucleic acid molecule comprising the nucleic acid sequence of the insert of the plasmid deposited with the ATCC and having Accession No. PTA-125038.
[0341] E96. The method of any one of E1 to E95, wherein the antibody or antigen-binding fragment thereof is encoded by a nucleic acid molecule comprising the nucleic acid sequence of the insert of the plasmid deposited with the ATCC and having Accession No. PTA-125039.
[0342] E97. The method of any one of E1 to E96, wherein the antibody or antigen-binding fragment thereof is encoded by a nucleic acid molecule comprising the nucleic acid sequence of the insert of a plasmid deposited with the ATCC and having accession number PTA-125038, and the nucleic acid sequence of the insert of a plasmid deposited with the ATCC and having accession number PTA-125039.
[0343] E98. The method of any one of E1-E97, wherein the subject is a human.
[0344] E99. The method of any one of E1 to E98, wherein the antibody or antigen-binding fragment thereof is administered subcutaneously.
[0345] E100. The method of any one of E1 to E99, wherein the antibody or antigen-binding fragment thereof is administered intravenously.
[0346] E101. The method of any one of E1 to E100, wherein the antibody or antigen-binding fragment thereof is administered about twice per week, once per week, once every 2 weeks, once every 3 weeks, once every 4 weeks, once every 5 weeks, once every 6 weeks, once every 7 weeks, once every 8 weeks, once every 9 weeks, once every 10 weeks, twice per month, once per month, once every 2 months, once every 3 months, or once every 4 months, once every 5 months, once every 6 months, once every 7 months, once every 8 months, once every 9 months, once every 10 months, once every 11 months, or once every 12 months.
[0347] E102. The method of any one of E1 to E101, wherein the antibody or antigen-binding fragment thereof is administered once a week at a dose of between about 0.1 mg and about 1000 mg.
[0348] E103. The method of any one of E1 to E102, wherein the antibody or antigen-binding fragment thereof is administered once a week at a dose of between about 1 mg and about 500 mg.
[0349] E104. The method of any one of E1 to E103, wherein the antibody or antigen-binding fragment thereof is administered once a week at a dose selected from the group consisting of about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg and about 500 mg.
[0350] E105. The method of any one of E1 to E104, wherein the antibody or antigen-binding fragment thereof is administered once every two weeks at a dose of between about 0.1 mg and about 500 mg.
[0351] E106. The method of any one of E1 to E105, wherein the antibody or antigen-binding fragment thereof is administered once every two weeks at a dose of between about 10 mg and about 250 mg.
[0352] E107. The method of any one of E1 to E106, wherein the antibody or antigen-binding fragment thereof is administered once every two weeks at a dose selected from the group consisting of about 5 mg, about 12 mg, about 20 mg, about 25 mg, about 30 mg, about 40 mg, about 60 mg, about 90 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg and about 500 mg.
[0353] E108. The method of any one of E1 to E123, wherein the antibody or antigen-binding fragment thereof is administered at a dose of between about 0.1 mg and about 500 mg once every four weeks.
[0354] E109. The method of any one of E1 to E108, wherein the antibody or antigen-binding fragment thereof is administered at a dose of between about 10 mg and about 500 mg once every four weeks.
[0355] E110. The method of any one of E1 to E109, wherein the antibody or antigen-binding fragment thereof is administered once every four weeks at a dose selected from the group consisting of about 15 mg, about 40 mg, about 60 mg, about 75 mg, about 100 mg, about 115 mg, about 200 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg and about 500 mg.
[0356] E111. A method for preventing, ameliorating and / or treating primary mitochondrial myopathy, comprising administering to a subject in need thereof a therapeutically effective amount of: (a) LCDR-1 comprising the amino acid sequence of SEQ ID NO: 95; (b) LCDR-2 comprising the amino acid sequence of SEQ ID NO: 28; (c) LCDR-3 comprising the amino acid sequence of SEQ ID NO:9; (d) HCDR-1 comprising the amino acid sequence of SEQ ID NO: 32; (e) HCDR-2 comprising the amino acid sequence of SEQ ID NO: 165; and (f) HCDR-3 comprising the aa sequence of SEQ ID NO: 52 Administering an antibody or antigen-binding fragment thereof comprising:
[0357] E112. A method for treating primary mitochondrial myopathy, comprising administering to a subject in need thereof a therapeutically effective amount of: (a) LCDR-1 comprising the amino acid sequence of SEQ ID NO: 95; (b) LCDR-2 comprising the amino acid sequence of SEQ ID NO: 28; (c) LCDR-3 comprising the amino acid sequence of SEQ ID NO:9; (d) HCDR-1 comprising the amino acid sequence of SEQ ID NO: 32; (e) HCDR-2 comprising the amino acid sequence of SEQ ID NO: 165; and (f) HCDR-3 comprising the amino acid sequence of SEQ ID NO: 52 Administering an antibody or antigen-binding fragment thereof comprising:
[0358] E113. A method for treating primary mitochondrial myopathy, comprising administering to a subject in need thereof a therapeutically effective amount of (a) LCDR-1 comprising the amino acid sequence of SEQ ID NO: 95; (b) LCDR-2 comprising the aa sequence of SEQ ID NO: 28; (c) LCDR-3 comprising the aa sequence of SEQ ID NO:9; (d) HCDR-1 comprising the aa sequence of SEQ ID NO: 32; (e) HCDR-2 comprising the aa sequence of SEQ ID NO: 165; and (f) HCDR-3 comprising the aa sequence of SEQ ID NO: 52 wherein administration of the antibody results in improvement in physical fatigue, muscle weakness and / or exercise tolerance in the subject compared to before administration.
[0359] E114. The method of any one of E111 to E113, wherein the antibody or antigen-binding fragment thereof comprises a VH comprising the amino acid sequence of SEQ ID NO: 166 and a VL comprising the amino acid sequence of SEQ ID NO: 163.
[0360] E115. The method of any one of E111 to E114, wherein the antibody comprises a HC comprising the amino acid sequence of SEQ ID NO: 164 and a LC comprising the amino acid sequence of SEQ ID NO: 162.
[0361] E116. Use of an antibody or antigen-binding fragment thereof that specifically binds to GDF15 in the method of the invention according to any one of the preceding embodiments.
[0362] E117. An antibody or antigen-binding fragment thereof that specifically binds to GDF15, for use according to any one of the preceding embodiments.
[0363] E118. An antibody or antigen-binding fragment thereof that specifically binds to GDF15, in the manufacture of a medicament for use in a method according to any one of the preceding embodiments.
[0364] E119. An antibody or antigen-binding fragment thereof that specifically binds to GDF15 for use in the prevention, amelioration and / or treatment of primary mitochondrial myopathy, (a) LCDR-1 comprising the amino acid sequence of SEQ ID NO: 95; (b) LCDR-2 comprising the aa sequence of SEQ ID NO: 28; (c) LCDR-3 comprising the aa sequence of SEQ ID NO:9; (d) HCDR-1 comprising the aa sequence of SEQ ID NO: 32; (e) HCDR-2 comprising the aa sequence of SEQ ID NO: 165; and (f) HCDR-3 comprising the aa sequence of SEQ ID NO: 52 An antibody or an antigen-binding fragment thereof comprising:
[0365] E120. The antibody or antigen-binding fragment thereof for use according to E119, comprising a VH comprising the amino acid sequence of SEQ ID NO: 166 and a VL comprising the amino acid sequence of SEQ ID NO: 163.
[0366] E121. The antibody or antigen-binding fragment thereof for use according to E119 to E120, comprising an HC comprising the amino acid sequence of SEQ ID NO: 164 and an LC comprising the amino acid sequence of SEQ ID NO: 162.
[0367] Equivalent The above description and the following examples detail certain specific embodiments of the present disclosure and describe the best mode contemplated by the inventors. However, no matter how detailed the above may appear in the text, it is understood that the present disclosure can be implemented in many ways and that the present disclosure should be implemented according to the appended claims and any equivalents thereof.
[0368] Although the disclosed teachings have been described with respect to various applications, methods, kits and compositions, it is understood that various changes and modifications can be made without departing from the teachings of the present specification and the following claimed disclosure. The following examples are provided to better illustrate the disclosed teachings and are not intended to limit the scope of the teachings presented herein. Although the teachings of the present specification have been described with respect to these exemplary embodiments, those skilled in the art will readily appreciate that numerous variations and modifications of these exemplary embodiments are possible without undue experimentation. All such variations and modifications are within the scope of the teachings of the present specification.
[0369] All references cited herein, including patents, patent applications, articles, textbooks, and the like, and the references cited therein, to the extent not already cited, are hereby incorporated by reference in their entirety. In the event that one or more of the incorporated literature and similar materials differs from or conflicts with this application, including, but not limited to, defined terms, term usage, techniques described, etc., this application controls.
[0370] General technology It should be understood that the present invention is not limited to the specific synthetic method of making it, which can of course vary.Unless otherwise defined herein, scientific and technical terms used in conjunction with the present invention shall have the meanings that are commonly understood by those skilled in the art.Furthermore, unless otherwise required by context, singular terms shall include plural, and plural terms shall include singular.In general, the nomenclature used in conjunction with cell and tissue culture, molecular biology, immunology, microbiology, genetics, and protein and nucleic acid chemistry, and hybridization described herein, and the techniques thereof, are well known and commonly used in the art.
[0371] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are within the skill of the art. Such techniques are described in detail in Molecular Cloning: A Laboratory Manual, 2nd Edition (Sambrook et al., 1989) Cold Spring Harbor Press; Oligonucleotide Synthesis (ed. M. J. Gait, 1984); Methods in Molecular Biology, Humana Press; Cell Biology: A Laboratory Notebook (ed. J. E. Elis, 1998) Academic Press; Animal Cell Culture (ed. R. I. Freshney, 1987); Introduction to Cell and Tissue Culture (J. P. Mather and P. E. Oberts, 1998) Plenum Press; Cell and Tissue Culture: Laboratory Procedures (eds. A. Doyle, J. B. Griffiths and D. G. Newell, 1993-1998) J. Wiley and Sons; Methods in Enzymology (Academic Press, Inc.); Handbook of Experimental Immunology (eds. D. M. Weir and C. C. Blackwell); Gene Transfer Vectors for Mammalian Current Protocols in Molecular Biology (eds. JM Miller and MPCalos, 1987); Current Protocols in Molecular Biology (eds. FMAusubel et al., 1987); PCR: The Polymerase Chain Reaction (eds. Mullis et al., 1994); Current Protocols in Immunology (JEColligan et al., eds., 1991); Sambrook and Russell, Molecular Cloning: A Laboratory Manual, 3rd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (2001); Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, NY (2002); Harlow and Lane, Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1998); Colligan et al., Short Protocols in Protein Science, John Wiley & Sons, NY (2003); Short Protocols in Molecular Biology (Wiley and Sons, 1999); Immunobiology (CA Janeway and P. Travers, 1997); Antibodies (P. Finch, 1997); Antibodies: a practical approach (ed. D. Catty., IRL Press, 1988~1989); Monoclonal antibodies: a practical These approaches are fully described in such publications as: The approach (eds. P. Shepherd and C. Dean, Oxford University Press, 2000); Using antibodies: a laboratory manual (eds. E. Harlow and D. Lane, Cold Spring Harbor Laboratory Press, 1999); The Antibodies (eds. M. Zanetti and JD Capra, Harwood Academic Publishers, 1995).
[0372] Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein. The nomenclature used in conjunction with analytical chemistry, biochemistry, immunology, molecular biology, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein, and the laboratory procedures and techniques thereof, are those well known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.
[0373] biological deposit Representative material of the present invention was deposited on April 4, 2018 at the American Type Culture Collection, 10801 University Boulevard, Manassas, Va. 20110-2209, USA. Vector GDF15_001-VH, with ATCC accession number PTA-125038, contains a plasmid containing a DNA insert encoding the heavy chain variable region of antibody GDF15_001, and vector GDF15_001-VL, with ATCC accession number PTA-125039, contains a plasmid containing a DNA insert encoding the light chain variable region of antibody GDF15_001. These deposits were made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and the Regulations thereunder (Budapest Treaty). This ensures maintenance of a viable culture of the deposit for 30 years from the date of deposit. The deposit will be made available by ATCC under the terms of the Budapest Treaty, subject to an agreement between Pfizer Inc. and ATCC, which will ensure permanent and unlimited availability to the public of the progeny of the cultures of the deposit upon issuance of the relevant U.S. patent or upon the public disclosure of any U.S. or foreign patent application, whichever occurs first, and to such persons as the Director of the U.S. Patent and Trademark Office determines to be qualified pursuant to 35 U.S.C. 122 and the Director's regulations thereunder, including, in particular, 35 U.S.C. 1.14 relating to 886 OG 638.
[0374] The assignee of the present application has agreed that, should cultures of the deposited material die, are lost or destroyed when cultured under appropriate conditions, such material will be promptly replaced with others of the same kind upon notice. Availability of the deposited material is not to be construed as a license to practice the invention in contravention of rights granted under the authority of any government pursuant to its patent laws. EXAMPLES
[0375] Example 1 Anti-GDF15 antibody A panel of antibodies (see Tables 2 and 5 and FIG. 29) was generated and compared across a variety of binding and biophysical assays.
[0376] The anti-GDF15 antibodies of the present invention were analyzed based on their amino acid sequences and the presence of "hot spots" (e.g., potential glycosylation, oxidation and chemical degradation sites) in the CDR regions. The hot spot sequence analysis of the anti-GDF15 antibodies is shown in Table 5 below. GDF15_005, GDF15_006, GDF15_007, GDF15_008, GDF15_009 and GDF15_200 demonstrated the presence of N-linked glycosylation sites in the CDR regions and were not selected for further study.
[0377] [Table 6-1]
[0378] [Table 6-2]
[0379] Example 2 Binding properties of anti-GDF15 antibodies: Binding activity to human, cynomolgus monkey and mouse GDF15 by SPR The binding affinity of antibody GDF15_001 (comprising a VH comprising the amino acid sequence of SEQ ID NO: 166 and a VL comprising the amino acid sequence of SEQ ID NO: 163) to human, cynomolgus monkey and mouse GDF15 was determined using a BIAcore T200 instrument (GE Healthcare) at 37° C. with a collection rate of 10 Hz. Mouse Fc-human GDF15 (Mu IgG1Fc_Fxa_Hu GDF15; SEQ ID NO: 2), mouse Fc-mouse GDF15 (Mu IgG1Fc_Fxa_Mu GDF15; SEQ ID NO: 5) and mouse Fc-cynomolgus monkey GDF15 (Mu IgG1Fc_Fxa_Cyno GDF15; SEQ ID NO: 4) were captured on three different flow cells on a CM4 sensor chip (catalog number BR100534, GE Healthcare) using a Mouse Antibody Capture Kit (BR100838, GE Healthcare) according to the manufacturer's protocol. The running and sample buffer was 10 mM HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.05% P-20 (HBS-EP+). The final capture levels of Mu IgG1Fc_Fxa_Hu GDF15, Mu IgG1Fc_Fxa_Mu GDF15 and Mu IgG1Fc_Fxa_Cyno GDF15 were 40 resonance units (RU), 32 RU and 25 RU, respectively. Flow cell 1 was used as the reference flow cell. A two-fold dilution series of GDF15_001 with concentrations ranging from 10 nM to 0.625 nM was injected over the sensor surface for 120 seconds. Dissociation was monitored for 2.8 hours and the surface was regenerated with 10 mM glycine pH 1.7. Binding affinities and kinetic constants were determined for mouse and cynomolgus GDF15 by fitting the resulting sensorgram data to a 1:1 Langmuir model using BIAcore T200 Evaluation software version 2.0 (GE Healthcare). Affinity values were determined as shown in Table 6 below.
[0380] The binding affinity of several clones of GDF15-binding antibodies to mouse Fc-human GDF15 was also determined using the methodology described herein in Example 2 and is shown in Table 6 below. All clones tested in bivalent format demonstrated apparent KD values below 150pM, suggesting that they are strong binders to human GDF15. Furthermore, the binding of clone GDF15_001 to cynomolgus monkey and mouse GDF15 was measured using the BIAcore assay mentioned above (Table 7). Clone GDF15_001 showed strong binding to cynomolgus monkey GDF-15 (apparent KD 8.28pM) and maintained binding to mouse GDF15 (apparent KD 142.3pM), making clone GDF15_001 suitable for preclinical studies in both species.
[0381] [Table 7-1]
[0382] [Table 7-2]
[0383] [Table 8]
[0384] Example 3 Binding properties of anti-GDF15 antibodies: Binding activity of monomeric anti-GDF15 antibodies to human, cynomolgus monkey and mouse GDF15 by SPR To understand the KD value of GDF15_001 binding to GDF15 without avidity effects, monomeric Fc-Fab was produced and tested in the same assay used in Example 2. The binding affinity of monomeric GDF15_001 to human, cynomolgus monkey and mouse GDF15 was determined using a BIAcore T200 instrument (GE Healthcare) at 37°C with a collection rate of 10Hz. Mu IgG1Fc_Fxa_Hu GDF15, Mu IgG1Fc_Fxa_Mu GDF15 and Mu IgG1Fc_Fxa_Cyno GDF15 were captured on three different flow cells on a CM4 sensor chip (catalog number BR100534, GE Healthcare) using a Mouse Antibody Capture Kit (BR100838, GE Healthcare) according to the manufacturer's protocol. The running and sample buffer was 10 mM HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.05% P-20 (HBS-EP+). The final capture levels of Mu IgG1Fc_Fxa_Hu GDF15, Mu IgG1Fc_Fxa_Mu GDF15 and Mu IgG1Fc_Fxa_Cyno GDF15 were 19 resonance units (RU), 22 RU and 19 RU, respectively. Flow cell 1 was used as the reference flow cell. A two-fold dilution series of monomeric GDF15_00 with concentrations ranging from 10 nM to 1.25 nM was injected over the sensor surface for 120 seconds. Dissociation was monitored for 1200 seconds and the surface was regenerated with 10 mM glycine pH 1.7. Binding affinity and kinetic constants were determined by fitting the resulting sensorgram data to a 1:1 Langmuir model with BIAcore T200 Evaluation software version 2.0 (GE Healthcare). Monomeric clone GDF15_001 demonstrated strong binding to human (KD 21.3 pM) and cynomolgus GDF15 (KD 62.0 pM), with weaker binding to mouse GDF15 (KD 1965.0 pM), as shown in Table 8 below.
[0385] [Table 9]
[0386] Example 4 Binding properties of anti-GDF15 antibodies: Binding specificity of GDF15_001 to human GDF15 To assess the binding specificity of GDF15_001 to human GDF15, GDF15_001 binding to additional TGFβ family members was examined. Analysis was performed on an Octet Red instrument.
[0387] OctetRED 384 (ForteBio, Menlo Park, CA) was used to detect human GDNF (R&D, 212-GD / CF), human inhibin A (R&D, 8506-AB / CF), human activin B (R&D, 659-AB / CF), human TGFβ-1 (R&D, 240-B / CF), human BMP2 (R&D, 355-BM / CF), human BMP3b (R&D, 1543-BP / CF), human BMP6 (R&D, 507-BP / CF), human BMP9 (R&D, 3209-BP / CF), human BMP11 (R&D, 1958-CD / CF), human GDF8 (Pfizer, 41075-201) and the control human GDF15 (Mu IgG1Fc_Fxa_Hu Off-target binding of monomeric GDF15_001 (CH23LS-GBT-GDF15_001) to 10 TGFβ family members including GDF15 was evaluated. TGFβ family members were diluted to 10ug / ml in 10mM sodium acetate pH 4.5 and amine coupled onto AR2G biosensors (cat. no. 18-5092, ForteBio) according to the manufacturer's instructions. Monomeric GDF15_001 was diluted to 200nM in kinetics buffer (cat. no. 18-5032 ForteBio). Octet assays were performed at room temperature with an association time of 300 seconds and a dissociation time of 180 seconds. Data were double referenced (Myszka, D., J. Mol. Recognit 1999;279-284) and analyzed with Octet Data Analysis software version 8.1 (ForteBio).
[0388] GDF15_001 bound to human GDF15 as expected. No binding to other TGFβ family members (GDF-11, BMP-9, GDF-8, BMP-2, BMP-6, TGFβ-1, activin-B, inhibin-A) was detected with the monomeric clone GDF15_001 at 200 nM, demonstrating the high specificity of GDF15_001, which does not bind to these other related family members. The high specificity of GDF15_001 minimizes the risk of off-target binding, indicating that GDF15_001 is a potential novel and useful human therapeutic agent.
[0389] Example 5 Anti-GDF15 antibodies prevent GDF15 binding to GFRAL The ability of GDF15_001 to prevent human GDF15 binding to the extracellular domain of GFRAL was assessed by competitive assay. Analysis was performed using a BIAcore T200 instrument (GE Healthcare, Chicago, IL).
[0390] GDF15_001 was titrated into 10 nM human GDF-15 at concentrations ranging from 10 nM to 2.5 nM. Mixtures GDF-15, GDF15_001 and controls were injected over the extracellular domain of human GFRAL directly immobilized on a CM4 sensor chip. Concentration-dependent inhibition of human GDF15 binding to GFRAL was observed. Binding of human GDF15 to human GFRAL ECD was completely blocked by 7.5 nM GDF15_001.
[0391] These data demonstrate that GDF15_001 can block the interaction between human GDF15 and its cognate receptor GFRAL, thereby disrupting GFRAL signaling, further demonstrating that GDF15_001 may be a novel, potentially useful therapeutic agent for decreasing activity mediated by GDF15 binding to GFRAL.
[0392] Example 6 Biophysical properties of anti-GDF15 antibodies: Thermal stability The thermal stability of anti-GDF15 antibodies was evaluated by differential scanning calorimetry (DSC). Proteins were diluted in phosphate buffer solution (PBS) to 0.3 mg / ml in a volume of 400 μl. PBS was used as a buffer blank in the reference cell. PBS contained 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4 and 1.47 mM KH2PO4, pH 7.2. Samples were dispensed into the sample tray of a MicroCal VP-Capillary DSC using an Autosampler (Malvern Instruments Ltd, Malvern, UK). Samples were equilibrated at 10°C for 5 minutes and then scanned to 110°C at a rate of 100°C per hour. A filtering period of 16 seconds was selected. Raw data was baseline corrected and protein concentrations were normalized. Data were fitted to the MN2-State Model with the appropriate number of transitions using Origin Software 7.0 (OriginLab Corporation, Northampton, Mass.).
[0393] The transition temperatures are shown in Figures 1A, 1B and 1C and listed in Table 9. m 1, C of the antibody H T 2 indicates the temperature at which the molecule is 50% unfolded. m T 2 indicates the temperature at which the Fab of the antibody is 50% unfolded. m 3, C of the antibody H 3 indicates the temperature at which the protein is 50% unfolded. The melting temperature (T m All clones with 1) are designed as stable clones, which are stable during production and storage.
[0394] [Table 10]
[0395] Example 7 Biophysical characterization of anti-GDF15 antibodies: Size exclusion chromatography Antibody clones were analyzed by analytical size exclusion chromatography (aSEC). Proteins were diluted to 1.0 mg / ml in phosphate buffered saline (PBS) and analyzed by aSEC on a YMC-Pack Diol-200, 300 x 8 mm column with an isocratic running buffer containing 20 mM sodium phosphate pH 7.2, 400 mM NaCl. Native SEC was used to determine the relative amounts of high molecular weight (aggregates) and monomeric intact antibody. Percent aggregates were calculated as the high molecular weight peak area divided by the total (aggregates and monomers) peak area multiplied by 100. Retention times in minutes were recorded and compared to assay controls. Antibody clones with standard retention times and peak shapes from aSEC analysis may suggest minimal interactions with the stationary phase resin and optimal hydrophobicity, which are useful characteristics and indicate that the antibody may be a potential useful therapeutic agent.
[0396] The retention times for each antibody clone tested are shown in Table 10. GDF15_002 exhibited a delayed retention time and broad peak shape and therefore was not studied further.
[0397] [Table 11]
[0398] Example 8 Biophysical properties of anti-GDF15 antibodies: Stability at low pH Antibody was purified by Protein A capture and elution was at low pH conditions, so anti-GDF15 antibody clones were tested for low pH maintenance stability. Antibody at 1.0 mg / ml in PBS, pH 7.2 was acidified with glycine pH 3.4, incubated at 25° C. for 5 hours, then neutralized with Tris base and run on aSEC to determine the amount of high molecular weight species (HMMS) and low molecular weight species (LMMS), Table 11. All clones tested show an acceptable increase (<5%) in the amount of HMMS after low pH challenge. This indicates that anti-GDF15 antibody remains stable during the purification process and could potentially be a useful therapeutic agent.
[0399] [Table 12]
[0400] Example 9 Biophysical properties of anti-GDF15 antibodies: Viscosity The viscosity of GDF15_001 was analyzed by Anton Paar instrument. GDF15_001 was concentrated to 215 mg / mL using a 30 kDa molecular weight cut-off Amicon centrifugal filter unit (EMD Millipore, Billerica, MA). A series of dilutions ranging from 46 to 178 mg / mL were prepared using 20 mM histidine, 85 g / L sucrose, 0.05 mg / ml EDTA pH 5.8 buffer as diluent. Protein concentration was determined by 280 nm analysis on a SoloVPE Variable Pathlength System (C Technologies, Inc, Bridgewater, NJ). Viscosity measurements were performed using a CP25-1 cone and plate on an MCR-302 rheometer (Anton Paar USA Inc., Ashland, VA) at a constant rotation speed of 150 rpm at 25 °C. A total of 10 measurements of 10 seconds each were collected per sample and data was analyzed using Rheoplus (Anton Paar USA Inc.) V 3.62 software. Viscosity is reported in centipoise (cP).
[0401] The viscosity of GDF15_001 is shown in Figure 2. The data shows that an acceptable viscosity limit (20 cP) is reached at approximately 140 mg / ml, making subcutaneous injection of GDF15_001 feasible, further indicating that this antibody is a useful potential therapeutic agent.
[0402] Example 10 Immunogenicity of anti-GDF15 antibodies Based on the detection of non-germline T cell epitopes and the calculated tReg-adjusted scores, the immunogenicity of the anti-GDF15 antibodies of the present invention and other anti-GDF15 antibodies known in the art, such as hu01G06 (the VH and VL sequences of hu01G06 are provided herein as SEQ ID NO: 177 and SEQ ID NO: 178, respectively (VH, SEQ ID NO: 248 of WO2014 / 100689, and VL, SEQ ID NO: 254 of WO2014 / 100689)) was predicted. A lower tReg-adjusted score predicts a lower potential immunogenicity risk.
[0403] The sequences were analyzed to identify epitopes using two protocols (Protocols 1 and 2 below). Any sequence identified by the rules described herein for either protocol was considered an epitope. The sequences were tested at the amino acid 9-mer level.
[0404] Protocol 1 - ISPRI / EpiMatrix: Sequences were subjected to EpiMatrix analysis in the ISPRI software package (ISPRI v 1.8.0, EpiVax Inc., Providence, RI (2017); Schafer et al. Vaccine 16(19), 1880-84 (1998)). The raw results provide a ranking of the likelihood of binding of each 9-mer amino acid fragment to eight different HLA types. Thus, for each 9-mer, there are eight predictions ("observations"). These 9-mers are generated starting at each individual linear numbering position of the sequence. It is possible for the same 9-mer to occur more than once in the same sequence. If any four observations indicate that a 9-mer is in the top 5% of binding partners, meaning that it is in the top 5% of binding partners for at least four HLA types, the 9-mer is considered a predicted epitope. Alternatively, if any one of the eight predictions indicates that a 9-mer is in the top 1% of connectors, then this 9-mer is also considered a predicted epitope.
[0405] Protocol 2 - IEDB Consensus Method: Sequences were subjected to analysis using the MHC-II binding Consensus Method (Wang et al., BMC Bioinformatics 11, 568 (2010); Wang et al., PLoS Comput Biol. 4(4), e1000048 (2008)) in the Immune Epitope Database (IEDB) (IEDB MHC-II Binding Predictions, http: / / www.iedb.org; Vita et al., Nucleic Acids Res. Jan 28(43), D405-12 (2015)). The software output places the results in 15-mer order. A consensus score and percentile ranking are provided for each combination of 15-mer and HLA type. However, the individual scores from which each 15-mer consensus is derived are rankings of the particular 9-mers found in the 15-mer: each method used for consensus reports percentile ranks for the 9-mers within the 15-mer, and the consensus taken as a value for the entire 15-mer is the prediction for the 9-mer with the median score. A 9-mer is classified as an epitope if (a) it is selected as the consensus representative of the 15-mer, and (b) it has a percentile ranking in the top 10% of binding partners for the HLA type being considered, and if criteria (a) and (b) occur for three or more distinct HLA types (i.e., three observations) for the same 9-mer. The HLA types considered were DRB1, DRB2, DRB3, DRB4, DRB5, DRB6, DRB7, DRB8, DRB9, DRB10, DRB11, DRB12, DRB13, DRB14, DRB15, DRB16, DRB17, DRB18, DRB19, DRB110, DRB111, DRB12, DRB13, DRB14, DRB15, DRB15, DRB16, DRB17, DRB18, DRB19 ... * 01, 1 * 03, 1 * 04, 1 * 07, 1 * 08, 1 * 11, 1 * 13 and 1 * 15, which are the same HLA types in the standard ISPRI / EpiMatrix report. For ease of comparison with Protocol 1, the data are reinterpreted to obtain a list of predicted 9-mer epitopes, but the primary output of the consensus method is a ranking of the 15-mers.
[0406] Each epitope is classified as a germline or non-germline epitope. For antibodies, each epitope is further classified based on its position in the antibody (e.g., CDR or non-CDR). The sequence of human V domain obtained from IMGT (www.imgt.org) is filtered to remove germline annotated as pseudogene or open reading frame. Any predicted 9-mer epitope found in the remaining sequence is considered as a germline epitope. Epitopes found in J or C regions (including IgG1, IgG2, IgG3 and IgG4) or the junction between these regions are also classified as germline epitopes. Otherwise, the epitope is classified as a non-germline epitope.
[0407] CDR definition is based on the method of Kabat, where CDRs are defined to include the following residues: HCDR-1 (H26-H35, including insertions below H36, e.g. H35A), HCDR-2 (H50-H65, inclusive), HCDR-3 (H95-H102, inclusive), LCDR-1 (L24-L34, inclusive), LCDR-2 (L54-L56, inclusive), LCDR-3 (L89-L97, inclusive). A predicted 9-mer epitope is defined as a CDR epitope if any one of its amino acids is part of the CDR region.
[0408] Global sequence score (tReg adjusted score): For individual chains, or for pairings of antibody VH and VL domains, a global score can be calculated by summing each of the component 9-mers, as described below.
[0409] Every individual combination ("observation") of 9-mer and HLA type was tested, regardless of whether the 9-mer was an epitope or not. If a particular observation indicates that the peptide is in the top 5% of binders for a given HLA type, the EpiMatrix Z-score for this observation is added to the intermediate total associated with the entire protein sequence. The total number of observations tested is also recorded. The only exception is that all observations for 9-mers identified by ISPRI as "T-resitopes" (amino acid sequences within monoclonal antibody framework regions that can potentially activate natural regulatory T cells and reduce unwanted immune responses) are assumed to have an EpiMatrix score of zero.
[0410] The midpoint total is 0.05 * A baseline score of 2.2248 is subtracted from each observation (including the T-registope). The final score is calculated as follows: tReg adjusted score = (intermediate sum) * 1000 / (number of observations).
[0411] The calculated scores are listed in Table 12. As mentioned above, a lower score indicates a lower predicted immunogenicity potential. The anti-GDF15 antibodies of the present invention had a lower score than hu01G06. Clones GDF15_001, GDF15_004, GDF15_005 and GDF15_013 had the lowest scores and therefore the lowest potential predicted risk of eliciting an immunogenic response. This further indicates that the antibodies of the present invention are potential useful therapeutic agents.
[0412] [Table 13]
[0413] The predicted T cell epitopes of GDF15_001 and hu01G06 were also compared based on the above in silico method.As shown in Table 13 below, hu01G06 has two predicted T cell epitopes in the heavy chain and one predicted T cell epitope in the light chain, while GDF15_001 does not have any predicted T cell epitopes.This indicates that GDF15_001 also has a lower potential risk of eliciting immunogenic response when compared with hu01G06.This further indicates that GDF15_001 is a potential useful novel therapeutic agent with improved characteristics.
[0414] [Table 14]
[0415] Example 11 Inhibition of human and mouse GDF15 in healthy mice The ability of GDF15_001 to inhibit human GDF15 activity was evaluated in healthy C57Bl6N mice treated with adeno-associated virus (AAV)-human GDF15. Two weeks after AAV-human GDF15 treatment, circulating human GDF15 levels increased to approximately 17 ng / mL (Figure 3), and body weight was reduced by 15% (Figure 4). Administration of GDF15_001 rapidly reversed body weight (Figure 4), fat (Figure 5), and lean mass loss (Figure 6) in AAV-human GDF15-treated mice compared to IgG controls. GDF15_001 had no effect in AAV control vector-treated mice.
[0416] The ability of GDF15_001 to inhibit mouse GDF15 activity was also evaluated in healthy C57Bl6N mice treated with AAV-mouse GDF15. Eleven days after AAV-mouse GDF15 administration, circulating mouse GDF15 levels increased to approximately 3 ng / mL (Figure 7), and body weight was reduced by approximately 10% (Figure 8). Administration of GDF15_001 rapidly reversed the weight loss (Figure 8) and increased food intake (Figure 9) in AAV-human GDF15-treated mice compared to IgG control. GDF15_001 had no effect in AAV control vector-treated mice.
[0417] These data demonstrate that GDF15_001 reverses weight loss resulting from both lean and fat mass loss and increases food intake in healthy mice, even in the presence of increased levels of GDF15.
[0418] Example 12 Mitochondrial mutator mice (PolgA) D257A ) Treatment material and method animal Male wild type (WT) and homozygous (Polg D257A / D257A ) mitochondrial DNA (mtDNA) mutator (referred to herein as PolgA D257A Mice were obtained from the Jackson Laboratory (stock number 017341). D257AThe mutant allele harbors a D257A mutation in the N-terminal "proofreading" exonuclease domain of the DNA polymerase gamma gene (Polg), rendering the expressed mutant protein deficient in polymerase proofreading function in mitochondria. All mice were individually housed in thermoneutral conditions (27 ± 1 °C) and maintained on a standard light-dark cycle (6 a.m. to 6 p.m.). Mice were allowed free access to water and food (Purina Rodent Diet 5061; Purina Mills, St. Louis, MO, USA) except when specified for food intake measurements. All procedures were approved by the Pfizer Groton and Cambridge Animal Care and Use Committees in accordance with the ethical standards established in the 1964 Declaration of Helsinki and its later amendments.
[0419] Plasma GDF15 and FGF21 measurements Tail blood samples were collected from WT and PolG mice at 3, 6 and 10 months of age. Plasma GDF-15 and FGF21 levels were measured using R&D system ELISA kits (catalog no. MGD150 for GDF-15 and MF2100 for FGF-21, R&D Systems, Minneapolis, MN, USA). Assays were performed according to the manufacturer's instructions and using calibrators provided by MSD. Only PolG samples for 6 and 10 months of age were diluted 1:4 in assay buffer.
[0420] Voluntary wheel-running measurements To measure spontaneous wheel-running activity, mice were housed in neutral temperature conditions with a standard light-dark cycle (6 a.m.-6 p.m.) and free access to a wheel (Columbus Instruments, Chicago, IL, USA), food, and water ad libitum. Wheel counts, indicating running distance, were measured daily for 5 days after a 3-day acclimation period with access to spontaneous wheel running.
[0421] In vivo muscle force production measurements Mice were anesthetized with 2% isoflurane and placed supine on a platform heated to 37°C via a circulating water bath. The right leg was shaved down to the patella and the right knee was stabilized via a knee clamp. Once stabilized, the right foot was affixed to a Dual Mode Foot Plate (300-C FP, Aurora Scientific Inc., Aurora, Canada) and two electrodes were placed subcutaneously near the mid-belly of the gastrocnemius muscle to achieve plantar flexion. Electrical stimulation at 1 Hz (0.2 sec duration, 1 sec between stimuli) was delivered via a stimulator (701C, Aurora Scientific Inc.) at increasing amperes up to 50 Hz, 100 Hz and 150 Hz to generate maximum twitch measurements. All data were collected and analyzed using manufacturer-supplied software (DMC and DMA, Aurora Scientific Inc.). Mice were housed at neutral temperature prior to analysis.
[0422] Treadmill Running Rating All mice were acclimated for 2 days before the test day. The first acclimation day consisted of placing the mice on a stationary belt for 25 minutes, then running the mice at 3 m / min for 5 minutes. The next day, all mice were acclimated to the stationary belt for 20 minutes, then running the mice at 3 m / min for 5 minutes. On the test day, mice were placed on the stationary treadmill for 20 minutes, then running the mice at 8 m / min for 2 minutes. The speed was increased to 12 m / min for another 2 minutes, then increased by 3 m / min every 2 minutes until exhaustion, where the mice stayed on the shock grid for 3 consecutive seconds on three consecutive occasions. All tests were performed on a Columbus Instruments Modular Enclosed Metabolic Treadmill for Mice (4 lanes in total) with a 10 degree incline and a shock grid set at 2 Hz.
[0423] Anti-GDF15 intervention Anti-GDF-15 antibody: GDF15-0301, also referred to herein as mAB2, was used in this study. PolG mice (9 months old) were randomized into two groups: PolG-vehicle and PolG-mAB2. WT littermates were also included for the study. Mice were subcutaneously injected with 10 mg / kg of either GDF15 antibody, mAb2 (PolG-mAB2) or control IgG (PolG-vehicle) once weekly throughout the duration of the study. Body weight was measured weekly. Lean and fat mass were assessed using the EchoMRI™ 4100 system.
[0424] Tissue collection Mice were euthanized under CO2 and cardiac stick. Mice were exsanguinated by performing a puncture stick. The gastrocnemius and tibialis anterior (TA) muscles were harvested, weighed, and snap frozen under liquid nitrogen.
[0425] statistical analysis Data are expressed as mean ± SE. Statistical analysis was performed by either T-test, one-way and two-way ANOVA, and Tukey HSD test for multivariate analysis. Statistical significance is indicated in the figures using the following symbols: * P < 0.05, ** P < 0.01, *** P<0.001.
[0426] result Plasma GDF15 levels were measured in WT and PolG mutator mice at 3, 6, and 10 months of age. Circulating GDF15 levels were comparable between WT and PolG mice at 3 months of age (Figure 1A). GDF15 levels were lower than 200 ng / ml in WT mice from 3 to 10 months of age. In contrast, GDF15 increased significantly from 3 to 10 months of age in PolG mice, reaching above 1.3 ng / ml at 10 months of age (Figure 1A). Circulating FGF21 was also significantly higher in PolG mice compared to their WT littermates at 10 months of age (Figure 1B).
[0427] Physical performance and muscle function were assessed in WT and PolG mice by measuring voluntary wheel-running activity and in vivo muscle force production. Wheel-running distance and muscle force production were reduced by 33% and 13.5%, respectively, in PolG mice compared to WT littermates (Figures 2 and 3), indicating reduced exercise tolerance and muscle strength.
[0428] To evaluate whether GDF15 neutralization could ameliorate the diseased condition in PolG mutator mice, 9-month-old PolG mutator mice that had shown weight loss, muscle dysfunction, and exercise tolerance were treated with a selective and potent GDF15 antibody (mAB2) or an IgG control (vehicle). WT littermates were also included in the study. PolG mice had lower body weight compared to their WT littermates (Figure 4). PolG mice treated with GDF15 mAB2 gained significantly more body weight compared to vehicle-treated PolG mice (Figure 4). Body composition assessed by EcoMRI showed that PolG mice treated with GDF15 mAB2 gained significantly more lean mass compared to vehicle-treated mice at 22 and 57 days after treatment (Figure 5A). The GDF15 mAB2-treated group had significantly higher body fat mass compared to the vehicle-treated group at 22 days after treatment (Figure 5B). Hindlimb muscles were removed and weighed at the end of the study (day 87 after treatment). Gastrocnemius and tibias from PolG mice treated with GDF15 mAB2 were significantly heavier than those from vehicle-treated PolG mice (Figures 6A and B).
[0429] To assess whether the increased muscle mass by GDF15 mAB2 resulted in improved muscle function, muscle force generation was assessed in vivo during electrical stimulation. Muscle force generation in the PolG-GDF15 mAB2 treatment group was significantly higher compared to the vehicle-treated group in PolG mice. Unexpectedly, the maximum force of PolG mice treated with GDF15 mAB2 was restored to a similar level to that of WT mice (Figure 7). Furthermore, PolG mice treated with GDF15 mAB2 ran significantly longer on the treadmill compared to the PolG vehicle-treated group, indicating improved exercise capacity (Figure 8A). Voluntary wheel running distance was also increased by GDF15 mAB2 treatment compared to vehicle-treated PolG mice (Figure 8B).
[0430] conclusion Data from this study demonstrated that GDF15 mAB2 treatment improved body weight gain and increased lean muscle mass and skeletal muscle mass. GDF15 mAB2 fully restored muscle strength as assessed by force production in vivo. Furthermore, GDF15 mAB2 treatment improved treadmill running and voluntary wheel running distance, indicating improved exercise capacity in PolG mice. These results demonstrate that GDF15 inhibition offers a novel therapeutic approach for primary mitochondrial myopathies.
[0431] Example 13 Study of the Effect and Safety of Ponceglomab on Health-Related Quality of Life in Patients with Heart Failure (GARDEN TIMI74) The primary objective of this study is to evaluate the effect of repeated subcutaneous administration of ponsegromab (PF-06946860; also referred to herein as GDF15_001) on the frequency, severity, and burden of symptoms and physical limitations, and elevated circulating GDF-15 concentrations in participants with heart failure. The study will also evaluate the safety, tolerability, PK, PD, and immunogenicity of ponsegromab.
[0432] Condition: Heart failure intervention: Drug: Poncegromab 100mg Drug: Poncegromab 200mg Drug: Poncegromab 300mg Other: Matched dose placebo
[0433] Phase 2 Allocation: Randomized
[0434] [Table 15]
[0435] In this study, ponsegromab will be administered at doses of 100, 200 or 300 mg by subcutaneous injection every four weeks for a total of six doses. Participants will be randomized to one of three doses of ponsegromab or placebo.
[0436] Primary endpoint: Change from baseline in Kansas City Cardiomyopathy Questionnaire 23 Clinical Summary Score [Time Frame: 22 weeks] To compare the effects of ponsegromab versus placebo on heart failure disease-specific health status in participants with heart failure
[0437] Secondary endpoints: Change from baseline in Kansas City Cardiomyopathy Questionnaire 23 Overall Summary Score, Total Symptom Score, and Physical Limitations [Time Frame: 22 weeks] To compare the effects of ponsegromab versus placebo on overall HF disease-specific health status in participants with HF Response defined by a ≥ 5-point increase from baseline in Kansas City Cardiomyopathy Questionnaire 23 Clinical Summary Score (CSS), Overall Summary Score (OSS), Total Symptom Score (TSS) and Physical Limitations (PL) [time frame: 22 weeks] To compare the effects of ponsegromab versus placebo on HF disease-specific health status in participants with HF Change from baseline in 6-Minute Walk Distance [Time frame: 22 weeks] To compare the effect of ponsegromab versus placebo on physical function in participants with HF Change from baseline in Heart Failure Daily Diary fatigue score [Time frame: 22 weeks] To compare the effect of ponsegromab versus placebo on fatigue reported by participants with HF Change from baseline in Patient-Reported Outcomes Measurement Information System Fatigue 7a [Time frame: 22 weeks] To compare the effect of ponsegromab versus placebo on fatigue reported by participants with HF Incidence of treatment-emergent adverse events [time frame: 22 weeks] To describe the safety and tolerability of ponsegromab in participants with HF Incidence of treatment-emergent serious adverse events [time frame: 22 weeks] To describe the safety and tolerability of ponsegromab in participants with HF Incidence of Anomalous Lab Results [Timeframe: 22 weeks] To describe the safety and tolerability of ponsegromab in participants with HF Incidence of abnormal vital signs [Time frame: 22 weeks] To describe the safety and tolerability of ponsegromab in participants with HF
[0438] [Table 16]
[0439] Eligibility
[0440] [Table 17]
[0441] standard Inclusion Criteria: - Male and female participants aged 18 years or older - Clinical evidence of HF by each of the following criteria: a. LVEF < 50% at most recent measurement (within the last 12 months) b. NYHA class II-IV at screening c. NT-proBNP ≥ 400 pg / mL at screening - Serum GDF-15 concentration ≥ 2000 pg / mL at screening - KCCQ-23 CSS<75 at screening - Evidence of cachexia or fatigue or functional impairment demonstrated by at least one of the following: Non-edematous involuntary weight loss ≥ 5% in the last 6 months associated with subjective fatigue or anorexia, or current BMI < 20 kg / m 2 ;or b. Fatigue at least three times per week and at least moderately bothersome fatigue in the past 2 weeks; or c. A score of <60 on the Physical Limitations Domain of the KCCQ 23 administered at screening.
[0442] Exclusion criteria: - Acute decompensated HF within 1 month prior to randomization - Cardiac resynchronization therapy device implantation or valve repair or replacement within 3 months prior to randomization, or intention to do so during the study - History of cardiac transplant, currently listed for cardiac transplant, or scheduled mechanical circulatory support - Acute coronary syndrome within 1 month prior to randomization - Coronary revascularization (percutaneous coronary intervention or coronary artery bypass graft) within 3 months prior to randomization or willingness to undergo coronary revascularization during the study - An untreated indication for an implantable cardiac defibrillator or pacemaker to treat a cardiac rhythm abnormality (i.e., tachyarrhythmia or bradyarrhythmia) - Previous administration of an investigational product (drug or vaccine) within 30 days (or as determined by local requirements) or 5 half-lives (whichever is longer) preceding the first dose of the investigational intervention used in this study. Treatment with an investigational biological agent within 6 months or 5 half-lives (whichever is longer) of Day 1. - Kidney disease requiring dialysis - Cirrhosis with evidence of portal hypertension not due to HF
[0443] References Breen et al., Cell Metab. 2020 Dec1;32(6):938-950 Breit et al., Annu Rev Physiol. 2021 Feb 10;83:127-151 Grorman et al., Ann Neurol. 2015 Nov 78(5):814-23 Mancuso et al. Neuromuscul Disord. 2017 Dec; 27(12):1126-1137 Montano et al., Neurol Genet. 2020 Oct 20; 6(6):e519 Lerner et al., 2015, J. Cachexia Sarcopenia Muscle, 6: 317-324
[0444] Although the disclosed teachings have been described with respect to various applications, methods, kits and compositions, it is understood that various changes and modifications can be made without departing from the teachings herein and the invention as claimed below. The above examples are provided to better illustrate the disclosed teachings and are not intended to limit the scope of the teachings presented herein. Although the teachings herein have been described with respect to these exemplary embodiments, those skilled in the art will readily appreciate that numerous variations and modifications of these exemplary embodiments are possible without undue experimentation. All such variations and modifications are within the scope of the teachings herein.
[0445] All references cited herein, including patents, patent applications, articles, textbooks, and the like, and the references cited therein to the extent not already cited, are incorporated herein by reference in their entirety for all purposes. In the event that one or more of the incorporated literature and similar materials differs from or conflicts with this application, including, but not limited to, defined terms, term usage, techniques described, etc., this application controls.
[0446] It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope or spirit of the invention. Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.
Claims
1. A method of treating primary mitochondrial myopathy (PMM), comprising administering to a subject in need thereof a therapeutically effective amount of an isolated antibody that binds to GDF-15.
2. 2. The method of claim 1, wherein the primary mitochondrial myopathy is selected from the group consisting of Leigh syndrome, Kearns-Sayre syndrome, Alpers-Huttenlocher syndrome, mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) and ataxic neuropathy syndrome.
3. 3. The method of any one of claims 1 to 2, wherein the administration of the anti-GDF15 antibody results in an improvement in one or more signs or symptoms of PMM compared to before administration.
4. 4. The method of claim 3, wherein the one or more signs or symptoms of PMM include physical fatigue, muscle weakness and / or exercise tolerance.
5. 5. The method of any one of claims 3 to 4, wherein the improvement in one or more signs or symptoms of PMM comprises increased weight gain, increased lean muscle mass, increased skeletal muscle mass, restored muscle strength, and / or improvement in athletic performance.
6. 6. The method of any one of claims 1 to 5, wherein the subject does not have cachexia, cancer and / or heart failure.
7. The method of any one of claims 1 to 6, wherein the subject has elevated GDF15 levels and / or activity prior to administration of the isolated antibody or antigen-binding fragment thereof.
8. The method of any one of claims 1 to 7, wherein the antibody or antigen-binding fragment thereof comprises LCDR-1 comprising the amino acid sequence of SEQ ID NO:95, LCDR-2 comprising the amino acid sequence of SEQ ID NO:28, LCDR-3 comprising the amino acid sequence of SEQ ID NO:9, HCDR-1 comprising the amino acid sequence of SEQ ID NO:32, HCDR-2 comprising the amino acid sequence of SEQ ID NO:165, and HCDR-3 comprising the amino acid sequence of SEQ ID NO:
52.
9. The method of claim 8, wherein the antibody or antigen-binding fragment thereof comprises a VH comprising the amino acid sequence of SEQ ID NO: 166 and a VL amino acid sequence of SEQ ID NO:
163.
10. The method of claim 9, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 164 and a light chain comprising the amino acid sequence of SEQ ID NO:
162.
11. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is administered subcutaneously.
12. The method of any one of claims 1 to 10, wherein the antibody or antigen-binding fragment thereof is administered intravenously.
13. 13. The method of any one of claims 1 to 12, wherein the antibody or antigen-binding fragment thereof is administered about twice per week, once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, once every eight weeks, once every nine weeks, once every ten weeks, twice per month, once per month, once every two months, once every three months, or once every four months, once per five months, once per six months, once per seven months, once per eight months, once per nine months, once per ten months, once per eleven months, or once per twelve months.
14. 14. The method of any one of claims 1 to 13, wherein the antibody or antigen-binding fragment thereof is administered once a week at a dose of between about 0.1 mg and about 1000 mg.
15. 15. The method of claim 14, wherein the antibody or antigen-binding fragment thereof is administered once a week at a dose of between about 1 mg and about 500 mg.
16. 14. The method of any one of claims 1 to 13, wherein the antibody or antigen-binding fragment thereof is administered once every two weeks at a dose of between about 0.1 mg and about 500 mg.
17. 14. The method of any one of claims 1 to 13, wherein the antibody or antigen-binding fragment thereof is administered at a dose of between about 0.1 mg and about 500 mg once every four weeks.
18. 18. The method of any one of claims 1 to 17, wherein the antibody or antigen-binding fragment thereof comprises the amino acid sequence encoded by an insert in a plasmid deposited with the ATCC and having ATCC Accession No. PTA-125038, and the amino acid sequence encoded by an insert in a plasmid deposited with the ATCC and having ATCC Accession No. PTA-125039.
19. 1. A method of treating primary mitochondrial myopathy (PMM), comprising administering to a subject in need thereof a therapeutically effective amount of an isolated antibody that binds GDF-15, wherein the subject has elevated GDF15 levels and / or activity prior to administration, and wherein the administration of the anti-GDF15 antibody results in an improvement in physical fatigue, muscle weakness and / or exercise tolerance in the subject compared to prior to administration, and wherein the antibody or antigen-binding fragment thereof comprises an LCDR-1 comprising the amino acid sequence of SEQ ID NO:95, an LCDR-2 comprising the amino acid sequence of SEQ ID NO:28, an LCDR-3 comprising the amino acid sequence of SEQ ID NO:9, an HCDR-1 comprising the amino acid sequence of SEQ ID NO:32, an HCDR-2 comprising the amino acid sequence of SEQ ID NO:165, and an HCDR-3 comprising the amino acid sequence of SEQ ID NO:
52.
20. The method of claim 19, wherein the antibody or antigen-binding fragment thereof comprises a VH comprising the amino acid sequence of SEQ ID NO: 166 and a VL amino acid sequence of SEQ ID NO:
163.
21. The method of claim 20, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 164 and a light chain comprising the amino acid sequence of SEQ ID NO: 162.
Citation Information
Patent Citations
Anti-pro / latent myostatin antibodies and their use
JP2017536354A
Anti-GDF15 Antibodies, Compositions and Methods of Use
JP2021526847A
GDF15 as biomarker for diagnosing mitochondrial diseases
WO2015108077A1
